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Haematopoiesis is a dynamic process by which the full array of blood cell types 
originates from multipotent haematopoietic stem cells (HSCs). The blood system has 
long been an attractive model to explore how cell fate decisions are conducted at the 
molecular level, to generate the vast diversity of blood cell types. Blood cell fate choice 
is for the most part regulated by transcription factors and epigenetic modifiers. The 
enzymatic activities of epigenetic regulators are of particular importance in 
malignant haematopoiesis such as leukaemia, given their reversible nature and 
potential for therapeutic targeting. Epigenetic histone modifiers are often found 
within large multi-subunit complexes, whereby their catalytic activity is exercised. 
However, very little is known about how epigenetic enzymes take advantage of their 
participating chromatin complexes in order to accomplish their functions. In the 
blood system, no studies have formally examined how different epigenetic complexes 
with the same enzymatic component coordinate cell fate choices. Here, I focus on 
KAT2A, a lysine acetyltransferase responsible for Histone 3 Lysine 9 acetylation 
(H3K9ac), and a vulnerability in Acute Myeloid Leukaemia (AML), as well as its 2 
containing complexes: Ada-Two-A-Containing (ATAC) and Spt-Ada-Gcn5-
Acetyltransferase (SAGA). I combine cell functional and molecular assays of human 
cord blood (CB) haematopoietic cells and AML cells to dissect KAT2A roles depending 
on its participation in ATAC or SAGA complexes. Firstly, I demonstrate that KAT2A 
regulates CB erythroid progenitor specification and survival. I uncover unique 
contributions of the ATAC complex to erythroid lineage specification, whereas SAGA 
acts late in differentiation. This suggests that KAT2A plays stage-specific roles, which 
are unique to the complexes it integrates. While KAT2A regulates specification and 
survival of erythroid progenitors via ATAC through control of biosynthetic activity, it 
fine-tunes progression of erythroid differentiation through participation in SAGA. 
Secondly, I explored the roles of ATAC and SAGA in leukaemic haematopoiesis. I 
found that ATAC regulates proliferation through control of biosynthetic activity. 
Instead, SAGA participates in maintenance of the characteristic block in AML cell 
differentiation, compatible with a generic control of cell identity through preservation 
of cell-type specific transcriptional programmes. My data is consistent with a model 
in which the ATAC complex has pervasive roles in maintenance of self-renewing cells, 




Understanding ATAC and SAGA unique chromatin regulatory mechanisms has 









































Work done by / and assistance received by others: 
 
Selinde Winde and Elena Foerner 
Cloning of some of the shRNAs used, some of the CB experiments  
 
Elena Foerner  
ChIP-seq experiment  
 
Dr Rashmi Kulkarni 
Bioinformatic analysis of RNA-sequencing and ChIP-sequencing data  
 
Genomics Core, CRUK Cambridge Institute 
RNA-sequencing and ChIP-sequencing 
  
Cell Phenotyping Hub NIHR BRC 
Assistance in CB cell sorting  
 
Dr Joana Cerveira at the Flow Sorting Facility of the Department of Pathology, 
University of Cambridge 
Assistance in sorting of cell lines  
 
Published work related to this thesis: 
Ana Filipa Domingues, Rashmi Kulkarni, George Giotopoulos, Shikha Gupta, Laura 
Vinnenberg, Liliana Arede, Elena Foerner, Mitra Khalili, Rita Romano Adao, 
Shengjiang Tan, Keti Zeka, Brian J. Huntly, Sudhakaran Prabakaran, Cristina Pina. 
Loss of KAT2A enhances transcriptional noise and depletes acute myeloid leukaemia 
stem-like cells. eLife, January 2020.  
 
Liliana Arede, Cristina Pina. Buffering noise: KAT2A modular contributions 
to stabilization of transcription and cell identity in cancer and development.  




Liliana Arede, Elena Foerner, Selinde Wind, Rashmi Kulkarni, Ana Filipa Domingues, 
George Giotopoulos, Svenja Kleinwaechter, Ryan Asby, Shikha Gupta, Elisabeth 
Scheer, Brian J.P. Huntly, Laszlo Tora, Cristina Pina. KAT2A complexes ATAC and 
SAGA play unique roles in cell maintenance and identity in hematopoiesis and 
leukemia (manuscript under review). 
 
Note: some of the results and figures in the following Chapters have previously been 






I couldn’t have completed this project without the support and encouragement of 
many people. First, I would like to thank my supervisor, Dr Cristina Pina for her 
scientific guidance these last few years. Key to this journey were also members of the 
lab, past and present, who in a way or another all imparted some combination of 
their expertise, insight and inspiration. A special thank you to Filipa, for getting me 
started at the bench and sharing her technical knowledge, to Wade and Shikha, my 
PhD pals, who shared many happy hours in and outside the lab, and to Keti for her 
always direct approach in all things.  
 
My research would not have been possible without the financial support of the 
Rosetrees Trust and Lucy Cavendish College. Likewise, I am grateful for the 
collaborations that made this work possible, in particular, with the labs of Dr Laszo 
Tora, Dr Antonio Curti and Professor Brian Huntly.  
 
During my time at Haematology, I was lucky to meet Chiara, Rita, Joana and Pepe, 
their friendship over the years and collective comic genius has been the best! As the 
lab transitioned to the Department of Genetics, I want to thank particularly the first-
floor teams and Dr Felipe Karam Teixeira for all the help settling in and throughout. 
It’s been a great opportunity to get to know and to learn from them.  
 
Away from the lab, I am thankful to my rowing team for kick-starting so many early 
mornings with energy and focus while pushing through pain (a bit like when things 
don’t work in the lab!), as well as amusing me with beautiful Cambridge sunrises. I’m 
also thankful to my SIU friends. I’m indebted to all those who made England a home 
for me over the past couple of years, including Jay, Aeh, Marta and Danny, Laetitia, 
Peter, Fabio, and Stephanie, as well as all the encounters and experiences brought 
up by deciding to commit to this project.  
 
I can’t help but reflect on the COVID-19 pandemic which made 2020 quite surreal. 
Despite it all, it brought a lot of perspective and I learned just how vast my support 




Finally, as ever, I’m immensely grateful to my parents and their unwavering support 
as I ventured into “Terras de Sua Majestade’’ on what would have been a short 
Erasmus placement with a return ticket. Despite not really understanding what I do 
you always believe in me and in what I decide to follow. Mãe e Pai: OBRIGADA. Thank 
you also to my grandparents, who brought me close to the beauty of the natural 
world since I was little. Now, may I continue to “pay attention, be astonished, and tell 



































Abstract ……………………………………………………………………………….... i 
Preface …………………………………………………………………………………. iii 
Acknowledgments …………………………………………………………………………………. v 
List of Figures …………………………………………………………………………………. xi 
List of Tables …………………………………………………………………………………. xvii 
Abbreviations …………………………………………………………………………………. xviii 
Chapter 1 
 
Introduction ………………………………………………………………. 1 
1.1 Haematopoiesis ……………………………………………………………. 2 
1.1.1 Haematopoietic stem cells (HSCs) …………………………………….. 2 
1.1.1.1 Origin, identification and isolation ……………………………………. 2 





Regulation of haematopoietic fate decisions ………………………… 
 
6 
1.1.2.1 The role of cytokines ……………………………………………………… 7 
1.1.2.2 Transcriptional regulation ………………………………………………. 7 






Myelopoiesis and its regulation ……...………………………………… 
 





1.2 Acute Myeloid Leukaemia (AML) ………………………………………. 18 
1.2.1 AML as a clinical entity ………………………………………………….. 18 
1.2.2 Biology of leukaemia stem-like cells ………………………………….. 19 
1.2.3 AML classification …………………………………………………………. 20 
1.2.4 Genomic and epigenomic landscape of AML ………………………… 21 
1.2.5 AML treatment ……………………………………………………………… 24 
1.3 Epigenetics ………………………………………………………………….. 27 




1.3.2 Epigenetic regulation of haematopoiesis ……………………………… 32 
1.3.2.1 Histone acetyltransferases / deacetylases …………………………… 32 
1.3.2.2 Histone lysine (K) methyltransferases / demethylases ……………. 33 
1.3.2.3 DNA Methylation: the roles of DNMTs and TET proteins …………. 36 
1.3.2.4 ATP-dependent nucleosome remodelling complexes ………………. 37 
1.4 KAT2A ………………………………………………………………………... 40 
1.4.1 KAT2A roles in development ……………………………………………. 40 
1.4.2 KAT2A contributions to cancer ………………………………………… 41 
1.5  SAGA and ATAC – KAT2A chromatin complexes …………………… 44 
1.5.1 SAGA complex ……………………………………………………………… 45 
1.5.2 ATAC complex ………………………………………………………………. 46 
1.5.3 SAGA and ATAC roles in cancer …………………………….………….. 48 
1.6  Thesis overview …………………………………………………………….. 52 
Chapter 2 Materials and Methods …………………………………………………. 54 
2.1 Cell lines …………………………………………………………………….. 55 
2.2 Human Cord Blood CD34+ Cells ………………………………………. 56 
2.3 Primary Human AML Cells ………………………………………………. 56 
2.4  Cell Cryopreservation, Thawing and Counting ……………………… 57 
2.5 Lentiviral Packaging and Transduction ………………………………. 58 
2.6 Functional Cellular Assays ……………………………………………… 60 
2.6.1 Flow Cytometry …………………………………………………………….. 60 
2.6.1.1 Human CB CD34+ Cell Sorting ………………………………………… 60 
2.6.1.2 Cell Cycle Analysis ………………………………………………………… 62 
2.6.1.3 Apoptosis Analysis ………………………………………………………… 63 
2.6.1.4 Cell Divisional Tracking ………………………………………………….. 63 
2.6.2 Colony-Forming Cell (CFC) Assays …………………………………….. 64 




2.6.4  Cytospins ……………………………………………………………………. 65 
2.7 Molecular Assays …………………………………………………………… 66 
2.7.1 Cloning of shRNA Constructs …………………………………………… 66 
2.7.2 RNA Extraction, cDNA Synthesis ………………………………………. 72 
2.7.3 Quantitative Real Time PCR (qRT-PCR) ………………………………. 72 
2.8 RNA-sequencing (RNA-seq) ……………………………………………… 74 
2.9 Chromatin Immunoprecipitation (ChIP) ……………………………… 74 
2.9.1 Cross-link for suspension cells, cell lysis ……………………………. 74 
2.9.2 Immunoprecipitation ……………………………………………………… 76 
2.9.3 DNA purification …………………………………………………………… 76 
2.10 Western Blot (WB) …………………………………………………………. 79 
2.10.1 SDS-PAGE …………………………………………………………………... 79 
2.10.2 Sample preparation and WB analysis ………………………………… 79 
2.11 Statistical Analysis ………………………………………………………… 81 
2.12 Data Deposition ……………………………………………………………. 81 
2.13 Resources …………………………………………………………………… 81 




3.1 Introduction ………………………………………………………………… 83 
3.2 Chapter overview ………………………………………………………….. 84 
3.3 Results and discussion …………………………………………………… 85 
3.3.1 KAT2A regulates human CB erythroid progenitor specification 
and survival ………………………………………………………………… 
 
85 
3.3.2 The ATAC complex is selectively required for erythroid 
specification from CB HSC, while SAGA facilitates erythroid 





3.3.3 KAT2A-containing ATAC and SAGA complexes have unique 
targets in haematopoietic cells …………………………………………. 
 
103 




Chapter 4 Cellular investigation of KAT2A-complex dependencies in 
human AML cell lines …………………………………………………… 
 
117 
4.1 Introduction ………………………………………………………………… 
 
118 
4.2 Chapter overview …………………………………………………………… 120 
4.3 Results and discussion …………………………………………………… 120 
4.3.1 KAT2A complexes uniquely maintain proliferation and identity of 
MLL-AF9 AML cells ………………………………………………………. 
 
121 
4.3.2 KAT2A complexes have distinct contributions to proliferation and 
cell identity of CD34+ AML cell lines …………………………………. 
134 
139 
4.4 Conclusions and future work …………………………………………… 146 
Chapter 5 Functional characterisation of the role of KAT2A and ATAC 






5.1 Introduction ………………………………………………………………... 151 
5.2 Chapter overview …………………………………………………………... 152 
5.3 Results and discussion …………………………………………………... 153 
5.3.1 Clonogenic growth of AML patient samples is hindered by 
treatment with MB-3, the KAT2A small molecule inhibitor ………. 
 
155 
5.3.2 MS-5 co-culture system preserves growth, CFC-capacity and 
phenotype of human primary AML cells ……………………………… 
 
156 
5.3.3 KAT2A lentiviral-mediated knockdown mimics its chemical 






5.3.4 KAT2A ATAC complex activity maintains propagation of human 
primary AML cells in MS-5 co-culture ………………………………… 
 
163 
5.4 Conclusions and future work …………………………………………… 165 
Chapter 6 Conclusions ………………………………………………………………... 168 
Bibliography ………………………………………………………………………………….. 177 




List of Figures  
Chapter 1     Introduction 
 
FIGURE 1.1  
 
Classical model of haematopoiesis  4 
FIGURE 1.2  
 
Alternative models of HSC lineage commitment  9 
FIGURE 1.3 
 
Model of definitive erythroid cell differentiation 13 
FIGURE 1.4 
 
Functional categories of mutated genes involved in AML 
pathogenesis  
21 
FIGURE 1.5 Timeline of currently approved AML therapies  
 
25 











Schematic representation of the human SAGA (left) and ATAC 











Analysis of dependencies and lineage associations of ATAC and 
SAGA-unique elements in CRISPR drop-out screens of cancer cell 







Chapter 2     Materials and Methods  
 
FIGURE 2.1  
 
AML cell lines used in this study and their known oncogenic 
mutations 
55 
FIGURE 2.2  
 
pCMV-VSV-G packaging plasmid 59 
FIGURE 2.3 
 
pMD2.G VSV-G-expressing envelope plasmid 60 
FIGURE 2.4 
 
Flow cytometry gating strategy for sorting the human CB CD34+ 








FIGURE 2.5 Flow cytometry gating strategy for cell cycle analysis of human 
CB CD34+ cells and cell lines 
 
62 
FIGURE 2.6 Flow cytometry gating strategy for apoptosis analysis of human 





Chemical structure of α-methylene- γ-Butyrolactone 3 (MB-3), 





pLL3.7 lentiviral transfer plasmid 66 
FIGURE 2.9 
 
Assessment of shRNA insertion into pLL3.7 vector using PCR and 





Assessment of shRNA insertion into pLL3.7 vector by BamH1 








Assessment of gene knockdown in lentiviral-producing 293T cells 71 
FIGURE 2.12 
 
Assessment of optimal chromatin sonication conditions for 








Chapter 3      The role of KAT2A and its chromatin complexes in   
                     normal haematopoiesis  
 
FIGURE 3.1  
 
Schematic of the adopted CB experimental strategy 85 
FIGURE 3.2 
 
Progenitor activity of KAT2A knockdown CB CD34+ cells 86 
FIGURE 3.3 
 
CFC-efficiency of KAT2A lentiviral transduced, sorted, human 





FIGURE 3.4 Erythroid cell differentiation in human CD34+ CB cells 
progresses independently of KAT2A absence 
 
89 
FIGURE 3.5 Transcriptional analysis of CTRLsh vs KAT2Ash CB HSCs 91 
FIGURE 3.6 
 
Analysis of apoptosis and cell cycle status of human CB stem and 














CFC-efficiency of human stem and progenitor CB cells 














Expression pattern of SAGA-specific elements during in vitro 











ChIP-seq analysis of KAT2A-containing ATAC and SAGA 





KAT2A-containing ATAC and SAGA complexes have unique 








KAT2A-containing SAGA complex facilitates erythroid cell 
differentiation in hematopoietic K562 cells 
 
GFP+ percentage in CTRLsh, KAT2Ash and ZZZ3sh-K562 cells in 









Chapter 4      Cellular investigation of KAT2A-complex dependencies 
                     in human AML cell lines  
 
FIGURE 4.1  
 
KAT2A is a genetic vulnerability in AML 118 
FIGURE 4.2  
 
Schematic of the adopted experimental strategy. 120 
FIGURE 4.3 
 
Knockdown of ATAC and SAGA-specific components hinders 





Analysis of MOLM-13 metabolism and self-renewal gene 
signature upon depletion of KAT2A, SAGA-specific SUPT20H and 




FIGURE 4.5 H3K9ac ChIP-qPCR analysis of ribosomal protein genes and self-
renewal genes in MOLM-13 cells upon knockdown of SAGA 




FIGURE 4.6 Cell cycle analysis of MOLM-13 cells upon knockdown of SAGA 





Cell divisional tracking of MOLM-13 cells upon knockdown of 








Differentiation analysis of MOLM-13 cells upon depletion of 







Apoptosis analysis of MOLM-13 cells upon depletion of KAT2A, 





Quantification of flow cytometry analysis of cell cycle and 
apoptosis in MOLM-13 cells transduced with shRNA construct 






Cell cycle analysis of THP-1 cells upon knockdown of KAT2A and 





Representative photographs of THP-1 cytospins upon depletion 







Apoptosis analysis of THP-1 cells upon depletion of KAT2A, 













Cell cycle assay in MV4-11 cell line upon knockdown of SAGA-













Apoptosis analysis of MV4-11 cells upon knockdown of SAGA-







Quantification of flow cytometry analysis of cell cycle in KG1a 
AML cells transduced cells with shRNA constructs against 








Quantification of flow cytometry analysis of apoptosis by Annexin 
V staining in KG1a cells transduced cells with shRNA constructs 








Quantification of flow cytometry analysis of cell cycle and 
apoptosis in KG1a cells transduced with shRNA construct 






Analysis of differentiation status of KG1a cells upon knockdown 








Cell cycle analysis of Kasumi-1 cells upon knockdown of KAT2A, 







Analysis of differentiation status of Kasumi-1 cells upon 
knockdown of SAGA specific SUPT20H and TADA2B and ATAC 






Apoptosis analysis of Kasumi-1 cells transduced with KAT2Ash, 
SAGA specific SUPT20Hsh and TADA2Bsh and ATAC-specific 







Chapter 5     Functional characterisation of the role of KAT2A and 
                    ATAC and SAGA complexes in human AML primary 
                    samples  
 
FIGURE 5.1  
 
Experimental strategy adopted for investigating the role of KAT2A 
and its participating complexes in human primary AML cells 
 
153 
FIGURE 5.2  
 
KAT2A small molecule inhibitor, MB-3, reduces CFC-capacity of 





MS-5 co-culture system preserves growth, expansion and 







KAT2A chemical inhibition with MB-3 suppresses growth and 





FIGURE 5.5 Flow cytometry gating strategy used for analysis of primitive AML 
CD34+ and GMP-like (L-GMPs) cell populations 
 
159 
FIGURE 5.6 Flow cytometry profiling of KAT2A transduced (GFP+) cells over a 






KAT2A knockdown reduces expansion of human primary AML 





Flow cytometry profiling of transduced (GFP+) cells over a 3-week 





ATAC-ZZZ3 knockdown reduces expansion of human primary 





Chapter 6     Conclusions  
 
FIGURE 6.1  
 
Working model of cell dependence on ATAC and SAGA complexes 





Appendices    Appendix E   
 
FIGURE E-1  
 
Single-cell transcriptomics identifies a KAT2A-dependent 





pHAGE vector containing a dCas9-KAT2A-core fusion 240 
 
 
FIGURE E-3 Western blot analysis of dCas9- KAT2A-Core fusion protein 
 
241 
FIGURE E-4 Region encompassing the human CHEK1 locus on chromosome 
11 (125,586,692-125,701,556; GRCh38/hg38 assembly) 
 
241 
FIGURE E-5 CRISPR gRNA expression vector 
 
242 
FIGURE E-6 Experimental strategy 243 
FIGURE E-7 Cell proliferation curves of Kasumi-1 cells transduced with 
dCas9-KAT2A-Core fusion and with dCas9 only, together with 




FIGURE E-8 Cell viability of Kasumi-1 cells transduced with dCas9-KAT2A-





FIGURE E-9 ChIP-qPCR analysis of H3K9ac at the CHEK1 and E2F3 
promoters   
 
245 








List of Tables   
Chapter 1     Introduction 
 
TABLE 1.1  
 
Main haematopoietic transcription regulators and their roles 10 
TABLE 1.2  
 
Major erythroid transcriptional regulators 17 
TABLE 1.3 
 
WHO Classification of Acute Myeloid Leukaemia and its subtypes 





Risk stratification of AML according based on its genetics 22 




TABLE 1.6 Phenotypes of epigenetic disruption in haematopoiesis 38 
 
Chapter 2     Materials and Methods  
 
TABLE 2.1  
 
Antibodies used in flow cytometry analysis and cell sorting 62 
TABLE 2.2  
 








Sequences of primers used for qRT-PCR analysis 
 
74 
TABLE 2.5 Buffers used in chromatin immunoprecipitation (ChIP) 
 
77 














Chapter 4     Cellular investigation of KAT2A-complex dependencies 
                     in human AML cell lines  
 
 
Chapter 5    Functional characterisation of the role of KAT2A and 
                   ATAC and SAGA complexes in human AML primary 
                   samples  
 










































Ethylene diamine tetra acetic acid 
ESC 
 
Embryonic stem cells  
FBS 
 
Fetal Bovine Serum 
GFP 
 
Green fluorescent protein  
GMP 
 
Granulocyte monocyte progenitors  
HAT  
 








Haematopoietic stem cells  
KAT 
 
Lysine acetyltransferases  
KAT2A 
 






Megakaryocyte erythrocyte progenitors  







Myelo-lymphoid progenitors  
MNC 
 
Mononuclear cells  
MPP 
 
Multipotent progenitors  
PBS 
 
Phosphate Buffered Saline  
PCAF 
 















Transcription factors  
TSS 
 
Transcriptional start site  




Wild type  
YEATS2  YEATS Domain Containing 2 
 




















































 2  
1.1 Haematopoiesis  
 
 
The process of blood cell development is termed haematopoiesis, deriving from the 
Greek: haima, meaning “blood”, and poiéō, meaning “to make”. The blood is made up 
of an aqueous fraction, the plasma, and of a broad repertoire of cells that carry out 
vital functions. Red blood cells supply oxygen/export carbon dioxide to/from tissues, 
megakaryocytes and their platelet progeny are involved in thrombus formation, and 
immune cells provide protection against pathogens. Specifically, phagocytic 
(macrophages and neutrophils) and lymphoid cells (natural killer T cells) employ 
innate immunity, whereas B and T cells are the players of the acquired immune 
system. In a healthy individual, approximately 300 billion blood cells are produced 
in bone marrow (BM) every day. Abnormalities in the production of blood cells can 
lead to benign complications such as anaemias, as well as severe tumours like 
leukaemia. Thus, the detailed study of haematopoiesis has immediate implications 
with regard to understanding the origin of blood-related diseases, but also to 
decipher the biological mechanisms by which it unfolds, allowing the different blood 
cell types to attain their unique functions.   
 
1.1.1 Haematopoietic stem cells (HSCs) 
 
1.1.1.1 Origin, identification and isolation 
 
Haematopoiesis begins with rare multipotent stem cells - haematopoietic stem cells 
(HSCs), the progeny of which differentiate and proliferate into the fully functioning 
mature cells found in the blood [1]. Our knowledge of blood cells began with studies 
that sought to understand the effects of radiation following the bombings in 
Hiroshima and Nagasaki in 1945. Jacobson and colleagues discovered that mice 
could be protected from lethal irradiation by shielding the animal’s spleen with lead 
[2]. Lorenz et al. then observed the same protective effect by transplanting BM post-
irradiation into mice [3]. These, and subsequent studies demonstrated that the 
transfused BM cells were responsible for protecting the mice from otherwise lethal 
irradiation, pioneering research of the cells of the marrow. The first functional 
description of HSCs, however, came a few years later when Tim and McCulloch 
showed that if BM was taken from one mouse and injected into another, rare and 
specialised cells would migrate to the spleen, divide and form colonies – colony 
forming unit spleen (CFU-S) [4], which contained a mixture of different blood cell 
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types. Incredibly, when the colonies were removed and re-transplanted into another 
animal, new colonies appeared in the spleen of the secondary recipient. Although it 
is now understood that CFU-S were formed not by HSCs, but by myeloid progenitor 
cells [5], this and successive experiments pointed out two key properties of HSCs: (1) 
self-renewal i.e., the ability to perpetuate itself during extended cell divisions; and 
(2) differentiation along a certain cell lineage (s), giving rise to specialised cells. From 
then onwards, HSCs became functionally defined as cells capable of reconstituting 
multi-lineage haematopoiesis in lethally irradiated recipient mice upon 
transplantation. Conversely, progenitor cells are defined by the absence of extended 
self-renewal and restricted lineage differentiation capacity, being lost within 2-3 
weeks post-transplantation [1] 
 
Following HSC identification, subsequent research concentrated on their isolation, 
first from mice and later from humans. Initially, HSCs were isolated based on 
physical properties in CFC assays, and via dye exclusion with reagents such Hoechst 
33342, or by 5-fluorouracil [6–7]. Eventually, with the advent of fluorescence 
activated cell sorting (FACS) and monoclonal antibodies, HSCs and progenitors could 
be purified on the basis of specific combinations of cell surface markers [8]. Mouse 
HSCs were first purified and characterised by Spangrude and colleagues as a lineage-
negative Sca-1+ c-Kit+ (LSK) population [9–10]. Later on, research on candidate 
human HSCs lead do the discovery that cells expressing CD34 marker (CD34+) 
contained primitive progenitor activity in vitro [11] and in vivo [12]. Hence, CD34 was 
the first marker shown to enrich human HSCs and progenitors, and it is been widely 
used since to isolate blood stem cells for clinical purposes such as human 
haematopoietic stem cell transplantation [13].  
 
The knowledge that transplantable HSCs originate progenitors that can be traced in 
in vitro assays, and in vitro progenitors lack multilineage repopulation capacity in an 
in vivo setting, combined with FACS, lead to the eventual isolation and 
characterisation of the downstream HSC progeny [14–15]. As a result, a hierarchical 
arrangement of haematopoiesis was proposed [16–17] (Fig. 1). In this classical 
representation of haematopoietic development, HSCs, at the apex, undergo a series 
stepwise of bifurcations associated with progressive commitment to increasingly 
differentiated progenitors and ultimately to terminally differentiated cell types. HSCs 
initially restrict their self-renewal capacity to generate multipotent progenitors 
(MPPs); MPPs separate into common myeloid progenitors (CMP), or common 
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lymphoid progenitors (CLP). CMPs give rise to either megakaryocyte/ erythrocyte 
progenitors (MEP) or granulocyte/ macrophage progenitors (GMP), whereas CLPs 
originate Natural Killer cells, T and B cells.  
 
 
FIGURE 1.1 Classical model of haematopoiesis. This model is based on the identification 
of common myeloid (CMP) and common lymphoid (CLP) progenitors. 
Accordingly, the first lineage commitment step of HSCs results in a complete 
separation myelopoiesis and lymphopoiesis. Each step is associated with a 
binary lineage branchpoint, resulting in a tree-like model. This representation 
defines a set of progenitors and mature lineages and links them with a discrete 
set of differentiation stages. The mature cell types can be traced back to the 
HSCs through the hierarchical organisation. HSCs, haematopoietic stem cells; 
MPP, multipotent progenitor; CLP, common lymphoid progenitor; CMP, common 
myeloid progenitor; MEP, megakaryocyte/erythrocyte progenitor; GMP, 
granulocyte/macrophage progenitor.  
 
 
Of note, the classical model is based on the idea that the starting HSC pool is a 
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1.1.1.2 HSCs and haematopoiesis throughout life  
 
Haematopoiesis is generally preserved across vertebrate evolution, although not 
entirely identical [18], beginning in the early embryo and continuing throughout life. 
It occurs in distinct temporal waves – primitive and definitive, and at different 
anatomical sites. In humans, the most primitive blood cells arise in the yolk sac 
during embryogenesis and consist mainly of nucleated erythrocytes [19]. In turn, 
definitive haematopoiesis from which HSCs emerge, originates in the aorta-gonad-
mesonephros (AGM) from a specialised endothelium called the haemogenic 
endothelium – a process termed endothelial to haematopoietic transition [19]. After 
their emergence in the AGM region and as gestation progresses, HSCs colonise the 
foetal liver (FL), which remains the location for foetal haematopoiesis, before finally 
lodging in the BM where they reside for the adult life of the organism [20–22]. 
Occasionally, HSCs can also be found in the spleen [22] and lungs [23]. Moreover, 
even though the majority of HSCs resides in the BM, a small percentage is released 
in the peripheral blood with circadian-clock controlled rhythms [24].  
 
During a lifetime, the properties of HSCs differ slightly at each anatomical organ. For 
instance, studies in mice indicate that FL and BM HSCs can efficiently engraft 
lethally irradiated animals, whereas HSCs isolated from the AGM do so less 
efficiently. Moreover, HSCs obtained from the foetus are capable of more robust 
haematopoietic reconstitution of irradiated recipients and have greater proliferative 
and differentiation capacity than those isolated from adult BM [25]. HSCs in the BM 
are mostly dormant, or quiescent. Indeed, quiescence is an important trait of HSCs 
and regulation of the balance between quiescence and cell cycle entry is key for 
healthy haematopoiesis. Other characteristics of HSCs include an autophagy-
dependent, glycolytic metabolism, low mitochondrial activity and tightly controlled 
levels of protein synthesis [26–27].  
 
The distinct properties of HSCs observed across different organs highlight the 
contribution of the microenvironment commonly referred to as ‘niche’ in the support 
of blood stem and progenitor cell development (reviewed in [28]). The niche is a 
complex system where a variety of non-haematopoietic cells are present, and thereby 
can interact with the cells of the blood, to provide cytokines and growth factors, 
oxygen tension and nutrients [29].  
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Two distinct HSC niches have been identified: the endosteal HSC niche, which 
contains osteoblasts as the main supportive cells, and the vascular nice, where HSCs 
associate with the sinusoidal endothelium in the BM and spleen [30]. Interestingly, 
a recent study showed that even within the same niche, HSCs and progenitors do 
not seem to occupy the same locations, indicating spatial segregation of blood linages 
to distinct BM regions [31].  
 
In addition to maintaining steady-state haematopoiesis throughout life, HSCs are 
able to respond to environmental stressors such as infection, and readily produce 
the cell type(s) in need [32].  
 
The diversity in healthy haematopoietic cells is also shaped by factors including age 
and genetic mutation [33]. Both proliferative and differentiation potential of HSCs 
are known to decline with age [7]. Moreover, with age, a tendency for accumulation 
of HSCs that produce preferentially myeloid output has been reported [34]. Besides, 
as we age, healthy blood cells can acquire mutations, a phenomenon termed clonal 
haematopoiesis, and which is present in virtually all adults over 65 years old [35]. 
Importantly, the majority of these mutations arise in HSCs and is associated with an 
increased risk to develop haematological malignancies [36–37].  
 
To perpetuate themselves and to maintain an appropriate blood production 
throughout life, HSCs must then coordinate alternative fates of self-renewal, 
multilineage differentiation, quiescence or apoptosis in response to not only extrinsic 
stimuli (mostly provided by the niche), but also to cell-intrinsic cues.   
 
 
1.1.2 Regulation of haematopoietic fate decisions  
 
First, it is important to clarify the notion of “cell fate decision”, and how it differs 
from “cell lineage potential”. Lineage potential refers to the capacity of HSCs to self-
renew or to differentiate along a certain developmental lineage; it encompasses a 
range of possible fates. Cell fate decision is the actual behaviour or identity the cell 
assumes; the fate of a cell is more restricted than its potential. Understanding how 
a stem cell decides to remain a stem cell or to differentiate towards a certain lineage 
relies on the ability to interrogate not only extrinsic cues (e.g.: cytokine availability), 
but also cell-intrinsic properties, such as transcriptional and epigenetic regulation.  
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1.1.2.1 The role of cytokines  
Hematopoietic cytokines were first identified and purified on the basis of their 
abilities to support in vitro formation of hematopoietic colonies in semisolid media 
[38]. Cytokines are a large family of extracellular ligands that bind to their respective 
receptors to stimulate a specific biological response, acting in concert with 
transcription factors (TFs) and epigenetic regulators. Some affect preferentially HSC 
self-renewal, whereas others stimulate the growth and proliferation of multiple 
haematopoietic lineages. HSC-acting cytokines include Stem cell factor (SCF), 
Thrombopoietin (TPO), Interleukins (Ils) 6 and 11, IL-6 and IL-11 respectively.  
 
1.1.2.2 Transcriptional regulation   
 
TFs bind specific DNA motifs within promoter or enhancer regions and recruit 
epigenetic complexes (detailed in section 1.3) to modify the structure of chromatin 
and activate or repress gene expression. Different classes of TFs have different 
consensus binding motifs. Critical TFs in HSC function are presented in Table 1.1. 
The set of interactions between TFs and their targets is often represented in gene 
regulatory networks that associate with a certain cell fate/identity. Thus, one 
mechanism underpinning cell fate choice is that lineage-determining TFs expressed 
in HSCs and progenitors can instruct fate specification [39]. In other words, a specific 
cell fate is implemented by transcriptional networks that prompt patterns of gene 
expression for a particular lineage – instructive model.  
 
On the other hand, lineage-specific TFs are expressed at low levels in multipotent 
blood progenitors that have not yet committed to a specific fate, so-called 
multilineage priming [40]. This associates with the existence of multiple 
transcriptional possibilities that, at the point of fate decision, can be employed in a 
random way – stochastic model [41–42]. Indeed, stochastic activation of 
transcriptional regulators was shown to drive lineage commitment prior to 
establishment of a lineage-determining programme [43]. According to the stochastic 
hypothesis, commitment occurs independently of extrinsic signals. Instead, it 
predicts that the function of cytokines is to provide survival and proliferation signals 
[44]. Since for the most part, cytokine receptors are required for survival /expansion 
of single lineages, but not lineage commitment events, their instructive roles do not 
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completely diverge with stochasticity in blood differentiation. Both the instructive 
and stochastic models have been proposed as mechanisms that result in the 
upregulation of one lineage program over another. In either case, when cells make a 
decision, they upregulate the expression of the set of genes of their chosen fate [43].  
 
Recent gene expression analysis of single cells (e.g., by single-cell RNA-seq, in vivo 
lineage tracing) provided further insights into the mechanisms governing lineage fate 
trajectories from HSCs, challenging the long-standing classical view of 
haematopoiesis (Fig. 1.1). This is to do with 3 main observations:  
 
(1) Confirmation of HSC lineage biases  
(2) Proof of transcriptional / multilineage priming  
(3) Early lineage segregation from HSCs 
 
(1) Confirmation of HSC lineage biases  
Back in the 1980s, experiments tracking HSC progeny using retroviral inserts 
proposed differences in HSC self-renewal capacity and production of mature 
lineages. This functional heterogeneity prompted the eventual description of lineage-
biased HSCs [45]. More recently, single cell transplantation assays confirmed the 
variability in HSC lineage output and a “bias” towards the generation of a certain 
lineage. Indeed, some HSCs preferentially produce myeloid or lymphoid output [46–
47]. Platelet biased HSCs have also been identified [48]. These observations defy the 
classical haematopoietic model in which HSCs are thought to contribute equally 
towards the production of all mature cell lineages.  
 
(2) Proof of transcriptional / multi-lineage priming  
Single cell profiling of mouse and human HSCs demonstrated transcriptional / 
multi-lineage priming [49–50]. These analyses suggest that transcriptional lineage 
programs are already existent within the HSC compartment, which is in line with 
functional lineage biases in (1).  
 
(3) Early lineage segregation from HSCs 
Unexpected commitment “shortcuts” from HSCs into mature lineages have been 
described [48–51–53]. This is conflicting with the classical, stepwise model of 
haematopoiesis. Whether direct lineage commitment is a rare occurrence, or an 
inherent characteristic of HSC differentiation remains controversial.  
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Altogether, these findings led to the realisation – and now widely accepted view in 
the field – that HSCs represent a heterogenous population, resulting in revised 








FIGURE 1.2 Alternatives models of HSC lineage commitmnet. (A) Combined view of the 
fisrt proposed alternatives to the classical model. Here, the myeloid and 
lymphoid branches remain associated further down in the hierarchy via the 
lymphoid-primed multipotent progenitor (LMPP) population. Upon loss of GM 
potential, LMPPs generate MLP. Megakaryocyte specification can happen 
directly from HSCs. (B) Early-separation model. In this model of haematopoetic 
hierarchy, lineage commitment is specified very early in the HSC/MPP, as 
opposed oligopotent progenitors. (C) Continuum model. Snapshots from single-
cell transcriptomics propose that cells differetiate through continous/ smooth 
tranjectories from a low primed HSC pool. Often portrayed in Conrad 
Waddington’s landscape (compare Fig. 1.1).  
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Regulatory function in HSCs 
 
Ref. 
Erg ETS Essential in haematopoietic development [54] 
Fli1 ETS Essential in haematopoietic development; megakaryopoiesis  [55] 
Foxo3a - Critical for HSC self-renewal [56] 
Gata1 GATA Overexpression restricts HSC self-renewal and induces erythroid differentiation  [57–58] 
Gata2 GATA Essential for HSC formation in the AGM and adult HSC survival; erythropoiesis [59] 
Gata3 GATA Required for HSC cell cycle entry and proliferation; roles in T-cell development   [60] 
Hoxa5 HOX Overexpression decreases HSC pool, inducing erythroid differentiation [61] 
Hoxa9 HOX Overexpression results in expansion of HSC and early progenitors  [62] 
Lyl1 bHLH Essential for maintenance of adult HSCs in the absence of SCL [63] 
Myb - Required for definitive haematopoiesis – HSC self-renewal and multilineage 
differentiation with roles in myelopoiesis and erythropoiesis  
[64] 
Runx1 - Essential for primitive (foetal) haematopoiesis; colocalizes with TFs specific for the 
HSC/MPP compartment  
[65] 
PU.1 ETS Critical in supporting HSC self-renewal, as well as commitment and maturation of 
myeloid and lymphoid lineages  
[66] 
SCL/Tal1 bHLH Essential for the formation, but not maintenance, of adult HSCs [63] 
 11  
1.1.3 Overview of myelopoiesis and erythropoiesis  
 
1.1.3.1 Myelopoiesis and its regulation  
 
Myelopoiesis refers to the origin of myeloid cell types, which are the dominant cellular 
population in the BM. As described earlier, myeloid cells are derived from HSCs, 
which differentiate towards MPPs, followed by CMPs and GMPs that in turn, become 
granulocytes and monocytes. In recent years, additional progenies of GMPs have 
been proposed, namely macrophage and dendritic cell (DC) precursors, and common 
monocyte progenitors [67]. Thus, GMPs are now thought to constitute a pool of cell 
types with a spectrum of differential possible fates, ranging from exclusive 
neutrophil, monocyte or DC progeny. Moreover, the majority of DCs was found to 
derive from an interleukin-7 (IL-7) receptor-positive progenitor, highlighting their 
predominant lymphoid origin [68].  
 
Several molecular mechanisms are involved in myeloid cell lineage specialisation. 
Regulators of central importance to myelopoiesis are growth factors necessary for the 
proliferation and differentiation of progenitors such as granulocyte-colony 
stimulating factor (G-CSF), monocyte-CSF (M-CSF), and GM-CSF that foster 
differentiation towards their name-given lineages. Furthermore, myeloid gene 
expression is regulated by key TFs, including the CCAAT/enhancer-binding proteins 
(C/EBPs), PU.1 and its interacting proteins such as c-Jun and GATA-1), Core binding 
factors (CBFs), c-Myb and Egr-1 [69]. CEBPA in particular, is a major regulator of   
commitment into the myeloid lineage, and its deletion results in a complete block of 
monocyte and neutrophil (but not DCs) specification downstream of the GMP [70]. 
Myeloid cells also express characteristic cell surface markers, that are used for their 
identification and isolation. Early myeloid differentiation antigens include CD13 and 
CD33 [71].  
 
Atypical myelopoiesis is prevalent in hematologic malignancies including multiple 
myeloma, lymphomas and leukaemias [72]. In fact, many of the same TFs that 
regulate normal myeloid differentiation are now known to participate in the 
development of leukaemia. In this respect, acute and chronic myeloid leukaemias 
are considered the most extreme cases of deregulated myelopoiesis, as I will be 
addressing later for AML.  
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Relevant experimental strategies to investigate the myeloid compartment under 
normal or malignant settings include immunologic phenotyping, functional studies 
e.g. gene disruption assays including inducible Cre/loxP recombination systems to 
control gene activity in a site and time-specific manner and cell transcriptomic 
approaches.  
 
1.1.3.2 Erythropoiesis and its regulation 
Red blood cells are the most abundant cell type in the blood and healthy adults 
produce an average of 2 million new red blood cells per second, in a process called 
erythropoiesis [73]. This is adjusted on demand, depending on oxygen levels, growth 
factor availability, iron metabolism or pathological conditions involving blood loss. 
Erythropoiesis occurs in 2 waves, primitive and definitive [74]. Primitive 
erythropoiesis is a single event that occurs during embryonic development, in the 
yolk sac as previously mentioned, and is essential for the survival of the embryo. 
These primitive erythroid cells synthesise embryonic globin forms and are nucleated 
and short-lived [75]. 
Definitive erythropoiesis, in turn, happens first in the FL and later, in postnatal BM 
throughout life, in different stages (Fig. 1.3). Classically, it evolves from HSCs to bi-
potent MEPs, to erythroid progenitors, erythroblast precursors and finally 
erythroblasts. The first, early stage of definitive erythropoiesis, is defined by the 
presence of two immature erythroid-restricted progenitors: the burst-forming unit 
erythroid (BFU-E) and colony-forming unit erythroid (CFU-E). As the name suggests, 
these progenitors have the ability to form colonies in semisolid media. Typically, 
human CFU-E progenitors require 7-10 days to form mature colonies [76]. The 
second stage is that of terminal erythroid differentiation, occurring in erythroblastic 
islands, and which begins with the appearance of immature proerythroblasts that 
undergo 3-4 rounds of cell division. First, they divide to become basophilic 
erythroblasts followed by polychromatic erythroblasts and orthochromatic 
erythroblasts, which expel their nucleus, originating reticulocytes [75].  
These cellular transformations are accompanied by changes in cell surface marker 
expression, cell size, shape, and a progressive increase in adult haemoglobin forms 
such as ß-globin (HBB) [77]. Reticulocytes then migrate from the BM to the 
bloodstream where they finally maturate in erythrocytes. The lack of nucleus and 
their characteristic biconcave shape is important because (1) it permits an increased 
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storage of haemoglobin to be delivered to the body and (2) it allows flexible movement 
through small blood vessels for efficient tissue oxygenation. 
 
 
FIGURE 1.3 Model of definitive erythroid cell differentiation. The early stage of definite 
erythropoiesis gives rise to the burst-forming unit erythroid progenitor (BFU-E) 
and the colony-forming unit erythroid (CFU-E). In the terminal stage, 
proerythroblasts divide originating progressively smaller cells with increased 
chromatin condensation and increased levels of haemoglobin. Reticulocytes lose 
their nucleus and give rise to RBCs or erythrocytes found in blood circulation. 
Expression of commonly used cell surface markers to identify the various stages 
is indicated by the bars. Depicted are EPOR, CD71/transferrin receptor and 
CD235a/ glycophorin A. EPOR is expressed in low levels in HSCs and BFU-Es 
and in high levels in CFU-Es and proerythroblasts. CD71 is responsible for iron 
uptake and expressed mainly in cells synthesising haemoglobin, with its 
expression decreasing during terminal differentiation. CD235a is expressed in 
later stages of erythroid differentiation. Opposing patters of GATA1 and GATA2 
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Erythropoiesis is regulated at multiple levels [78], requiring growth factors as well as 
the concerted action of a plethora of TFs (Table 1.2). Further players include 
hormones (thyroid, androgens, activin/ inhibin), iron metabolism, vitamins (folic acid 
and vitamin B12), as well as epigenetic mechanisms [79]. Here, I will briefly describe 
the role of erythropoietin (EPO), the master erythroid cytokine, and the main 
erythroid transcriptional regulators. 
 
Erythropoietic cytokines – the role of erythropoietin (EPO) 
Erythropoietin (EPO), a glycoprotein hormone, is considered the master cytokine for 
erythropoiesis [80]. Indeed, EPO governs proliferation, differentiation, and activation 
of anti-apoptotic mechanisms during erythroid development [81–82]. Low oxygen 
levels prompt the kidneys to release EPO, which then binds to its receptor (EPOR). 
EPO binding induces receptor conformational changes, triggering downstream 
signalling cascades through JAK2, STAT5, PI3K/AKT, and MAPK pathways [82] for 
activation of transcription. Both EPO and EPOR-null mice die during embryogenesis 
due to severe anaemia, with a complete lack of definitive erythrocytes [80]. More 
specifically, the defect was observed at the CFU-E stage, whereas prior stages 
developed normally, indicating that erythroid lineage commitment is not affected by 
lack of either EPO or EPOR [80]. More recently, however, EPO has been suggested to 
play important functions during earlier stages than previously thought [83]. 
Specifically, it was shown to potentiate erythroid lineage commitment through 
suppression of non-erythroid fate choices at the HSC/MPP compartment [83] 
 
Major erythroid TFs 
 
The GATA TFs  
The GATA family of TFs binds the DNA consensus sequence (A/T)GATA(A/G) [84], 
present in a number of erythroid-affiliated genes such as globins, KLF1 and EPOR. 
Of the 6 members of the GATA family, GATA1, GATA2 and GATA3 are involved in 
haematopoiesis [85]. GATA1 is considered the “master” erythropoietic TF as it 
regulates all aspects of erythroid maturation and function[84]. GATA2 is most highly 
expressed during early blood cell development, and its expression in erythropoiesis 
declines as cells differentiate, whereas GATA1 expression increases (Fig. 1.3). 
Moreover, GATA1 inhibits GATA2 expression during terminal erythroid 
differentiation [84–85]. GATA1 KO mice exhibit embryonic lethality at around day 
E10.5-E11.5 due to severe anaemia [86], and GATA1-null cells do not progress 
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beyond the proerythroblast stage, undergoing apoptosis [87]. GATA2-null animals, 
in turn, exhibit severe anaemia [88]. Despite having similar binding motifs, other 
GATA-binding proteins cannot compensate for the absence of GATA1, highlighting 
its critical function erythroid development [86]. Typically, GATA1 acts in multiprotein 
complexes with specific transcriptional repressor or activator functions, including 
with TAL1/SCL, LMO2, and FOG1 [84–89–91]. Besides, erythroid fate specification 
might centre on the antagonism between GATA1 and PU.1 [75–92]. Higher GATA1 
expression activates MEP molecular programs while acting to repress myeloid 
specification by direct interaction with PU.1, blocking its transcriptional targets [92].  
TAL1/SCL 
TAL1/SCL encodes a basic helix-loop-helix (bHLH) type TF pivotal for both embryonic 
and adult haematopoiesis [90]. TAL1-deficient mice die of severe anaemia between 
embryonic days E9.5-10.5 [90]. Specifically, in erythropoiesis, TAL1 acts at the MEP 
level, supporting MEP survival, downstream of c-KIT, and establishing a positive 
feedback loop in MPP and MEP [89].   
 
KLF1 
Krüppel-like factor 1, KLF1, is essential for the development and survival of 
erythrocytes, with KLF1-deficient mice dying of anaemia at E15.5 [93]. More 
specifically, KLF1 participates at the MEP stage, where it acts in a cross regulatory 
circuit with FLI1, to regulate megakaryocytic vs erythroid commitment decision [93]. 
Additionally, it plays critical functions at the terminal maturation stages, regulating 
the expression of several erythroid-specific genes including globins, heme 
biosynthetic enzymes, cytoskeletal proteins and blood group antigens [94]. KLF1 
expression is restricted to erythroid cells and their precursors.  
 
FOG 
The Friend of GATA (FOG) family of proteins contain a conserved zinc finger (ZF) 
domain that bind GATA TFs, modulating their activity. Mice lacking FOG die of 
anaemia between E10.5 and12.5, although, FOG role in primitive erythropoiesis is 
thought occur by GATA-independent mechanisms [95]. In terminal, erythroid 
maturation, mutated GATA-1, unable to interact with FOG, fails to support erythroid 
development due to deregulated expression of GATA-1 target genes [91].  
 
 
 16  
LMO2  
LMO2 is a LIM domain-containing protein unable to bind DNA itself. It does so by 
interacting with SCL/TAL1 and GATA1, forming complexes that drive erythroid gene 
expression programmes. LMO2 is highly expressed in proerythroblasts, and its 
expression decreases with differentiation. Also, LMO2 interacts with the DNA 
replication complex that drives entry into S phase in erythroid precursors, 
preventing commitment to terminal erythroid maturation [96]. 
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Regulatory function in erythropoiesis  
 
Ref. 
Fli1 ETS Overexpression inhibits erythroid differentiation  [97–98] 
Fog ZF Ablation blocks erythroid maturation at the proerythroblast stage [99] 
Gata1 GATA Overexpression restricts HSC self-renewal and induces to erythroid differentiation  [84] 
Gata2 GATA Expressed during early stages of erythropoiesis [85] 
Klf1  bHLH Severe anaemia; beta globin deficiency  [58–94] 
Lmo2  LIM Bloodless mice-absence of yolk sac haematopoiesis [100] 
PU.1 ETS Interacts with GATA1 during erythroid differentiation, repressing GATA1 mediated 
transcription 
[92] 
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1.2 Acute Myeloid Leukaemia (AML) 
 
1.2.1 AML as a clinical entity  
 
Early descriptions of leukaemia as “globules of pus and mucous” date back 200 
years, and amount to the work of a number of physicians including Alfred Donné, 
John Hughes Bennett and Rudolf Virchow [102].  
 
Acute myeloid leukaemia (AML) is one, very aggressive, type of leukaemia 
characterised by the uncontrolled expansion of immature myeloid cells. These cells 
arrested in differentiation, so called “blasts”, infiltrate BM, peripheral blood and 
occasionally other tissues [103]. Critically, their accumulation in the BM blocks 
normal haematopoiesis, ultimately leading to BM failure. As a consequence, patients 
with AML usually present with bruising and/or bleeding caused by anaemia or 
thrombocytopenia, infections due to low white blood cells, persistent tiredness, and 
weight loss, amongst other symptoms. AML diagnosis is usually established by the 
presence of >20% blasts in the BM or blood. The median age at diagnosis is 67 years 
old. Further diagnosis relies on testing for myeloperoxidase activity (to confirm 
myeloid origin), karyotyping, immunophenotyping, and more recently, on sequencing 
techniques [103–104].  
 
AML is the most common type of leukaemia in adults, with an incidence of 4 per 
100,000 females and 6 per 100,000 males in the UK per year. Furthermore, its 
incidence increases with age to 15 cases per 100,000 at the age of 75 [104]. With 
respect to its aetiology, AML can arise in patients with an underlying, pre-leukaemic 
blood malignancy, or as a consequence of prior therapy. Indeed, non-cancerous 
myeloproliferative neoplasms can transform into AML [105]. Likewise, treatments for 
unrelated malignant diseases involving radiation or cytotoxic drugs can also increase 
the chance of developing AML, referred to as “therapy-related AML”. Other factors 
associated with the likelihood of developing the disease include Down Syndrome and 
being a direct relative of an AML patient. In the majority of cases, however, AML 
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1.2.2 Biology of leukaemia stem-like cells  
 
At the cellular level, AML is a clonal proliferation of myeloid cells in differentiation 
arrest that acquired a survival advantage over their normal counterparts. In the 
1990s, transplantation of AML cells (lineage-negative CD34+ CD38-) into non-obese 
diabetic / severe combined immunodeficiency disease mice (NOD/SCID mice) was 
shown to mimic the leukaemic characteristics observed in human patients [106]. 
Bonnet and Dick then established a hierarchical model of AML where leukaemia-
initiating cells (LICs) present in the CD34+ CD38- fraction, were able to maintain the 
disease long-term in SCID mice [107]. LICs comprised approximately 1 in 1 x 106 
leukemic blasts and possessed two key properties akin to physiological stem cells: 
(1) self-renewal i.e., they gave rise to leukemic engraftment that could be propagated 
for multiple serial transplants and (2) differentiation, i.e. they produced leukaemia 
progeny equivalent to the cellularity in patients, including those cells unable to 
engraft. Thereby, AML leukaemia-initiating cells resembled normal HSCs. In a more 
rigorous definition, cells that meet both criteria (1) and (2) are termed leukaemia-
stem cells (LSCs) [108]. Later studies performed in better engrafting mouse strains 
including NOD SCID Gamma (NSG) mice, expanded the characterisation and 
understanding of self-renewing leukaemia stem cells. Indeed, Taussig and colleagues 
demonstrated that progenitor cells (CD34- CD38+) derived from AML patients were 
able to recapitulate the leukaemic phenotype [109]. This and other observations, 
proved that both HSC-like and progenitor-like immunophenotypes could generate 
AML when transplanted in recipient mice [110–111]. Accordingly, Sarry et al.  
showed that AML leukaemic stem-like cells reside in CD38+ and CD45RA+ 
populations, which upon transplantation recapitulated the primary AML [112]. 
Similarly, the Vyas group demonstrated that, rather than resembling HSCs, the 
majority of leukaemic initiating cells from CD34+ AMLs, have immunophenotype and 
gene expression signatures characteristic of GMP or LMPP-like progenitors [113]. 
Together, this established the notion that most candidate LICs in CD34+ AML are 
progenitor-type cells with underlying dysregulated self-renewal programmes. 
Importantly, the properties and frequency of LICs vary greatly across different AML 
subtypes, emphasising the heterogeneity of the disease. Moreover, they can also 
change during the course of the disease. Indeed, at relapse the frequency of 
leukaemia-stem cells, able to resist chemotherapy, is often higher that it was prior 
treatment [114].  
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1.2.3 AML classification  
 
As alluded to before, AML is heterogeneous, and it is often said that is not one 
disease, but “many diseases”. In fact, there are a number of distinct subgroups, 
which are categorised on the basis of cell morphology, cytogenetics and molecular 
profile. A morphological classification of AML centred on the cytological 
characteristics of leukaemia blasts was in use until the end of the last century. This 
classification by the French American British (FAB) system, consist of 8 subtypes: 
FAB M0-M7 [115]. Presently, the World Health Organisation (WHO) classification 
system, 2016, defines AML as 6 major disease entities: (1) AML with recurrent genetic 
abnormalities; (2) AML with myelodysplasia-related changes; (3) Therapy- related 
neoplasms; (4) AML not otherwise specified; (5) Myeloid sarcoma and (6) Myeloid 
proliferations related to Down syndrome (Table 1.3) [116]. Category (4) incorporates 
elements of the FAB classification. 
 
Table 1.3 WHO Classification of Acute Myeloid Leukaemia and its subtypes (revised  
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1.2.4 Genomic and epigenomic landscape of AML 
 
In recent years, genomic sequencing has significantly advanced knowledge of the 
molecular landscape of AML. Critically, those studies led to the identification of new 
AML mutations, as well as patterns of co-occurrence or exclusivity amongst them. A 
landmark study by The Cancer Genome Atlas (TCGA) Research Network analysed 
the genomes of 200 newly diagnosed AML patients using whole genome and whole 
exome sequencing, RNA sequencing and DNA methylation profiling [117]. The 
authors categorised AML mutated genes into distinct functional categories, being:  
TF gene fusions; NPM1; tumour suppressor genes; myeloid TF genes, members of the 
cohesin complex, spliceosome-genes and two groups of epigenetic modifiers (Fig. 
1.4).  
FIGURE 1.4 Functional categories of mutated genes involved in AML pathogenesis. Nine 
functional categories were identified. Each AML case may have several gene 
mutations in different functional categories. PTPs, protein tyrosine 
phosphatases; MLL PTD, MLL partial tandem duplication. Data from The Cancer 
Genome Atlas (TCGA) Research Network. Adapted from Chen et al. 2013 [117].   
 
A striking observation from this study was that, despite being characterised by lower 
levels of genetic mutations compared to other cancers, a large percentage of AML 
mutations was found in epigenetic regulators (>70% AML cases). Epigenetic 
regulation will be discussed in detail in section 1.3. Moreover, variant-allele 
frequency analysis revealed that >50% of AML cases had a founding clone and 
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subclones, indicating possible clonal evolution during disease progression [117]. 
Mutations with cooperative nature were found to be those in FLT3, DNMT3A and 
NPM1 genes. On the contrary, mutations in TF fusion genes, NPM1, RUNX1, TP53 
and CEBPA had higher mutually exclusivity patterns [117]. Interestingly, roughly 
45% of the patients harbour a normal karyotype at diagnosis. Acquired genetic 
mutations can be identified in approximately 97.3% cases of AML.  
 
More recently, Papaemmanuil and colleagues have profiled the genomes of more than 
1000 AML patients who have undergone treatment. Importantly, they correlated 
newly identified genetic mutations with clinical outcome [118]. This new information 
on AML genetics was used to risk stratify patients, in order to inform the likely 
prognosis by the European Leukemia Net (ELN) (Table 1.4). In particular, AML with 
mutated TP53, RUNX1 and ASXL1 were included in the adverse risk group. About 
60% of AML patients are considered of intermediate risk cytogenetics, and in these 
cases genetic mutations add important prognostic value. As examples, NPM1 alone 
and CEBPA with double mutation are of favourable prognosis, whereas FLT3-ITD 
carry dismal prognosis [118]. 
Table 1.4 Risk stratification of AML according based on its genetics. Adapted from the 
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Additionally, altered chromatin status in AML associates with poor prognosis [119]. 
Notably, non-mutated chromatin regulators also perform critical functions in 
sustaining AML e.g.: DOT1L, BRD4 and LSD1 [120–121], which I will consider in 
more detail further ahead.  
 
Sequencing studies also revealed that many AML patients harboured a population of 
mutated pre-leukaemic HSCs, evident in patients both at diagnosis and remission 
[122]. Further analysis shown that the clonal evolution in AML proceeds through the 
stepwise acquisition of mutations in self-renewing pre-leukaemic HSCs. This led to 
the suggestion that relapse could either happen from leukaemic clonal or sub clonal 
outgrowth but also from further evolution of pre-leukaemia mutated clones. 
Moreover, mutations in pre-leukaemic HSCs were enriched in epigenetic modifiers 
such as TET2 and DNMT3A, underscoring a role for epigenetic dysregulation in 
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1.2.5 AML treatment   
 
As previously mentioned, AML is molecularly heterogeneous, which poses significant 
challenges in terms of its therapy. Patients <60 years of age present curable 
outcomes of ~40% with standard cytotoxic chemotherapy regimens established in 
the 1970s, but elderly patients, unable to tolerate the intensive therapy will 
eventually die of the disease [103]. Remarkably, mainstay treatments for the majority 
of AML subtypes have remained relatively unchanged over the past 30 years. Only 
recently, with the advent of sequencing techniques and identification of new targets, 
novel therapeutics have been developed (Fig. 1.5).  
 
Given the pervasive epigenetic dysregulation in AML (discussed in detail in section 
1.3), therapeutic strategies aimed at modulating epigenetic mechanisms have gained 
a lot of interest in recent years [121–124–125]. The first group of epigenetic 
compounds approved for the treatment of AML was that of DNA hypomethylating 
agents, which include Azacytidine and Decitabine (Fig. 1.5) and act by depleting 
DNA methyltransferase enzymes (explained in section 1.3). Another way to exploit 
epigenetic regulators for therapeutic benefit is by changing the levels of their required 
metabolites. As examples, 2 drugs: Ivosidenib and Enasidenib which inhibit mutant 
isocitrate dehydrogenase (IDH) family of proteins - IDH1 and IDH2, respectively, have 
been approved for the treatment of AML (Fig. 1.5). Both drugs reduce levels of 2-
hydroxygluterate (2-HG), abolishing inappropriate inhibition of Ten-Eleven 
Translocation (TET) enzymes, and ultimately resulting in lower levels of DNA 
methylation with release of differentiation block induced by these mutations.  
 
Targeting epigenetic modifiers that repress differentiation programmes are another 
therapeutic strategy. For instance, pre-clinical studies have shown that inhibition of 
histone demethylase 1 (LSD1) results in LSC differentiation [126], and inhibition of 
histone lysine methyltransferase DOT1-like (DOT1L), reduces leukaemogenic 
potential particularly in MLL-rearranged leukaemias [127]. Bromo and extra terminal 
domain (BET) family of acetyl-lysine recognising proteins are also exciting 
therapeutic targets in AML, specifically for aggressive MLL-fusion leukaemias [121–
124]. For example, BRD4 contains 2 acetyl-reader bromodomains (BD1 and BD2), 
playing a key role in gene transcription elongation. By preventing the BRD4 
interaction with chromatin, BET inhibitors were shown to downregulate genes such 
as BCL2, c-MYC and CDK6, leading to apoptosis and cell cycle arrest of MLL–AF9 
 25  
(murine) and MLL–AF4 (human) leukaemias [124]. Of note, all these targets are not 
mutated in AML; instead, they constitute dependencies that sustain malignant 
transcriptional programmes. Emerging evidence indicates that the immune system 
plays important roles in the efficacy of epigenetic therapies. As such, many of these 
epigenetic agents are being tested in combination with immunotherapy [121]. A 
summary of the main clinical trials assessing combination strategies which include 
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Table 1.5 Combination strategies involving epigenetic therapies in clinical trials. 




A list of currently active clinical trials that involve epigenetic therapies in combination with targeted therapies, 
immunotherapies, and/or other epigenetic therapies for the treatment of AML. alloHSCT, allogeneic hematopoietic 
stem cell transplantation; AURKB, Aurora kinase B; BCL-2, B-cell lymphoma 2; DNMT, DNA methyltransferase; 
FGFR, fibroblast growth factor receptor; Grb2, growth factor receptor bound protein 2; HDAC, histone deacetylase; 
IDH, isocitrate dehydrogenase; IL3, interleukin 3; LSD1, lysine-specific histone demethylase 1; MDM2, mouse double 
minute 2; mTOR, mammalian target of rapamycin; PARP, poly ADP ribose polymerase; PD-1, programmed cell death 
protein 1; PDGFR, platelet-derived growth factor receptor; PD-L1, programmed cell death ligand 1; PLK1, polo-like 
kinase 1; PRMT5, protein arginine N-methyltransferase 5; Shh, Sonic hedgehog; TIM-3, T-cell immunoglobulin and 
mucin-domain containing-3; TLR-3, Toll-like receptor 3; VEGF, vascular endothelial growth factor. 
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1.3 Epigenetics  
 
As discussed in the previous section, epigenetic regulation plays a major role in the 
pathogenesis of AML. But what is epigenetics? In the early 1940s, developmental 
biologist Conrad H Waddington introduced the term “epigenetics” in an attempt to 
explain how gene regulation determines development [128]. He defined epigenetics 
as “the branch of biology which studies the causal interactions between genes and 
their products which bring the phenotype into being” [129]. This definition has 
evolved since then, and nowadays the term epigenetics is broadly used as a synonym 
for chromatin regulation. Indeed, epigenetic regulators are factors capable of 
changing chromatin structure, without altering the underlying DNA sequence, and 
which produce heritable changes in gene expression [130]. It has becoming 
increasingly clear that the action of specific epigenetic regulators, and the crosstalk 
between them, is essential for correct spatial and temporal gene expression.  
 
1.3.1 Epigenetic mechanisms  
 
In eukaryotic cells, genes are embedded in chromatin, which is composed of DNA 
and proteins. The fundamental repetitive unit of chromatin is the nucleosome, 
consisting of 147 base pairs of DNA wrapped around an octamer of core histones: 2 
molecules of H2A, H2B, H3 and H4; the linker histone H1 organises nucleosomes 
into higher-order structures, increasing chromatin compaction [131]. Both histone 
proteins and DNA can be chemically modified by “epigenetic writers” that execute the 
modifications, and readily removed by other types of enzymes, “epigenetic erasers”. 
Furthermore, a collection of different proteins, termed “epigenetic readers” can 
recognise the different varieties of modifications [132]. As referred earlier (Fig 1.5) 
the enzymatic activities of epigenetic modifiers are reversible, rendering them as 
potential therapeutic targets. Epigenetic mechanisms (Fig. 1.6) include covalent 
histone modifications, DNA methylation and nucleosome remodelling by ATP 
hydrolysis. In recent years, microRNAs and long noncoding RNAs, miRNAs and 
lncRNAs, respectively, have also been shown to play a role by targeting certain 
mRNAs for degradation or translation repression [132].  
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FIGURE 1.6 Main epigenetic regulatory mechanisms. DNA, in the nucleus, is wrapped 
around a histone octamer forming the primary functional unit of chromatin, the 
nucleosome. A. DNA methylation is achieved by DNMTs, which are responsible 
for the 5mC mark, associated with transcriptional silencing. TET enzymes 
oxidise 5mC to produce 5hmC, 5fC and 5aC. B. Histone modifications, such as 
acetylation (Ac, in orange), ubiquitination (Ub, in red) and methylation (Me, in 
blue) are instructive marks for both gene transcriptional activation and 
repression. Polycomb complexes PRC1 and PRC2 deposit H2AK119Ub and 
H3K27me3, respectively, both leading to repression of transcription. C. ATP-
dependent chromatin remodelling complexes can re-position or remove 
nucleosomes by ATP hydrolysis. The different families of epigenetic modifiers are 
highlighted. HATs – histone acetyltransferases; HDACs – histone demethylases; 
DUBs – deubiquitinating enzymes; KMTs – lysine histone methyltransferases; 
PRMTs – protein arginine N-methyltransferases; KDMs – lysine methyl 
demethylases. Arrows pointing up next to the group of epigenetic modifiers 
indicate that they promote the given modification, whereas arrows pointing 
down indicate removal.  
 
In general terms, these events all modulate the overall structure of chromatin, 
making it permissive or repressive to the binding of transcriptional machinery. 
Therefore, epigenetic mechanisms are key to the expression of gene programmes, 
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including those relevant in specifying a particular cell type or identity [130]. In this 
section I will describe the different flavours of epigenetic mechanisms. How they 
contribute to haematopoiesis and leukaemia is discussed further below. 
 
Covalent histone modifications 
Post-translational modifications of histones (PTMs) include acetylation, methylation, 
phosphorylation, ubiquitylation and sumoylation [133]. In 1964, Allfrey and 
colleagues demonstrated that histones can be modified by the addition of acetyl and 
methyl groups [134]. Histone acetylation and methylation are the most extensively 
characterised modifications. Acetylation neutralises the charge between histones 
(positive charge) and the DNA backbone (negative charge), promoting open chromatin 
structure and activation of gene expression. Levels of histone acetylation are tailored 
by the activity of 2 classes of enzymes: histone acetyltransferases (HATs), and histone 
deacetylases (HDACs), that respectively transfer and remove acetyl groups to/from 
lysine residues within histones [131]. HATs are also commonly referred to as KATs 
(lysine acetyltransferases). Both HATs and HDACs are generally conserved through 
evolution and are found with multisubunit complexes, with the functions of the 
catalytic subunit being dependent, for the most part, on the interaction with other 
elements present in those complexes [132–133]. For example, certain partner 
subunits contain bromodomains or chromodomains that recognise acetylated and 
methylated histones, respectively. Hence, HATs take advantage of their association 
with other subunits for their recruitment to distinct regions of the genome. HATs can 
be divided into 5 groups based on their structure and catalytic domains. These are: 
GNAT, MYST, p300/CBP, the general TF HATs and the nuclear hormone-related 
HATs. HDACs are also categorised (Class I – Class IV), a classification based on 
sequence and domain similarity [133–135]. Of note, HATs are also capable of 
modifying non-histone substrates [135].  
 
Histone methylation, in turn, occurs by the addition of methyl groups to both lysines 
and arginines, and is catalysed by histone methylases (HMTs) and removed by 
histone demethylases (HDMs). In a similar way to that of HATs and KATs, HMTs and 
HDMs are also commonly named KMTs and KDMs, by convention. While lysines can 
take up to 3 methyl groups – me, me2, me3, arginines can only be mono or 
demethylated [132]. Furthermore, arginine methylation correlates with an open 
chromatin state, whereas lysine histone methylation can be associated with either 
open or close chromatin structure, depending on the specific residues. Methylation 
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of histone H3K4, H3K36, and H3K79 is associated with transcriptional activation, 
while demethylation and trimethylation of H3K9 and H3K27 are associated with 
transcriptional repression.  HMTs also appear in multiprotein complexes and are 
classified in distinct families. Specifically, these enzymes are divided into 3 main 
groups, including 1 class of protein arginine methyltransferases (PRMTs) and 2 
classes of lysine-specific methyltransferases (KMTs), which I consider here in more 
detail. The first class of KMTs contains an evolutionarily conserved SET 
methyltransferase domain (named after Drosophila Su(var)3-9, Enhancer of zeste 
[E(z)] and trithorax (trx)). There are multiple families of SET-domain proteins, as 
examples: the SUV39 family (composed of SUV39H1, SUV339H2 and G9a), the SET-
1 family (including MLL1, MLL2, MLL3, MLL4, and SET1), the SET-2 family 
(including NSD1, NSD2, NSD3, HYPB and ASHI), the RIZ (containing PRDM1 and 
PRDM2), SMYD (SMYD1, SMYD3) and the SUV4-20 (SUV4-20H1 and SUV4-20H2) 
families [136]. The second class of KMTs, is represented by a single protein, DOT1L, 
the only known histone KMT without a SET domain [136]. DOT1L is the only enzyme 
mediating the mono-, di-, or trimethylation of histone H3 at lysine residue 79 
(H3K79). In turn, several methyltransferases show specificity for H3K9, including 
SUV39-H1/2, G9A, PRDMs, SETDB1 and SETDB2. Amongst these, SETDB1 is the 
only one catalysing all three forms of methylation (mono-, di-, and tri-). SETD2 and 
NSD2 deposit H3K36me [136]. In turn, MLL1 and MLL2 catalyse H3K4me. In 
addition to its transcriptional activating functions through H3K4me activity, and by 
the recruitment of HATs including MOF and CBP [137], the MLLs can also repress 
target genes via recruitment of HDACs proteins and Polycomb as discussed below. 
 
The PcG genes encode chromatin-associated proteins that assemble in 2 complexes 
- the Polycomb Repressive Complex 1 and 2, PRC1 and PRC2, respectively [138]. 
Both PRC1 and PRC2 activities involve repressive histone marks. PRC2 is responsible 
for H3K27 di- and trimethylation (H3K27me2 and H3K27me3). Its catalytic activity 
is mediated by two mutually exclusive KMTs, EZH1 and EZH2 [138–139]. Moreover, 
the complex contains two other elements, EED and SUZ12. In turn, PRC1 acts to 
stabilise H3K27m3 and, monoubiquitinates histone H2A on lysine 119 
(H2AK119ub1), resulting in chromatin compaction [139]. PRC1 core components 
include BMI1, RING1A/B, MEL18, RAE28 and at least one of the five Polycomb 
chromobox proteins (CBX2, 4, 6, 7, and 8), which are readers of H3K27me3 through 
their chromodomain [139]. 
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Demethylases also present specificity for different residues. Specific H3K4 
demethylases are represented by LSD1 (KDM1A) and LSD2 (KDM2A) or by the JARID 
enzymes (JARID1A, JARID1B, JARID1C and JARID1D). H3K9me erasers include 
PHF8 and JHDM2 and JHDM3 families, the later also removing H3K36me. Lastly, 
H3K27me demethylases are UTX, UTY, JMJD3 and PHF8 [136].  
 
Preferentially, histone modifications occur at the N-termini, so-called histone tails, 
but they can also be deposited in the globular domain, at the DNA binding surface 
of the nucleosomes [130]. The association between histone PTMs and transcriptional 
activity resulted in the “histone code” hypothesis, or in other words, the combination 
of post-translational marks on histones [130].  
 
DNA methylation  
DNA methylation consists in the stable addition of a methyl group to the 5C position 
of cytosines - 5-methylcytosine (5-mC), within the context of CpG dinucleotides. CpG 
dinucleotide enrichment occurs mainly in gene promoters and these CpG-rich 
locations are normally referred to as “CpG islands”. The presence of methyl groups 
in DNA results in closed chromatin structure and transcriptional silencing [140]. 
Accordingly, DNA methylation is essential during normal development, and regulates 
key gene silencing processes such as X-chromosome inactivation and genomic 
imprinting [141]. Mammalian cells balance levels of methylation via the positive 
action of DNA methyltransferases (DNMTs), which include DNMT1 and DNMT3A/B, 
and of negative regulators - the TET family of dehydrogenases, TET-1, -2 and -3 
[141].  
 
DNMT1 targets hemimethylated DNA at the replication foci during S phase of the cell 
cycle, thus maintaining existing patterns of methylation. On the other hand, 
DNMT3A and DNMT3B establish de novo methylation on unmethylated DNA regions 
during development and differentiation [142–143]. TET proteins, in turn, are 
responsible for the conversion of 5-mC into 5-hydroxymethylcytosine (5-hmC), 
preventing the binding of DNMTs to DNA, thereby keeping chromatin in an open, 
permissive way. Contrasting with 5-mC which is kept during cell division by DNMT1, 
5-hmC is lost during DNA replication [142–144]. As mentioned in 1.2, IDH1 and 
IDH2 also influence DNA methylation, although in an indirect way. These enzymes 
produce alpha ketoglutarate (a-KG), a key intermediary of the citric acid cycle, 
essential for cellular metabolism. TET function requires a-KG, catalysed by IDHs. 
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Mutations in IDH1/2 alter the enzymatic activity of these proteins, converting a-KG 
to 2-HG, which cannot be used by TET proteins leading to widespread DNA 
hypermethylation [144].  
 
ATP-dependent nucleosome remodelling complexes  
A number of ATP-dependent enzymes act to remodel nucleosome structure - their 
assembly, spacing or removal - along the DNA to free or block access to TFs and 
polymerases. These remodelling complexes include the imitation switch-containing 
(ISWI), which mediates nucleosome slinging, the switch/sucrose non-fermentable 
(SWI/SNF), containing BRG and BRM ATPases capable or removing histones from 
DNA, and the nucleosome remodelling and deacetylase (NuRD). Each has a unique 
ATPase(s) and reader domain (sant-, bromo- and chromo-domain, respectively) able 
to interact with specific chromatin substrates [143].  
 
 
1.3.2 Epigenetic regulation of haematopoiesis  
 
The epigenetic mechanisms described above shape blood biology at various levels: 
HSC quiescence vs self-renewal, lineage fate specification, aging and transformation 
into malignancy (reviewed in [142–145–146]). Studies in mouse models have provided 
valuable knowledge on the physiological role of epigenetic regulators, ranging from 
gene KOs to the generation of conditional KO alleles due to the early lethality 
resultant from ablation of many of these proteins. In this section I will review what 
is currently known about the role of individual epigenetic regulators of normal 
haematopoiesis and their associations with AML, which I summarised in Table 1.6.  
 
 
1.3.2.1 Histone acetyltransferases / deacetylases  
 
During haematopoiesis, the expression of genes involved in HSC self-renewal and  
lineage-differentiation is regulated by the recruitment of HAT and HDAC complexes 
to their promoters. For instance, in erythropoiesis GATA1 directly recruits CBP to 
the ß-globin locus, resulting in acetylation of H3 and H4 and globin gene expression 
[147]. Of note, GATA1 itself is also acetylated by CBP. The CBP/p300 family of HATs 
is also implicated in HSC self-renewal and differentiation by regulating c-Myb-
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dependent gene expression [148]. However, whereas removal of Cbp from HSCs 
results in differentiation defects, p300-null HSCs are only mildly impaired in their 
differentiation [149] Furthermore, Cbp+/- mice show a haematopoietic defect, 
whereas p300+/- are normal, suggesting different modes of action [149]. MOZ (MYST 
family) has been demonstrated to regulate HSC maintenance, proliferation and 
lineage commitment [150]. Specifically, Moz deficient mice are embryonic lethal and 
exhibit defects in erythroid and myeloid lineage maturation [151]. In line with its 
critical role in normal HSC function, MOZ-fusion proteins are a common feature in 
leukaemia [151] e.g.: MOZ-CBP, MOZ-p300 are generated by chromosomal 
translocations in AML. The interaction of HAT p300 with c-Myb is required for 
induction of AML, specifically, for the ability of MLL-AF9 fusion to confer self-renewal 
properties on myeloid progenitors [152]. Without this interaction, fusion proteins are 
unable to impose a differentiation block, causing, instead, terminal differentiation 
[153]. p300 can also enhance the self-renewal ability of LSCs through acetylating 
AML-1ETO, activating its target genes [149]. Recently, MOF or KAT8, was shown to 
be involved erythroid cell fate commitment through its H4K16ac activity [154]. 
Moreover, MOF interacts with MLL1 to maintain H4K16ac, activating gene 
transcription [154]. 
 
Unsurprisingly, HDCAs are also implicated in normal and malignant HSC function. 
In agreement, combined deletion of HDAC1 and HDAC2 results in severe HSC 
defects, causing anaemia and cytopenia [155]. Finally, SIRT1 (HDAC belonging to 




1.3.2.2 Histone lysine (K) methyltransferases / demethylases 
MLL has critical roles in the proliferation and lineage specification of haematopoietic 
progenitors during embryogenesis by maintaining (but not initiating) expression of 
HOX genes [156]. Homozygous deletion of Mll1 results in embryonic lethality at 
E10.5-E12.5. In turn, Mll1 heterozygous embryos exhibit defects in foetal 
haematopoiesis with reduced numbers of HSCs [157]. Chromosomal translocations 
involving the MLL gene and a number of different fusion partners, including AF4, 
AF9, ENL, AF10, ELL and AF6, are a recurrent theme in AML pathogenesis [145–
157]. These oncogenic fusions aberrantly regulate MLL- target genes, such as HOXA 
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and MEIS1, modifying genetic programmes of proliferation and differentiation [157]. 
Importantly, partners of MLL fusions were reported to be found in distinct chromatin 
complexes. The most common fusion partners, AF9 and AF4, are present in the super 
elongation complex (SEC), and in the DOT1L complex (DOTCOM), in the case of AF9. 
Interactions with different chromatin complexes, can occur via specific domains of 
MLL itself (containing a bromodomain, PHD domain and a SET domain), or of its 
fusion partners. For example, the AF9 YEATS domain has been reported to be 
critically involved in the recruitment of DOT1L to chromatin by MLL-AF9, and to 
H3K79me-mediated transcriptional control [158]. MLL-driven AML types have a poor 
prognosis and are thus classified as high-risk AML. Moreover, about 3-5% of de novo 
AML patients display partial tandem duplication of the MLL gene - MLLPTD, also 
acting as an oncogene by upregulating the expression of HOX genes, preventing cell 
differentiation and apoptosis. MLLPTD AML often display mutations in other 
epigenetic regulators, such as TET2 (16%), EZH2 (10%), IDH1/2 (31%), and ASXL1 
(6%). Moreover, a typical feature of MLLPTD is the absence of NPM1 mutations, and 
frequent co-occurrence with RUNX1 (23%) and STAG2 mutations (16%) [145].  
Dot1l KO mice are embryonic lethal between E10.5-13.5 due to a selective defect in 
erythroid differentiation [159]. In agreement, Dot1L is required for GATA2 activation 
(and repression of PU.1) during erythropoiesis [159]. Conditional deletion, however, 
results in reduction in both red and white blood cells, without complete abrogation 
of multilineage haematopoiesis. This suggests that DOT1L is not an absolute 
requirement for adult haematopoiesis [127]. Though not mutated, DOT1L has also 
been shown to play critical roles in leukaemia, in particular driven by MLL-fusions 
as mentioned above [160]. Indeed, DOT1L can be aberrantly recruited, directly or 
indirectly, to target genes of MLL fusion proteins such as HOXA and MEIS1, 
increasing expression of leukaemic programmes [161]. As referred to in section 1.2, 
inhibitors of DOT1L are in preclinical investigations, and were shown to reduce 
H3K79 methylation, together with expression of MLL-fusion target genes [121].  
 
Polycomb complexes are also involved in HSC functionality and leukaemogenesis. 
KO mice of PRC1 components Bmi1 and Rae28 are lethal in the neonatal period 
highlighting a requirement in adult haematopoiesis. Furthermore, mutations in both 
Bmi1 and Rae28 decrease HSC self-renewal. Specifically, deletion of Bmi1 results in 
cell cycle arrest and apoptosis, as well as de-repression of B-cell differentiation 
factors EBF1 and PAX5 [162]. KO of Mel18, in turn, increases HSC quiescence [162]. 
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Interestingly, CBX proteins play contrasting roles in HSC function - CBX8 is 
upregulated to promote differentiation, whereas CBX7 is highly expressed in HSCs, 
inducing HSC renewal and repressing lineage-differentiation genes [163]. Mice 
lacking PRC2 components EZH2, SUZ12 or EED are all embryonic lethal. Instead, 
heterozygous depletion of any of these elements enhances haematopoietic stem and 
progenitor cell activity [162]. In addition, PRC2- EZH2 can interact with all 3 DNMTs, 
influencing sites for DNA methylation [139]. PRC2 complex is also involved in 
erythropoiesis, with mice lacking EED presenting impaired erythroid differentiation 
[162], as well as lymphopoiesis, in which SUZ12 is essential for T and B cell 
maturation [163].  
 
In AML, CBX7 binds SETDB1 and its inhibition induces differentiation of leukaemic 
cells [163]. In the context of MLL fusions, CBX8 recruits histone acetyl transferase 
Tip60, thereby promoting fusion target gene expression, instead of mediating 
transcriptional repression [163]. EZH2 loss-of-function mutations have been 
described in myeloid malignancies, including AML, where it has been shown as a 
requirement for the maintenance of multiple genotypes [164]. Moreover, in the same 
study the authors demonstrated stage-specific roles of Ezh2, which functions as a 
tumour suppressor in AML induction, and as an oncogene once the disease is 
established [164]. In MLL-AF9 AML, EED is necessary for leukaemia initiation and 
progression [161].  
 
Histone demethylase LSD1 (KDM1A) is a key regulator of leukaemic stem-cell 
potential, and it acts at genomic loci bound by MLL-AF9, favouring its leukaemogenic 
programmes, thereby preventing cell differentiation and apoptosis [165]. As 
mentioned in section 1.2, LSD1 has emerged as a potential therapeutic target in 
AML, with small-molecule inhibitors showing efficacy in AML cells bearing different 
MLL rearrangements but also AML-1ET0 and PML-RARA [120]. LSD1 main function 
is demethylation of H3K4me1/2 and H3K9me1/2, which result in gene repression 
and activation, respectively. Reversing LSD1 activities through demethylation of 
H3K4 or H3K9, at the required anti-leukaemic doses, however, was shown to cause 
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1.3.2.3 DNA Methylation: the roles of DNMTs and TET proteins  
 
Levels of DNA methylation are highly locus dependent during haematopoiesis [167]. 
For instance, during commitment to a specific lineage, genes that function in keeping 
an undifferentiated status are hypermethylated, and thus repressed. Thus, when 
HSCs differentiate into a lineage commitment state, the methylation of stemness 
genes increases, while the methylation of lineage specific genes decreases [168]. 
PU.1, for example, is highly expressed in HSCs and mature B-cells but is 
hypermethylated in CD4+ and CD8+ T-cells [168]. The process of erythrocyte 
differentiation is also well characterised by DNA methylation changes. Indeed, 
studies of the globin gene locus revealed that these genes are expressed in a 
sequential manner, such that during erythrocyte maturation embryonic or foetal 
genes are silenced, and adult globin genes are turned on [74]. A recent study by Izzo 
et al. proposed that lineage-determining TFs might be particularly susceptible to 
global DNA methylation changes. Moreover, they show that erythroid-related TFs 
have higher CpG content in their binding motifs than myelomonocytic-associated 
TFs [166].  
 
All 3 DNMTs contribute to control of haematopoietic function, although with different 
effects. Specifically, Broke and colleagues have shown that constitutive DNA 
methylation is essential for HSC self-renewal activity [169]. Indeed, in a DNMT1 
conditional knockout (cKO), DNMT1-defficient HSCs fail to self-renew and show an 
aberrant increase in myeloid cell output [169]. On the contrary, loss of DNMT3A was 
shown to promote self-renewal, resulting in expansion of the HSC population [170]. 
Moreover, the increase in HSC function is most apparent in serial transplantation 
assays, in which DNMT3A-null HSCs are able to sustain at least 12 rounds of 
transplantation, whereas WT HSCs undergo just 4 rounds [171]. DNMT3B cKO 
resembles the DNMT3A phenotype, but with milder consequences. Finally, combined 
DNMT3A and DNMT3B perturbation also increases HSC number and results in a 
more severe differentiation block [170].  
 
DNA methylation is also critical in pathogenesis of AML, as mentioned in the previous 
section. Specifically, mutations in DNMT3A associate with hypomethylation, whereas 
mutations in TET2 and IDH1/2 result in DNA hypermethylation. Indeed, in AML, 
DNMT3A mutations are prevalent (17-34%), with the most common alteration being 
a missense mutation at arginine R882. This impairs the function of DNMT3A by 
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altering the flanking sequence preferences for DNA binding [172]. DNMT3A 
mutations are an early event in AML, and mutations in additional genes such as 
NPM1 or FLT3 may lead to malignant transformation of HSCs in leukaemic cells 
[172]. A recent study by Gebhard et al. proposes a division of AML into 2 subgroups 
based on methylation profile. The first group associates with PcG-mediated 
repression and is prevalent across AML samples. Instead, the second group is 
characterised by a more heterogenous behaviour and comprises both hypo and 
hypermethylated samples [173].  
  
TET2 is highly expressed in HSCs [174]. Functionally, loss of TET2 in HSCs results 
in increased self-renewal capacity with upregulation of MEIS1 and EVI1 stemness 
genes as well as increased number of GMP progenitor cells [174]. TET1 was first 
identified as a fusion partner of MLL in the context of AML [174]. Interestingly, 
despite having opposing functions individually, when DNMT3A and TET2 mutations 
are present simultaneously, they accelerate leukaemic transformation [172–175].  
 
 
1.3.2.4 ATP-dependent nucleosome remodelling complexes  
 
The human SWI/SNF complex was initially identified as an activator of ß-globin 
transcription by interacting with erythroid-affiliated TF KLF1 [98]. Roles for the 
SWI/SNF complex in myeloid and lymphoid lineages have also been demonstrated, 
with BAF155 subunit being a requirement in T cells [176]. Moreover, deletion of 
ARID1A, a core component of the same complex affects both myeloid and lymphoid 
lineage development. SMARCA4 is required for AML cell growth and survival by 
maintaining chromatin accessibility at essential enhancers [176]. NuRD ATPase 
Mi2b is required for HSC self-renewal [145]. 
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Table 1.6 Phenotypes of epigenetic disruption in haematopoiesis.  
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1.4 KAT2A 
 
General control non-depressible 5 (Gcn5) or Kat2a was the first HAT identified.  
Brownell and Allis discovered a catalytically active HAT subunit, p55, in 
Tetrahymena thermophila, later shown to be homologous to Gcn5 in yeast [177]. This 
finding linked, for the first time, histone acetylation to transcription. Belonging to 
the GNAT family, Kat2a acetylates preferentially H3K9 and to a lesser extent H3K14 
[178]. Kat2a acetylation activity was shown to occur post RNA Polymerase II 
recruitment to target promoters, indicating that it is not an absolute requirement for 
initiation of gene expression. Instead, it is involved in stabilising gene expression 
[179]. In addition to catalysing acetylation through its HAT domain, KAT2A contains 
a bromodomain, which makes it able to also recognise and be recruited to – 
acetylated chromatin sites [178]. More recently, Kat2a was shown to catalyse another 
histone lysine modification – succinylation, which also associates with active 
transcription [180].  
 
1.4.1 KAT2A roles in development 
Kat2a has a highly related paralogue in vertebrates: Kat2b/Pcaf [181]. However, 
Kat2a and Kat2b, have a largely mutually exclusive pattern of expression. Whereas 
Kat2a in mainly expressed in haematopoiesis and neural tissue, Kat2b dominates in 
skeletal muscle [181–182]. Kat2a plays essential roles in development along the 
evolutionary scale. It is essential for metamorphosis and oogenesis in D. 
melanogaster [183]. In the developing mouse embryo, Kat2a is ubiquitously 
expressed between E7.5 and E9.0, with the exception of heart and allantois, and its 
expression decreases after E16.5 [182], which could suggest reduced contribution in 
terminal differentiation. In turn, Kat2b is minimally expressed at early stages of 
development, and upregulated in adult tissues, particularly in the heart and skeletal 
muscle [182]. In line with this, Kat2a, but not Kat2b, is essential for mammalian 
embryonic development. Kat2a null mice die at E10.5, with extensive mesodermal 
apoptosis; embryos also display defects in notochord, somites, and in neural tube 
formation [182–184]. Kat2b null mice develop normally, but double Kat2a/Kat2b 
mutants have a more severe phenotype than single Kat2a null animals, and die 
earlier at E7.5, suggesting some functional redundancy [181]. Redundancy between 
the 2 paralogs has also been observed in zebrafish, where combined perturbation of 
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Kat2a and Kat2b leads to more severe heart and fin developmental defects than 
single gene loss [185].  
 
In the context of stem cells, Kat2a is not an absolute requirement for maintenance 
of pluripotent mouse embryonic stem cells (ESCs) [186]. However, it stabilises 
pluripotency gene regulatory networks [187] and allows progression of 
reprogramming in induced pluripotent stem (iPS) cells [188]. Additionally, Kat2a is 
required for cell survival and correct lineage specification and differentiation in 
embryoid bodies, through regulation of FGF signalling [189]. Kat2a acts as a co-
factor to Myc family proteins, namely c- and N-Myc, both of which play key roles in 
embryogenesis as well as in maintenance of pluripotency [190–191]. Furthermore, 
Kat2a acetylates Myc, promoting its stability [192], and is essential for activation of 
Myc target genes through histone acetylation [193]. Proliferation of neural stem and 
progenitor cells requires Kat2a, in which it phenocopies the role of N-Myc [194]. 
KAT2A has also been shown to regulate osteogenic differentiation of periodontal stem 
cells through inhibition of the Wnt/ ß-catenin pathway by DKK1 [195]. In more 
detail, KAT2A mediates H3K9/K14ac of DKK1 promoter, activating its expression 
[195]. 
 
In normal haematopoietic development, Kat2a has been implicated in the 
development of lymphoid blood lineages, but, interestingly, not in HSCs [196–197]. 
Specifically, Kat2a participates in maturation of B [198] and T cells [199], as well as 
in differentiation of invariant natural killer T (iNKT) cells  [200]. Kat2a functions in 
B and T cell development involve promoter histone acetylation. On the other hand, 
it modulates iNKT cell differentiation through activation of the transcription factor 
Egr2 via non-histone protein acetylation. Finally, contrary to the effect on Egr2, 
Kat2a-mediated acetylation of Cebpa, represses its transcriptional activity and 
impedes progression of terminal granulocytic differentiation [196].  
 
1.4.2 KAT2A contributions to cancer  
High KAT2A expression associates with bad prognosis in Breast Cancer [201–202], 
Non-Small Cell Lung Carcinoma [203–204] and Colon Cancer [205]namely through 
histone acetylation-mediated co-activation of E2F and MYC transcriptional targets 
to maintain cell proliferation and survival (Fig. 1.7A). In Melanoma, increased KAT2A 
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stability by WDHD1 leads to enhanced H3K9 and H3K56ac levels [206]. Increased 
expression of KAT2A also associates with poor survival in Renal Cell Carcinoma (Fig. 
1.7B), but the mechanism has not been elucidated. In contrast, high levels of KAT2A 
confer a survival advantage in Pancreatic Adenocarcinoma (Fig. 1.7C), and, to a 
lesser extent, in low grade Glioma (Cox coefficient = -0.167, FDR=0.125), suggesting 
that KAT2A may act in an oncogene-like, as well as in a tumour suppressor-like 
manner. Interestingly, KAT2A succinylation activity has recently been linked to 
tumour maintenance in Pancreatic Adenocarcinoma cell lines [207] (Fig. 1.7A). This 
raises the possibility that KAT2A may have cancer stage-specific roles, as shown for 
other epigenetic regulators [164], although mechanistic data in support of this 
hypothesis is currently lacking. Significantly, no recurrent KAT2A mutations have 
been described in cancer, suggesting that it is co-opted by tumour cells at an 
epigenetic level for establishment and/or maintenance of tumorigenic programs. The 
lack of mutations could indeed reflect conflicting roles of KAT2A loss or over-
expression at different stages of cancer progression, with no sustained selective 
advantage. This is contrast with disease-specific effects, which would more likely 
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FIGURE 1.7 KAT2A participates in cancer biology with oncogene-like and tumour-
suppressor roles. A. Described mechanisms of participation of KAT2A in 
different malignancies. B. KAT2A as an oncogene: Kaplan-Meier survival curves 
for Renal Clear Cell Carcinoma patients with high (25%) and low (25%) levels of 
KAT2A expression; log-rank analysis, p-value = 8.45e-11. C. KAT2A as a 
candidate tumour suppressor: survival curves for Pancreatic Adenocarcinoma 
patients with high (25%) and low (25%) levels of KAT2A expression; log-rank 
analysis, p-value = 0.025. Data in B and C were retrieved from OncoLnc 
(oncolnc.org; as of August 2020), a tool that links The Cancer Genomics Atlas 
(TCGA) survival data to mRNA, miRNA, or lncRNAs expression. Despite KAT2A 
requirements in individual cancers, including AML, KAT2A levels do not 
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1.5 SAGA and ATAC – KAT2A chromatin complexes 
 
Both KAT2A-containing complexes, respectively Spt-Ada-Gcn5-Acetyltransferase 
(SAGA) and Ada-Two-A-Containing (ATAC) (Fig. 1.8) are key to its efficient lysine 
acetylation activity [208]. SAGA is evolutionary conserved from yeast to human [209–
210], whereas ATAC is a smaller complex characteristic of multicellular organisms, 
first associated with chromatin functions in Drosophila [211]. Structural and 
functional organization of SAGA and ATAC complexes in model organisms has been 
reviewed in [209–210–212–213]. Herein, I will consider them briefly and include 
information from recent structural studies of the yeast SAGA core [214–215]. I will 
also present a timeline of relevant discoveries related to KAT2A and its complexes so 
far (Fig. 1.8). 
 
FIGURE 1.8 Schematic representation of the human SAGA (left) and ATAC (right) 
KAT2A-containing complexes. SAGA (left) is organized into distinct 
structural and functional modules. Subunits belonging to each module are 
coloured similarly. The KAT2A-containing histone acetyltransferase (HAT) 
module is depicted in orange and shared with ATAC (right), with exception of 
TADA2B, which is replaced by TADA2A in ATAC. The histone de-ubiquitinase 
(DUB) module is shown in red; the Core module in turquoise. TF-binding 
module, TRRAP, is shown in yellow. Splicing module is depicted in purple. 
TATA-binding protein (TBP), in grey, is not part of the complex architecture 
but it associates with SUPT3H to recruit SAGA to TATA box and facilitate 
transcription. Apart from the HAT domain, ATAC subunits do not have a 
modular organization.  
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1.5.1 SAGA complex  
 
Following the discovery of SAGA multimodular complex [213] (Fig. 1.9), great effort 
has been put in unveiling its molecular architecture. It is now well established that 
mammalian SAGA contains 20 subunits distributed into 5 functionally distinct 
modules, a structure highly conserved from yeast to human [178–209]. The HAT 
consists of: KAT2A (or the mutually exclusive KAT2B), SGF29, TADA3 and a complex-
specific TADA2 variant: TADA2B in SAGA, and TADA2A in ATAC. SGF29 is a tandem 
TUDOR domain protein that recruits KAT2A activity to active promoters marked by 
H3K4 tri or di-methylation [216]. TADA3, is a transcriptional activator adaptor 
required for transcriptional activity [212]. TADA2 variants are ZF proteins that can 
bind double-stranded DNA [212–217].  The central Core of SAGA is formed of TADA1, 
suppressor of Ty (SPT) elements, SUPT3H, SUPT7L and SUPT20H, and of TATA-
binding protein associated factors (TAFs) - TAF5L, TAF6L, TAF9, TAF10 and TAF12 
[209–212–218]. TAF5L and TAF6L are SAGA-specific, whilst the other TAFs are 
shared with TFIID complex, the RNA Polymerase II (PolII) General Transcription 
Factor.  
 
As previously mentioned, the structure of the yeast SAGA Core has been recently 
deciphered [214] (Fig. 1.9), revealing an octamer-like fold organization consisting of 
Taf6l-Taf9, Taf12-Ada1 (TADA1 orthologue), and Taf10-Spt7 (SUPT7L orthologue) 
pairs, each contributing with a Histone-Fold (HF) domain [214]. Spt3 (SUPT3H 
orthologue) contributes with 2HF domains and assumes a free conformation key to 
binding of SAGA to TATA-binding protein (TBP) [215]. The histone octamer connects 
to the remaining Core via Taf5l [214–215]. SAGA includes a large transcription factor 
interaction module, TRRAP, originally identified as cofactor of c-Myc and E2F 
proteins [219]. TRRAP is also found in NuA4/TIP60 HAT complexes [220] and in the 
ATP-dependent chromatin remodelling p400 complex [221], with possible complex-
unique as well as complex-shared or redundant functions. SAGA also contains a 
Splicing module composed of SF3B3 and SF3B5, which is only observed in 
multicellular organisms [222–223]. SF3B3 is a component of the splicing factor SF3B 
essential for spliceosome assembly, and links SAGA to the general splicing 
machinery [223–224]. Finally, SAGA comprises a lysine de-ubiquitination (DUB) 
module, catalysed by USP22, which targets H2B and H2A as well as non-histone 
proteins [225–226]. All 4 members of the DUB module – USP22, ATXN7L3, ATXN7 
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and ENY2 – are needed for full deubiquitinating activity [227–228]. ENY2 participates 
in another chromatin complex, TREX-2, involved in mRNA nuclear export [229]. In 
yeast, SAGA enzymatic modules HAT and DUB, associate with the central Core in a 
flexible way [214], which may be suggestive of functional independence. Indeed, 
previous studies showed that loss of DUB components does not impair SAGA 
complex integrity or HAT activity [230]. Additionally, HAT and DUB can exist as 
separate entities [231–233], supporting the notion of alternative HAT and DUB 
SAGA-independent roles.  
 
1.5.2 ATAC complex  
 
KAT2A was found to integrate a second epigenetic complex, ATAC, originally purified 
in human HeLa and HEK293T cell lines [234] (Fig. 1.9).  ATAC shares three subunits 
with the SAGA, all components of the HAT module: KAT2A, TADA3 and SGF29 [212]. 
Furthermore, ATAC structure includes: YEATS2, a H3K27ac reader [235], which 
allows for integration of additional transcription activation signals; DR1/NC2b, also 
present in the NC2 complex, which heterodimerizes with YEATS2 to interact with 
TBP; ZZZ3, a ZF protein that specifically binds H3 tails [236], and WDR5, shared 
with the MLL methyltransferase complexes [237], thus potentially important in 
establishing a crosstalk between H3K4me and H3K9ac chromatin marks, which 
complements or extends the roles of SGF29 double TUDOR domain. Moreover, Wdr5 
and Kat2a are bound by the WNT-interacting protein Pygo2, which brings together 
Mll2-containing and Kat2a-containing complexes to activate expression of WNT 
targets, including Myc in mammary epithelial cells [238]. Within the context of MLL 
complexes, WDR5 was identified as a candidate therapeutic target in CEBPA N-
terminal leukaemia [239] but its functions within ATAC, particularly in the context 
of cancer, including leukaemia, remain poorly understood. In an interesting 
additional link, two long non-coding RNAs were shown to promote gastric cancer 
through scaffolding of KAT2A and WDR5 at a subset of promoters and activation of 
gene expression [240–241]. The remaining ATAC components are MBIP, a MAP3K 
regulator exclusive to mammalian cell complexes; and a second HAT activity – KAT14 
[242]. YEATS2, MBIP and KAT14 are required for complex integrity [242]. In 
mammalian cells, ATAC acetylates both H3 and H4, preferentially through KAT2A 
and KAT14 respective activities  [242], whereas in Drosophila the complex 
preferentially targets H4 [243]. ATAC binds Host Cell Factor 1 (HCFC1), a scaffold to 
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multiple chromatin-modifying complexes [244], and POLE3, the DNA polymerase 
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1.5.3 SAGA and ATAC roles in cancer  
 
SAGA and ATAC have distinct sets of chromatin targets and, like KAT2A, participate 
in regulatory mechanisms that are ubiquitous amongst cells [245]. Thus, it is 
possible that both complexes contribute to transcription and cell identity – that is, 
the maintenance of the cell role in the long term. However, their contributions to 
identity of cancer cells remain poorly understood.  
 
Cancer cells depend on high protein production [246–247] and it is perhaps 
unsurprising that regulators of ribosome biogenesis constitute dependencies across 
multiple malignancies. Global analysis of CRISPR drop-out screens through 
interrogation of the Cancer Dependency Map (DepMap) Project at the Broad Institute, 
shows that 4 ATAC components – TADA2A, YEATS2, WDR5 and DR1 –, the first two 
of which are exclusive to ATAC, are called “essential”, as they constitute genetic 
vulnerabilities in >75% of the cell lines studied. In contrast, SAGA-specific elements 
were not called “essential”, suggesting more specific and potentially more targetable 
roles in cancer [248–249].  
 
However, ATAC and SAGA-specific subunits had distinct cancer lineage associations, 
as determined by statistical strength of dependencies across cell lines representing 
the same tissue. ATAC-specific elements ZZZ3 and YEATS2 have a strong statistical 
association with blood cells (Fig. 1.10A), specifically lymphocytic malignancies, 
likely reflecting the association between KAT2A and lymphoid cell differentiation.  
 
SAGA-specific elements also associate with blood malignancies of lymphocytic 
lineages – Non-Hodgkin Lymphoma and Multiple Myeloma but have stronger 
associations with tumours of the Central Nervous System and Renal Cell Carcinoma 
(Fig. 1.10B). Indeed, they mimic KAT2A dependencies, suggesting that ATAC may 
exert KAT2A-independent effects or compensate for its loss with other HAT activities. 
KAT2B does not constitute a dependency on any cell line analysed, while KAT14 is 
required in a small number of cell lines with B-lymphocyte bias, making it a more 
likely candidate for KAT2A redundancy.  
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Effects on control of transcriptional variability may nevertheless be exclusive to 
KAT2A, allowing for more subtle effects on cancer cell maintenance that do not 


















FIGURE 1.10 Analysis of dependencies and lineage associations of ATAC and SAGA-
unique elements in CRISPR drop-out screens of cancer cell lines. Data was 
extracted from the Cancer Dependency Map - DepMap 
(https://depmap.org/portal/) as of August 2020. Unique elements in each 
complex are highlighted with a black edge. A. ATAC elements (TADA2A, 
YEATS2, ZZZ3, MBIP, KAT14) are required in most cell lines and are called as 
'common essential genes'. Upon grouping of cell lines into specific tissues, or 
cell lineages, lineages for which requirements of individual genes were 
determined at p-value<0.0005 are considered as a lineage association bias. 
Bars reflect the total number of cell lines in each lineage associated with the 
various ATAC-unique elements. B. SAGA unique elements (TADA2B, 
SUPT20H, SUPT3H, SUPT7L, TAF5L, TAF6L, TADA1, ATXN7, ATXN7L3, 
USP22) are highlighted with a black edge. None of the elements was called 
'common essential'. Their lineage associations are depicted in the bar graph, 
as per the criteria in A. 
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When compared to KAT2A, SAGA-cancer dependencies are more similar with 
subunits of the DUB module, specifically with USP22 and ATXN7. Both associate 
with Renal Cell Carcinoma, and ATXN7 with Lymphoid malignancies. Indeed, ATXN7 
has been demonstrated to associate with prognosis of Renal Cell Carcinoma [250], 
and it confers susceptibility to Breast Cancer [251], where ATXN7 gene variants have 
been linked to post-operative prognosis of HBV-related Hepatocellular Carcinoma 
[252], all of these tumours to which KAT2A makes oncogene-like contributions [253]. 
USP22 acts as an oncogene in multiple malignancies [254–255], including in NSCLC 
[256] and in Gastric Cancer [257]. However, it also displays tumour-suppressor roles, 
specifically in Colorectal Cancer through decreased mTOR activity [258], and 
surprisingly, in AML [259]. In AML, USP22 deubiquitinates and stabilizes PU.1. In 
the absence of USP22, degradation of PU.1 leads to a block in myeloid cell 
differentiation, which promotes K-Ras mutant leukaemia progression [226].  
 
Interestingly, this is in contrast with Kat2a oncogenic functions in AML 
demonstrated by our lab [197–260]. A possible explanation is that this has to do with 
the relative independence between the DUB and HAT modules in SAGA. In 
alternative, the contrasting effects of Kat2a and Usp22 loss may be explained by the 
fact that different forms of AML were analysed in both studies. These may rely on 
distinct leukaemia-initiating cells and be driven by different mutational signatures, 
which may determine specific dependencies on activation or repression of individual 
genes. However, analysis of mouse ESCs also supports a degree of independence 
between Usp22 and Kat2a: Usp22 is uniquely required for appropriate differentiation 
into the 3 germ layers through repression of pluripotency master regulator Sox2 
[226], a role that exceeds the Kat2a requirement in pluripotent cells. Likewise, 
although Usp22 and Kat2a KO mouse models exhibit embryonic lethality at E10.5 
[261], Usp22 KO embryos present generalized apoptosis, which is not restricted to 
mesodermal structures as in Kat2a KO [182–184–262]. ATAC Kat14 KO mouse model 
[242], is also embryonic lethal at E10.5, with cell cycle defects and localised apoptosis 
that does not completely overlap with Kat2a, particularly in mesodermal structures.  
 
Together, these observations are in agreement with independent functions of the 
complexes, and within complexes, of the catalytic units. Additionally, there may be 
compensation by Kat2b, which like Kat2a can function in SAGA and ATAC 
complexes.  
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On the other hand, SAGA Core Supt20 hypomorphs, are more similar to Kat2a 
hypomorphic animals [263], with neural tube and axial skeleton developmental 
defects. Similarly, in mouse ESCs, Core components Taf5l and Taf6l maintain low 
levels of differentiation through activation of a MYC regulatory network [264], which 
is largely shared with Kat2a [194]. Therefore, loss of SAGA Core elements aligns 
better with loss of with Kat2a itself, resembling the pattern observed in lineage 
affiliation of cancer dependencies.  
 
However, in fly, KAT2A essential roles are closely aligned with ATAC. Accordingly, 
KAT2A is required in metamorphosis [183], and so is ATAC-Ada2a, whereas SAGA-
Ada2b or the SAGA DUB module, are dispensable at this stage [265].  
 
Taken together, the examples above suggest that ATAC is a generic requirement in 
cancer, whereas SAGA may have lineage specific functions. ATAC regulates 
biosynthetic functions, which are conveyed through Kat2a with some degree of 
participation of Kat14, which compensates for Kat2a loss, at least in some lineages. 
On the other hand, SAGA plays lineage-specific functions, with minimal 
compensation of Kat2a activity within the complex, and with some independence of 
function between HAT and DUB modules.  
 
It is likely that ATAC-mediated Kat2a acetylation activity maintains self-renewal 
and/or survival of proliferative and metabolically active cells, while Kat2a functions 
in the context of SAGA to maintain cell identity and prevent deviation from existing 
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1.6 Thesis overview   
 
Hypothesis  
KAT2A contributes to normal and leukaemic haematopoiesis with differential roles 
of the multi-modular HAT complexes it integrates.  
 
Objectives 
I investigate this hypothesis through development of 3 specific goals: 
 
I. Define the role of KAT2A complexes and the molecular programmes they 
regulate in normal haematopoiesis 
II. Define the role of KAT2A complexes and their targets in maintaining AML 
III. Explore KAT2A and complex-specific dependencies of patient AML cells 
with translational intent 
 
Overall, this project aims to investigate the cellular and molecular mechanisms by 
which both ATAC and SAGA- KAT2A complexes attain their uniqueness in the 
context of normal and leukaemic haematopoiesis. 
 
Thesis structure   
Following the literature review presented in this Chapter, I move on to presenting the 
experimental materials and methods in Chapter 2. This Chapter describes in detail 
the experimental design, techniques and tools used throughout this work. The 
experimental results are divided in Chapters 3 to 5. Each Chapter includes a brief 
introduction and short summary of the main findings. Chapter 3 explores the 
functions of KAT2A in normal haematopoiesis. I describe the effects of inhibiting 
KAT2A via shRNA in normal human cord blood (CB) specification. Furthermore, 
using the same genetic knockdown approach I characterise the roles of ATAC and 
SAGA in stem and progenitor blood development. To do so, I use complex-unique 
subunits as surrogates for the function of one or the other complex. ZZZ3 is 
representative of ATAC, whereas SUPT20H symbolises SAGA activities. In Chapter 
4, I move on to investigate the roles of KAT2A and its-containing ATAC and SAGA 
complexes in blood malignancy, specifically in acute myeloid leukaemia (AML). For 
this I make use of a panel of cell lines representative of different AML genetic 
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backgrounds. In Chapter 5 I explore the functions of KAT2A in human patient 
leukaemic cells by inhibiting its catalytic activity with a small drug, MB-3, or again 
via shRNA knockdown. To do so, I use of an in vitro co-culture protocol to sustain 
the leukaemic blasts for up to 3 weeks. Moreover, I attempted to dissect the functions 
of ATAC and SAGA complexes in the primary AMLs. Finally, all these findings are 
brought together in Chapter 6, where I discuss the main conclusions, potential 










































Chapter 2  
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This Chapter details the materials, protocols and resources used for the experimental 
work described in this thesis.  
 
2.1 Cell Lines  
 
AML cell lines used throughout this work were THP-1 (carrying a MLL-AF9 fusion), 
Kasumi-1 (with a t(8;21) chromosome translocation, giving rise to the AML1-ETO or 
RUNX1-RUNX1T1 fusion gene, and a c-kit mutation), MOLM-13 (carrying fusions 
FLT3- internal tandem duplication (FLT3-ITD) and MLL-AF9), MV4-11 (FLT3-ITD and 

















FIGURE 2.1 AML cell lines used in this study and their known oncogenic mutations.  
 
All AML cell lines were maintained in Roswell Park Memorial Institute-1640 media 
(RPMI, Sigma) supplemented with 20% FBS (Foetal Bovine Serum, Invitrogen), 1% 
Penicillin /Streptomycin /Amphotericin (P/S/A, Invitrogen) and 2mM L-Gln – R20. 
Cells were subcultured at the appropriate density and maintained in a 37°C, 5% CO2 
incubator.  K562 cell line is a chronic myelogenous leukaemia cell line, which was 
maintained in RPMI supplemented with 20% FBS (Foetal Bovine Serum, Invitrogen), 
1% P/S/A, and 2mM L-Gln as above. K562, THP-1, Kasumi-1, MOLM-13 and MV4-
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11 were a kind gift from Professor Brian Huntly, Cambridge, UK. KG1a were a kind 
gift from Dr Joanna Baxter, Cambridge Blood and Stem Cell Biobank. Human 
embryonic kidney (HEK-293T) cells were grown in Dulbecco′s Modified Eagle′s 
Medium (DMEM, Sigma) supplemented with 10% FBS, and P/S/A and 2mM L-Gln - 
D10. The stromal cell line MS5 obtained from the Bonnet Lab (Francis Crick Institute, 
London, UK), was maintained in Iscove’s Modified Dulbecco’s medium (IMDM, Sigma) 
supplemented with 10% FBS, 1% P/S/A and P/S/A and L-Gln - I10 and used 
between passage 3 to 5. 
 
2.2 Human Cord Blood CD34+ cells  
CB samples were obtained with informed consent under local ethical approval (REC 
07- MRE05-44). Samples were processed within 24h after collection and kept at 4°C 
prior processing. CB samples were first diluted 1:1 in Phosphate Buffer Saline (PBS, 
Sigma-Aldrich) supplemented with 2mM EDTA (Ethylene Diamine Tetra Acetic Acid, 
Sigma-Aldrich) to prevent mononuclear cell (MNC) aggregation. 30-70mL of blood 
was layered onto 15mL of Lymphoprep (Stem Cell Technologies) and MNC isolated 
by density gradient centrifugation. CB MNC were then enriched for CD34+ cells using 
the EasySep Human CB CD34+ Selection Cocktail (Stem Cell Technologies), 100 
µL/mL sample, and Dextran RapidSpheres (50 µL/mL sample). Cell-bead mix was 
subjected to magnetic incubation (MojoSort, BioLegend) for 3 minutes and washed 
with PBS-EDTA-0.5% Bovine Serum Albumin (BSA) for a total of 4 times until high 
purity CD34+ cells were obtained.  
2.3 Primary Human AML Cells  
AML cells were obtained at Addenbrooke's Hospital (Cambridge, United Kingdom) in 
collaboration with Professor Brian Huntly, and at Sant’Orsola Malpighi Hospital 
(Bologna, Italy), in collaboration with Dr Antonio Curti, University of Bologna, Italy. 
Details of patient samples, obtained under ethical approval (REC 07-MRE05-44), are 
listed in Table 5.1 (Chapter 5).  
 
Cells were maintained in a MS5 co-culture system for medium-term culture, which 
reflects AML engraftment in immunodeficient animals, and is thus of clinical 
significance [266]. MS5 monolayers were seeded onto 48-well plates pre-coated with 
Collagen (Thermo) at a density of 1.5x104 – 3x104 cells/mL until reaching 50-60% 
confluency, prior to culturing AML patient cells.  
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AML cells were thawed in PBS 2% FBS, 1% P/S/A and pre-stimulated for 
approximately 4h with H5100 (Stem Cell Technologies) supplemented with 
recombinant human IL-3, G-CSF, and TPO (20 ng/mL each, Peprotech), 1% HEPES 
(Gibco, 1M), 1%P/S/A – 3GT, herein called pre-stimulation media (PSM). Cells were 
then transduced with the desired lentiviral constructs in transduction media: H5100 
supplemented with SCF (100 ng/mL), Flt-3 (100 ng/mL), IL-3 (60 ng/mL), TPO (10 
ng/mL), 1% HEPES and 1% P/S/A. Cells were washed twice in PBS 2% FBS, 1% 
P/S/A and once in H5100 1% P/S/A and seeded onto MS5 stroma. Cultures were 
kept at 37°C, 5% CO2 for up to three weeks, with twice-weekly demi-population and 
fresh addition of H5100-3GT. For KAT2A inhibition experiments, AML cells were 
seeded onto MS5 stroma in H5100 in the presence of 100 µM MB-3 (Abcam) or DMSO 
(0.1%), and demi-populated as above with fresh addition of MB-3. Cells were stained 
for flow cytometry analysis once a week and surface phenotyping analysis performed 
on a Gallios instrument (Beckman Coulter).  
 
2.4 Cell Cryopreservation, Thawing and Counting 
All cells were cryopreserved in 80% FBS with 20% (v/v) Dimethyl Sulfoxide (DMSO, 
Thermo) and stored at -80°C in a Mr Frosty container (Thermo) prior to transferring 
to long term storage in liquid N2. Cells were rapidly thawed by gentle agitation in a 
37°C water bath and transferred to 10mL of pre-warmed complete media. Cells were 
then centrifuged at 400g for 5 minutes, re-suspended in complete media and seeded 
at the appropriate cell density. Cell counting and viability check were performed 
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2.5 Lentiviral Packaging and Transduction 
A 2ndgeneration lentiviral production system was used for stable cell transductions. 
Lentiviral particles were produced by mixing 1.28µg DNA of the packaging plasmid 
pCMV-VSV-G (Addgene 8454) (Fig. 2.2) and of the envelop plasmid pMD2.G 
(Addgene 12259) (Fig. 2.3), with 1.92µg DNA of the pLL3.7 shRNA-expressing vector 
(Addgene 11795) (Fig. 2.7). DNA mixtures in serum-free DMEM were then added to 
the transfection reagent Turbofect (Thermo) or TransIT (Mirus). Complexes were left 
to form at for 30 minutes at RT prior to adding dropwise to adhered HEK-293T cells 
(about 80% confluency) in D10. Media was changed at 24h and the lentivirus-
containing media harvested at 48h and 96h by pooling the media from the desired 
amount of T75 flasks followed by a 5-minute centrifugation 400g and transfer to a 
new collection tube until concentration overnight at 3,220g, 4°C. Supernatant was 
discarded, and viral pellets re-suspended in PBS, in the minimum volume required 
to achieve complete pellet dispersion. Lentivirus were used straight away or stored 
at -80°C until use. Cell lines were transduced overnight with 1-2 T75 packaging 
flask-equivalents (FE)/106 cells and washed the following day. For transduction of 
CD34+ CB, cells were pre-stimulated in serum-free medium (HSC expansion medium 
XF, Miltenyi Biotec) with SCF, TPO and Flt3L (respectively 200, 20 and 20 ng/mL) 
for up to 24h and transduced overnight using 2FE/ 2-3 x 105 cells. Cells were washed 
the following day and cultured in half the cytokine concentration for an additional 
2-3 days prior to sorting. The shRNA constructs express green fluorescent protein 
(GFP+), which was quantified on a Gallios flow analyser (Beckman Coulter) to 
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FIGURE 2.3 pMD2.G VSV-G-expressing envelope plasmid.  
 
2.6 Functional Cellular Assays  
2.6.1 Flow Cytometry 
2.6.1.1 Human CB CD34+ Cell Sorting  
CD34+ stem and progenitor cells were stained on ice for 20 minutes using the cell 
surface antibodies listed in Table 2.1. FcR blocking reagent (Miltenyi) was included. 
Cells were washed in PBS, re-suspended in 500µL PBS-EDTA-0.5% BSA and sorted 
on a BD FACSAria™ Fusion (BD Biosciences). Applied gating strategy used to sort 
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the different stem and progenitor compartments is shown in Fig. 2.4. Compensation 




























































FIGURE 2.4 Flow cytometry gating strategy for sorting the human CB CD34+ stem and 
progenitor compartments. Cells were first gated for live cells (SSC-A vs FSC-
A), from which a second gate was drawn to separate singlets from doublets (FSC-
W vs FSC-A). Singlets were gated for GFP positivity. The GFP+ gate was further 
analysed on CD34 and CD38 positivity. Of the CD34+38+ cells, surface 
expression was determined for CD45RA and CD123 to further isolate GMPs and 
MEPs. CD34+38- cells were subdivided in CD45RA positivity and CD90 
positivity. CD45RA+90- cells are MLP and CD45RA-90- are HSC/MPP. 
 
 
 62  
Table 2.1 Antibodies used in flow cytometry analysis and cell sorting. 
Antibody Fluorochrome Catalogue # Clone Dilution Supplier 
CD34 PE-Cy7 343515 581 1:200 BioLegend 
CD38 PE 356603 HB-7 1:100 BioLegend 
CD45RA APC 304118 HI100 1:100 BioLegend 
CD123 PE-Cy5 306008 HI264 1:100 BioLegend 
CD71 PE 334105 GY1G4 1:100 BioLegend 
CD235a PB 349103 H1264 1:100 BioLegend 
Annexin V APC 640941 - 1:100 BioLegend 
Hoechst 33342 - H3570 - 1:10000 LifeTechnologies 
Tag-it Violet APC 425101 - 5nM      BioLegend 
 
2.6.1.2 Cell Cycle Analysis  
Hoechst 33342 (Life Technologies) was used to determine the fraction of cells in 
different stages of the cell cycle. CD34+ stem and progenitor cells were stained with 
4µg/mL of Hoechst 33342, a fluorescent nucleic acid stain, and incubated for 2h at 
37 °C in a water bath, protected from the light, and vortexing every 15 minutes. Cells 
were then washed and re-suspended in 300µL of 0.2µg/mL Hoechst 33342 
maintenance solution in R20 (cell lines) or I10 (human CB), prior to examination by 




FIGURE 2.5 Flow cytometry gating strategy for cell cycle analysis of human CB CD34+ 
cells and cell lines.  
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2.6.1.3 Apoptosis Analysis  
Annexin-V was used to detect apoptotic cells based on its ability to bind to 
phosphatidylserine, a marker of apoptosis when present on the outer leaflet of the 
plasma membrane. Cells were treated with 3µL Annexin-V-APC (BD Biosciences) / 
100µL sample. Staining was performed for 15 minutes at room temperature (RT), 
protected from the light, along with counterstaining with a non-permeable 
fluorescent nucleic acid stain Hoechst 33258 (Life Technologies) 1:10,000 or DAPI 
(Thermo) 1:10,000. The combination of the two stainings allows for a distinction 
between viable cells (double negative), cells in early apoptosis (Annexin-V positive), 
cells in late apoptosis (double positive) and dead cells (Hoechst positive). The total 
number of Annexin-V positive cells was determined by FACS (Gallios, Beckman 
Coulter) and expressed as a percentage of dead cells. Gating strategy is shown in 








FIGURE 2.6 Flow cytometry gating strategy for apoptosis analysis of human CB CD34+ 
cells and cell lines.  
 
2.6.1.4 Cell divisional tracking  
For cell divisional tracking and proliferation, 1E6 cells/mL of cell suspension were 
stained as per manufacturer’s instructions using 1µL of 5 µM Tag-it Violet (BioLegend) 
in PBS. Cells were incubated for 20 min at RT, protected from light. Staining was 
quenched by adding 5 mL of cell culture medium R20. Pelleted cells were re-suspended 
in pre-warmed R20 incubated for 10 min at 37°C and analysed daily by flow cytometry 
on Day0 (loading) to Day3.  
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2.6.2 Colony-Forming Cell (CFC) Assays  
The colony-forming cell (CFC) assay was used to study the proliferation and 
differentiation pattern of CB stem and progenitor cells, as well as the proliferation 
ability of leukaemic patient blasts. CFC assays were performed in methyl-cellulose-
based semi-solid medium StemMACS-HSC-CFU complete with EPO (Miltenyi 
Biotech), which supports the growth of granulocyte (G) and monocyte (M) precursor 
cells, CFU-GM (Colony-Forming Unit Granulocyte Monocyte), erythroid progenitor 
cells or BFU-E (Burst-Forming Unit Erythroid), and of Mix or CFU-GEMM (Colony-
Forming Unit Granulocyte, Erythrocyte, Monocyte, Megakaryocyte) type colonies. For 
CB CD34+ cells, CFC-assays were set up immediately after sorting the different 
progenitor compartments. Preferably, 200 to 300 cells were re-suspended in I10 and 
embedded in falcon tubes containing 3mL of StemMACS-HSC-CFU with EPO. Tubes 
were vortexed and left at RT until bubbles disappear. Cells were then plated in 
duplicate onto 35 mm-dishes and incubated at 37 °C 5% CO2. Proliferation capacity 
of leukaemic patient cells post treatment with KAT2A inhibitor (Fig. 2.7), alpha-
methylene-gama-Butyrolactone 3 (MB-3) [267], or vehicle dimethyl sulfoxide (DMSO) 
(Sigma), was determined using 5x105 blasts per CFC-assay as above. The number 
and morphology of the colonies were scored under the light microscope 10-12 days 










FIGURE 2.7 Chemical structure of α-methylene- γ-Butyrolactone 3 (MB-3), the small 
molecule inhibitor of KAT2A. MB-3 has an IC50 of 100µM. The length of the 
aliphatic side chain of MB-3 is critical for its KAT inhibitory activity. The drug 
was dissolved in an appropriate volume of DMSO to provide a 100mM solution 
and stored in aliquots at -80°C until use. R- alkyl chain. Adapted from [267].  
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2.6.3 Erythroid differentiation cultures  
Transduced HSC were tested in erythroid differentiation conditions in serum-free 
liquid culture (HSC expansion medium XF, Miltenyi Biotec) in the presence of 
hydrocortisone (10-5M), SCF (100 ng/mL), TPO (10 ng/mL) and EPO (3U/mL). 
Cultures were followed up for 9 days with daily live and dead cell counts and regular 
flow cytometry analysis for CD34, CD71 and CD235a markers (Supplemental Table 
4). K562 cells were differentiated into the erythroid lineage in the presence of 1.5% 
DMSO as described29. Cells were monitored for differentiation markers (CD71 and 
CD235a) and/or activation of erythroid-affiliated molecular programmes during a 6-
day culture period. 
 
2.6.4 Cytospins  
Cells were centrifuged onto slides for 5 minutes at 700rpm, stained with rapid 
Romanowsky stain pack as per manufacturer's instructions and fixed with Depex 
(Sigma) mounting medium. Maturation of myeloid cells was assessed by examining 
the Romanowsky-stained cytospin smears for morphologic changes. In more detail, 
myeloid differentiated cells were classified if presenting an enlarged, irregular shape 
and when visible if the nucleus of the cell was multilobed and/or if it presented a 
‘band’ or ‘kidney bean’ shape. In turn, the myeloblasts or undifferentiated /blast-like 
cells, were classified if presented a round or oval shape with a large nucleus 
occupying pretty much the whole cell. Slides were classified blindly, both by me and 
by another person from the lab, as an independent observer. Alternatively, myeloid-
specific surface protein expression was analysed by flow cytometry, particularly 
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2.7 Molecular Assays  
2.7.1 Cloning of shRNA Constructs   
The human SAGA (SUPT20H and TADA2B) and ATAC (TADA2A and YEATS2) specific 
short hairpin RNAs (shRNAs) were cloned into the lentiviral plasmid pLL3.7 (Addgene 
11795) (Fig. 2.8), which expresses shRNA under the mouse U6 promoter; CMV-EGFP 













FIGURE 2.8 pLL3.7 lentiviral transfer plasmid. The plasmid contains a CMV-EGFP 
reporter cassete to monitor the expression of shRNAs. Restriction enzyme HpaI 
cuts the 3’ cloning site bluntly and XhoI cuts the 5’ cloning site, leaving a sticky 
end to bind the designed shRNAs, complementary to the restriction ends.  
 
shRNA design  
Two shRNAs were designed and synthesized per gene. The start base was adjusted 
from CCGG (Sigma-Aldrich library) to T; the loop sequence was adjusted from 
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CTCGAG to GGGATCC to permit a diagnostic restriction digestion with BamHI (NEB) 
and one T base was added to the poly T-tail, to match the Lab’s shRNA library. shRNA 
constructs for KAT2A, USP22 and ZZZ3 had previously been cloned in the Lab. All 
sequences of shRNA constructs used throughout this work can be found in Table 
2.1.  
 
Table 2.2 Sequences of shRNA constructs used in this work.  
Oligonucleotide  Sequence (5’ to 3’) 
KAT2A TGCTGAACTTTGTGCAGTACAAGGGATCCGTTGTACTGA 
CAAAGTTCAGCTTTTTTC 























pLL3.7 digestion  
The vector was digested at 37°C for 3h with the restriction enzymes HpaI and XhoI 
(NEB). HpaI cuts the 3’ cloning site bluntly, where XhoI leaves a sticky end when 
cutting the 5’ cloning site, allowing for the binding of the designed oligos to 
complement the restriction ends. Digested DNA was run on a 0.8% agarose gel in 1x 
TAE (Tris-Acetate-EDTA) with SYBR Safe gel stain (Invitrogen) for visualisation. DNA 
was then extracted from the gel and purified using the QIAquick gel extraction kit 
(Qiagen) as per manufacturer’s instructions. 
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Annealing, ligation and transformation 
Sense and antisense shRNA oligos were reconstituted at 100µM in nuclease-free 
water. A total reaction volume of 10µL, containing 0.12µM of each oligo, 1x 
concentrated EcoRI buffer (NEB) and nuclease-free water, were annealed using a 
thermal cycler (G-Storm GS0004M). The program was set to start at 95°C and drop 
~0.1°C/s down to RT.  Ligations into the digested vector were performed overnight at 
RT, using 0.02pmol of the linearized backbone, 0.06pmol of the annealed oligos, 1x 
buffer (NEB), of T4 DNA Ligase (NEB, 20,000 U) and water to a total volume of 10µL 
per reaction. Two controls were included: (1) insert replaced by water, which controls 
for single-cut and re-ligated, as well as undigested vector; (2) ligase replaced by 
water, which controls for undigested vector. Transformation of NEB-Stable 
chemically competent E. Coli was performed on ice for 30 minutes using 2µL of the 
ligation product, followed by a heat shock at 42°C for 30 seconds and another 
incubation on ice for 5 minutes. 200µL of pre-warmed Luria-Bertani (LB) broth 
media was added to the bacteria, followed by a 1h incubation at 30°C, 250rpm 
(Thermoshaker, Thermo). Cells were plated onto LB-agar plates with 100µg/mL 
ampicillin (Amp, Sigma) and cultured for 48h at RT. If transformation was deemed 
successful, 3-12 bacterial colonies were inoculated into 5mL LB with 5µL Amp and 
incubated overnight at 37°C, 250rpm Thermoshaker (Thermo). Bacterial colonies 
were miniprepped to isolate plasmid DNA using QIAprep Spin Miniprep Kit 50 
(Qiagen), as per manufacturer’s instructions. DNA concentration was measured by 
NanoDrop Lite Spectrophotometer (Thermo).  
 
Screening for positive clones 
Screening for positive clones was performed by 2 methods: (A) PCR and (B) BamHI 
restriction digestion, prior to validation by sequencing. 
A. PCR screen  
 
Successfully inserted clones were screened by PCR in a thermal cycler (G-Storm 
GS0004M). Primers used were as follows: FW: CTGTTCTTTTTAATACTAGC and RV: 
TATTAGGTCCCTCGACCTGCTGC. PCR reactions were set up following the 
HotStarTaq Plus Master Mix kit (Qiagen) protocol in a 20µL reaction volume. PCR 
controls included a non-template control (NTC) to test for contamination; a positive 
control using the pLL3.7-vector expressing the KAT2A shRNA to recognise positive 
clones and a negative control consisting of a pLL3.7 empty vector to distinguish 
negative clones. Thermal cycler profile was as follows: 95°C for 15 minutes, 35× [94°C 
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for 30 seconds, 48°C for 30 seconds, 72°C for 45 seconds], 72°C for 5 minutes and 
lastly 25°C for 10 minutes. Amplified PCR products were resolved on a 2% agarose 
gel in 1x TAE with 10µL SYBR Safe gel stain (Invitrogen) for visualization with a DNA 








FIGURE 2.9 Assessment of shRNA insertion into pLL3.7 vector using PCR and agarose 
gel electrophoresis. Representative gels. Positive ligated clones (red) were 
sent for sequencing validation.  
 
B. BamHI restriction digestion  
A diagnostic screen was performed for 600 ng purified bacterial DNA with BamH1 
(NEB) in a total reaction volume of 20 µL for 3h, at 37°C. Digested material was then 
resolved on a 0.8% agarose gel in 1x TAE with 10 µL SYBR Safe gel stain (Invitrogen) 
for visualization with a DNA ladder (Thermo).  
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Positive clones identified by a combination of both methods were sent for Sanger 
Sequencing (Source Bioscience), using the FW and RV primers at concentration of 
10pM. 5ng of DNA from successfully validated clones were transformed into 20µL of 
competent cells. Following a two-day incubation at RT, single colonies were 
inoculated in 3mL of LB with 3µL Amp (100µg/mL) and incubated 6-8h at 37°C, 225 
rpm. Bacterial colonies were then transferred to a 50 mL LB with 50µL Amp (100 
µg/mL) and cultured overnight at 37°C, 225rpm. Isolation of plasmid DNA was 
performed with the PureLink HiPure Plasmid Filter Midiprep kit (Invitrogen) as per 
manufacturer’s instructions, and DNA concentration measured by NanoDrop Lite 











FIGURE 2.10 Assessment of shRNA insertion into pLL3.7 vector by BamH1 restriction 
digestion using PCR and agarose gel electrophoresis. Representative gel. 
BamH1 cuts the shRNA loop sequence, which was adjusted from CTCGAG to 
GGGATCC to permit the diagnostic restriction digestion. Circular (uncut) 
plasmid DNA produces 3 bands on the gel, representing nicked (highest band), 
linear (middle band), and supercoiled (lowest band), whereas linear (cut) DNA 
appears as a single band, only if shRNAs are successfully inserted.  
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Assessment of gene knockdown in lentiviral producing HEK-293T cells 
When first producing lentivirus for the cloned shRNAs, prior to transducing into the 
experimental cells, mRNA was isolated from lentiviral-pancaking 293T cells to tested 
knockdown efficiency (Fig, 2.11).  
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2.7.2 RNA Extraction, cDNA Synthesis  
RNA extraction from Trizol (Invitrogen) homogenates was performed as follows: 
200µL of Chloroform (Sigma) was added to cells in 1mL of Trizol, mixed by hand for 
15 seconds and phase separation performed by centrifugation at 16, 000g for 15 
minutes at 4 °C. The upper aqueous phase was transferred into a new tube using 
0.5-1µL GenElute LPA (25 mg/mL, Sigma) or GlycoBlue (15 mg/mL, Invitrogen) as a 
carrier, to which 5/6 of the volume of the upper phase of Isopropanol (Sigma) was 
added and mixed well by hand. Samples were incubated for 30 minutes at RT and 
RNA precipitated at 16,000g for 10 minutes at 4 °C. Excess salt was removed with 
80% Ethanol (Sigma) by centrifugation at 16, 000g for 5 minutes at RT; pellet was 
released by vortexing. Residual Ethanol was removed by centrifugation at 16, 000g 
for 30 seconds at RT. RNA was finally resuspended in 3-5µL of RNase free water and 
incubated in a Thermoshaker (Thermo) at 50 °C, for 10 minutes at 300rpm. 
Complementary (c)DNA synthesis was performed from total RNA from equal numbers 
of cells using the SuperScript III Reverse Transcriptase Kit (Invitrogen) as per 
manufacturer’s instructions.  
 
2.7.3 Quantitative Real Time PCR (qRT-PCR) 
cDNA was analysed in triplicate by qPCR using Taqman Gene Expression Assays and 
Taqman Gene Expression Mastermix (Applied Biosystems). Additionally, qRT-PCR 
was performed using SYBR Green Mastermix (Takyon Rox SYBR Core Kit dTTP Blue, 
Eurogentec or Brilliant II SYBR Green Low Rox Master Mix, Agilent Technologies). 
Taqman probes and primers are listed in Table 2.3 and Table 2.4, respectively. 
Relative gene expression was calculated by the 2-DDCt method using HPRT1 as 
reference. NTC was used as control. Assays were carried out in 96-well, semi-skirted, 
white, PCR plates for Roche LightCycler (Starlab) on a LightCycler 480 System 
(Roche), or on a MxPro - Mx3000P Multiplex qPCR System (Agilent Technologies). 
Thermal cycler profile for SYBR qRT-PCR was as follows: 50°C for 2 minutes, 95°C 
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Table 2.3 Taqman probes.  
Gene Catalogue# Supplier 
CEBPA Hs00269972_s1 Applied Biosystems 
EPOR Hs00959427_m1 Applied Biosystems 
GATA1 Hs01085823_m1 Applied Biosystems 
GATA2 Hs00231119_m1 Applied Biosystems 
HPRT1 Hs02800695_m1 Applied Biosystems 
KAT2A Hs00221499_m1 Applied Biosystems 
KLF1 Hs00610592_m1 Applied Biosystems 
MPO Hs00924296_m1 Applied Biosystems 
CCDC101 Hs00540812_m1 Applied Biosystems 
ID2 Hs04187239_m1 Applied Biosystems 
MED13 Hs00192834_m1 Applied Biosystems 
RPL15  Hs04334752_g1 Applied Biosystems 
RPL3 Hs01581771_g1 Applied Biosystems 
TAL1 Hs01097987_m1 Applied Biosystems 
 
 
Table 2.4 Sequences of primers used for qRT-PCR analysis.  






















































USP22 GAGGCCATGGACGCCG AGATACAGGACTTGGCCTTGC 
YEATS2 AACCCCAGGGTCTGAATTTATTG CGGACGCATACACGTTCCT 
 
ZZZ3 GGACAGCAAAACAGGTTGCC GTGCTGTCGTCTGCTTGTTG 
 
2.8 RNA-sequencing (RNA-seq) 
RNA was extracted from CTRLsh or KAT2Ash HSCs obtained from 2 individual CB 
donors as described in 2.7.2. RNA-seq libraries were prepared at the Cambridge Stem 
Cell Institute Genomics Core Facility using the Ovation RNA-seq kit (NuGen) with 
incorporated DNase treatment, as per manufacturer's instructions. Libraries were 
sequenced on an Illumina HiSeq4000 instrument at the CRUK Cambridge Research 
Institute Genomics Core Facility using 50bp single-end reads. The raw fastq files 
were processed as per the RSEM v1.2.31 workflow and aligned to the reference 
human genome assembly GRCh37. Differentially expressed genes were obtained at 
10% FDR using the R packge edgeR. Gene signatures of down-regulated genes in 
KAT2Ash HSC for gene set enrichment analysis were obtained from MSigDB [268]. 
Erythroid differentiation (NES= -1.79, q-val=0.018) and platelet biology (NES= -2.05, 
q-val=0.004). 
 
2.9 Chromatin Immunoprecipitation (ChIP) 
2.9.1 Cross-link for Suspension Cells, Cell Lysis    
Cross-linking of 1x107 suspension cells was performed with 278µL 37% v/v 
Formaldehyde (Sigma) per 10mL of PBS. 571µL of 2.5M Glycine were added and 
samples incubated for 10 minutes, 50rpm, at RT prior to centrifugation at 2,000g for 
5 minutes at 4°C. Supernatant was discarded and 1mL ice-cold PBS added per 
1x107, with gentle shaking to re-suspend pellets. Samples were further aliquoted into 
1.5mL tubes (Eppendorf) and centrifuged at 2,000g for 5 minutes at 4°C. 
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Supernatant were removed and cross-linked pellets stored at -80°C or used straight 
after.  
 
Lysis buffer was added to either frozen or freshly cross-linked pellets such that the 
final concentration of the cell suspension was 15x106 cells/mL. Chromatin was 
sheared using 1.5mL TPX tubes (Diagenode) to a medium fragment size of 300bp on 
a Bioruptor XL (Diagenode). Sonication was performed at 4°C and conditions were 
optimised for each particular cell type: 9 sonication cycles, 30 seconds ON/30 
seconds OFF for K562 cells and MOLM-13 cell lines. Optimisation of sonication 




FIGURE 2.12 Assessment of optimal chromatin sonication conditions for MOLM-13 
(left) and K562 (right) cells using agarose gel electrophoresis. The number 
of cycles producing fragment sizes of about 300bp was selected.  
 
 
Following sonication, chromatin was transferred to regular 1.5mL tubes and samples 
span down for 5 minutes at 13,000rpm at RT. 2% of supernatant was saved as input 
and stored at -80°C.   
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2.9.2 Immunoprecipitation  
For ChIP-qPCR, chromatin was immunoprecipitated in dilution buffer, protease 
inhibitor cocktail (PIC, Sigma) and with the antibodies listed in Table 2.6, in a total 
reaction volume of 3mL for H3K9ac, H3K27ac, rabbit-IgG, and 10mL for Myc, mouse-
IgG. Chromatin was incubated 4 h-overnight with rotation at 4°C. The following day, 
ChIP Grade Protein A/G beads (Thermo) were prepared by washing with 500µL of 
dilution buffer (+ 0.15% sodium dodecyl sulfate (SDS), + 0.1% BSA). Beads were span 
down, placed in a magnetic rack (Diagenode) for 1 minute and supernatant removed. 
Beads were then dissolved in 15-20µL dilution buffer (+0.15% SDS, +0.1% BSA) per 
ChIP reaction and added to the chromatin/antibody mix, followed by incubation for 
1h, with rotation at 4°C. Washes (consisting of 1x wash buffer 1; 2x wash buffer 2; 
2x wash buffer3) were performed with 2mL of each buffer for 5 minutes on ice, with 
short spin down steps in between washes. Samples were eluted in 200µL of freshly 
prepared elution buffer with 5M NaCl and Proteinase K (Bioline) and left rotating for 
20 minutes at RT together with inputs retrieved from -80°C storage.  Samples were 
briefly span down, placed in the magnetic rack for 1 minute and supernatants 
collected. Cross-links were reversed overnight at 65 °C, 1,000rpm. 
 
2.9.3 DNA purification 
DNA was purified with a DNA Clean & Concentrator kit (Zymo Research) as per 
manufacturer’s instructions. Eluted DNA was diluted and quantified by SYBR green 
qPCR (see 2.6.3) using 2µl DNA per triplicate reaction (primers in Table 2.7). Peak 
enrichments relative to rabbit IgG or mouse IgG were determined using the -2ΔΔCt 
method with a reference gene or reference intergenic region. Detailed ChIP 
buffers/solutions are listed in Table 2.5. 
 
For ChIP-sequencing (ChIP-seq), chromatin was prepared in duplicate from K562 
cells (9 sonication cycles, 30 seconds ON/30 seconds OFF) and immunoprecipitated 
using anti-SPT20 and anti-ZZZ3 sera prepared in the Tora Lab [245]. Raw ChIP-seq 
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Table 2.5 Buffers used in chromatin immunoprecipitation (ChIP). 
Lysis Buffer Stock Final concentration Volume stock solution (10mL) 
1M 20mM HEPES 0.25 
10% 1% SDS 1 
PIC 1:100 0.1 
H2O  Fill up to 10ML 
Dilution Buffer Stock Final concentration Volume stock solution (100mL) 
10% 0.15% SDS 1,5 
20% 1% Triton 5 
0.5M  1.2mM EDTA 0.24 
1M 16.7mM Tris (pH 8.0) 1.76 
5M 167mM NaCl 3.34 
H2O  Fill up to 100ML 
Wash Buffer 1 Stock Final concentration Volume stock solution (400mL) 
0.5M  2mM EDTA 1.6 
1M 20mM Tris (pH 8.0) 8 
20% 1% Triton 20 
10% 0.1% SDS 4 
5M 150mM NaCl 12 
H2O  Fill up to 400ML 
Wash Buffer 2 Stock Final concentration Volume stock solution (400mL) 
0.5M  2mM EDTA 1.6 
1M 20mM Tris (pH 8.0) 8 
20% 1% Triton 20 
10% 0.1% SDS 4 
5M 500mM NaCl 40 
H2O  Fill up to 400ML 
Wash Buffer 3 Stock Final concentration 
Volume stock solution 
(1000mL) 
0.5M 1mM EDTA 2 
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1M 10mM Tris (pH 8.0) 10 
H2O  Fill up to 1000ML 
Elution Buffer Stock Final concentration Volume stock solution (5mL) 
10% 1% SDS 5 
1M 0.1M NaHCO3 5 
H2O  Fill up to 50ML 
 
 
Table 2.6 Antibodies used in chromatin immunoprecipitation (ChIP). 
Antibody Catalogue# Supplier 
H3K27ac Ab4729 Abcam 
H3K9ac 07-352 Millipore 
Myc sc-764 x  Santa Cruz Biotechnology 
rabbit IgG 12-370 Millipore 
mouse IgG Sc-2025 Santa Cruz Biotechnology 
 
 
Table 2.7 Sequences of primers used for ChIP-qPCR analysis. 









HBB GCCATCCATTTTTCTTAATTCTGAG TGAGGGCACCATTAGCCAG 
HOXA10 GTTTATAGCGGCGCATTCCA  CGGGTTTGATTTCTGAGCCC  
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MEIS1 CCAGAAGAAGACAGAGCGGA  CCCTCAGACCCAACTACCAA 













RPS7 CCTGCTCTCCGACAGAACTT CGGGTAATCGGCTGTATCCC 
 
 
2.10 Western Blot (WB) 
2.10.1 Sodium Dodecyl Sulphate – PolyAcrylamide Gel 
Electrophoresis (SDS-PAGE) Preparation 
 
For preparing the running gel, casting frames (Bio-Rad) were set on the casting 
stands (Bio-Rad) and two glass plates (Bio-Rad) clamped into the casting frames. 
Running gel ((30% (w/v) Acryl/Bis Solution, 1M Tris-HCl pH 8.8, (w/v) 10% SDS, 
ddH2O, 10% (w/v) ammonium persulfate (APS), Tetramethylethylenediamine 
(TEMED)), was poured into the gap between the glass plates. Isopropanol was added 
into the gap until overflow, in order to make the top of the running gel even. After 
letting the running gel solidify for about 40 minutes, the stacking gel (30% (w/v) 
Acryl/Bis Solution, 0.5M Tris-HCl pH 6.8, (w/v) 10% SDS, ddH2O, 10% (w/v) APS, 
TEMED) was prepared and poured above the running gel until overflow. A 15mm 15-
well gel comb (Bio-Rad) was inserted and following complete solidification of the 
stacking gel (about 30 minutes), the comb and glass plates were removed. Running 
buffer 1x (Bio-Rad) was poured into the electrophoresis tank (Bio-Rad) until reaching 
the required level for the number of gels being run.  
 
2.10.2 Sample Preparation and WB Analysis  
 
For western-blot analysis, collected cells were lysed in RIPA buffer (50mM Tris-HCL 
pH 7.4, 150mM sodium chloride, 2mM EDTA, 1% (v/v) IGEPAL CA-630, 0.5% (w/v) 
sodium deoxycholate, 0.1% (w/v) SDS and protease inhibitor (Roche) for 20 minutes 
at 4°C with rotation. Protein extracts from equal cell numbers (1x106 cells/extract) 
were mixed with Trident 6x Laemmli SDS sample buffer (GeneTex) and reducing 
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agent Tris (2-carboxyethyl) phosphine - TCEP 0.5M (Sigma) and denatured at 95°C 
for 5 minutes or at 70°C for 10min. Proteins were then resolved by SDS-PAGE (cast 
to a final acrylamide percentage between 7.5-10%) using a tris/glycine/SDS buffer 
system (Bio-Rad) for about 1h at 120V.  Precision Plus Protein Kaleidoscope (Bio-
Rad) was used as standard. Subsequently, transfer membranes (Immobilon-P PVDF 
pore size 0.45 µm, Millipore) were activated with Methanol (Sigma) for 5 minutes. 
Gels were transferred onto the transfer membrane for about 90 minutes at 100V. 
Membranes were stained with Ponceau for 1 minute, blocked in blocking buffer (5% 
skimmed milk in TBS-T (Tris 10 mmol/L, NaCl 50 mmol/L, Tween 0.005%)) for 1h 
at RT, washed and immunoblotted with primary antibodies diluted in blocking buffer 
overnight, at 4°C with rotation. The following day, membranes were washed in TBS-
T 3x for 10 minutes, and incubated with the appropriate fluorescently-labelled 
secondary antibody diluted in 1.5% skimmed milk in TBS-T for 1h at RT. Membranes 
were washed 2x in TBS-T and 1x in TBS for 10 minutes, subjected to 5 minute 
SuperSignal West Pico PLUS Chemiluminescent Subtract (Thermo) for detection of 
HRP, and developed on a SRX-101A Processor using the hypercassette method. After 
drying, membranes were taped onto a hypercassete (Amersham Biosciences) and 
exposed to X-ray film (exposure dependent on the antibody strength) prior 
developing. WB antibodies used are listed in Table 2.8.  
 
 
Table 2.8 Antibodies used in Western Blot (WB). 
Antibody Catalogue # Clone Dilution Supplier 
Cas9 C15200203-100  
Mouse 
monoclonal 1:6000 Diagenode 
CHEK1 EP691Y Rabbit monoclonal 1:10 000 Abcam 
Gcn5 ABE1934 Rabbit polyclonal 1:1000 Millipore 
Gcn5 (A11) sc-365321 Mouse monoclonal 1:1000 Santa Cruz 
Gcn5 (H75) sc-20698 Rabbit polyclonal 1: 2000 Santa Cruz 
ACTB  ab8227 Rabbit polyclonal 1:1000 Abcam 
CCDC101 ab204367 Rabbit polyclonal 1:1000 Abcam 
USP22 ab195289 Rabbit monoclonal   1:2000 Abcam 
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2.11 Statistical Analysis  
Statistical analysis was performed in GraphPad Prism 8.1.2 (GraphPad Software). 
Data are reported as mean ± SEM. Significance calculated by 2-tailed t-test at 
p<0.05, details are specified in the figure legends.   
 
2.12 Data Deposition   
ChIP-seq and RNA-seq data have been deposited in GEO (accession numbers are 
GSE128902 and GSE128512).  
 































Chapter 3  
The role of KAT2A and its chromatin 
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3.1 Introduction  
 
Our lab has previously shown that chemical inhibition of KAT2A activity had not 
impacted colony-formation from total CB CD34+ cells, suggestive of preservation of 
healthy blood development [260]Moreover, our lab and the Tenen group did not find 
a requirement for Kat2a in mouse BM haematopoiesis [196]. However, re-inspection 
of Kat2a expression in BM subpopulations of our conditional KO model found that 
gene expression ablation in MEP was less extensive than in myelo-monocytic cells. 
Mean Kat2a expression in Kat2a KO MEP cells is 0.39±0.20 (SD) of WT expression. 
However, it is 0.13±0.08 in GMP, compatible with selective preservation of unexcised 
Kat2a allele-carrying MEP cells, and a possible partial requirement for Kat2a 
expression (n=4; 2-tailed t-test p-val = 0.054). Thus, I went on to investigate in detail 
if KAT2A was required in normal human haematopoietic progenitor specification or 
differentiation. For that, I combined functional and transcriptomic analysis of human 
CB, a well-established model of human blood development [1]. I exploited RNA 
interference (RNAi) - shRNA-mediated lentiviral delivery - to silence KAT2A 
expression and assess phenotypes of functional, transcriptomic and ChIP-seq 
assays.  
 
In vitro functional studies of cell lineage potential can be done by two main strategies, 
employed here: (1) CFC-assays and (2) liquid differentiation cultures. CFC assays 
consist in plating cell populations in semi-solid methylcellulose-based media, which 
viscosity allows cells to grow separately as clonal entities that can be scored visually. 
Both stem and progenitor cells are able to form colonies in a CFC assay, as it 
measures differentiation and proliferative potential and not self-renewal (which can 
be assessed by serial re-plating). In liquid differentiation culture assays, lineage 
output is assessed by flow cytometry, providing more mechanistic detail into 
proliferative capacity of bulk populations.  
 
RNA-seq was used in order to detect transcripts showing differential expression in 
control (CTRLsh) vs KAT2Ash CB HSCs, thus aiming to understand transcriptional 
programmes regulated by KAT2A in normal blood. Briefly, RNA-seq involves isolation 
of RNA, preparation of RNA-seq library (reverse-transcribing the RNA to cDNA, 
fragmenting or amplifying cDNA molecules, ligating sequencing adaptors), and 
sequencing it on an NGS platform (Kukurba and Montgomery, 2015). 
 84  
Through ChIP-seq, a technique for genome-wide mapping of protein-DNA 
interactions, unbiased examination of the DNA binding sites of the KAT2A- 
chromatin complexes, ATAC and SAGA in haematopoietic K562 cells was performed.  
Specifically, by targeting unique subunits of either complex, ZZZ3, in case of ATAC 
and SPT20, in case of SAGA. K562 is a human cell line derived from a chronic 
myelogenous leukaemia patient in the blastic phase, in 1970 [270]. These cells have 
the capacity to differentiate towards the erythroid lineage upon treatment with 




3.2 Chapter overview  
This chapter details the results of experiments designed to investigate the role of 
acetyltransferase KAT2A to cell fate decisions in normal human haematopoiesis. 
Also, it dissects contributions of the two multimolecular complexes in which KAT2A 
participates, ATAC and SAGA. First, I describe the functional and molecular 
characterisation of KAT2A in normal human CB blood specification. By combining 
functional and transcriptomic (RNA-seq) analysis, I show that KAT2A is required for 
specification and survival of erythroid progenitor cells. I further demonstrate that 
lymphoid and myeloid lineages are not affected upon KAT2A loss. Additionally, 
KAT2A controls a common erythroid and platelet transcriptional program in blood 
stem and multipotent progenitor cells. Dissection of the macromolecular complex 
dependencies in normal blood production revealed that ATAC is selectively required 
for erythroid lineage specification, while SAGA may act later in erythroid cell 
differentiation, and more specifically contribute to cell identity. Finally, I demonstrate 
that ATAC and SAGA have unique sets of target genes in haematopoietic cells: ATAC 
controls biosynthetic activity including ribosomal protein machinery, while SAGA 
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3.3 Results and discussion   
 
3.3.1 KAT2A regulates human CB erythroid progenitor 
specification and survival  
 
I started by obtaining human CB from healthy donors, and isolating CD34+ cells, 
which were then transduced with a KAT2A shRNA construct. Transduced (GFP+) 
cells were flow-sorted for stem and multipotent progenitor cells (HSC), lineage-
restricted myelo-lymphoid (MLP), megakaryocytic-erythroid (MEP) and granulocytic-
monocytic (GMP) progenitors (Fig. 3.1). Experiments were performed against a 












FIGURE 3.1 Schematic of the adopted CB experimental strategy. 
 
I initially validated the KAT2A knockdown by WB, which showed robust reduction of 
protein levels (Fig. 3.2A). Inspection of progenitor activity of KAT2A knockdown CB 
CD34+ cells in CFC assays (Fig. 3.2B) detected a reduction in erythroid (E) colony 
formation (Fig. 3.2C). This was also apparent upon depletion of the Tudor-domain 
protein SGF29 (gene CCDC101) (Fig. 3.2D), a KAT2A partner common to its 
participating SAGA and ATAC complexes, and which KD was confirmed by WB in 
erythroid-affiliated K562 cells (Fig. 3.3E). Equally, differentiation of KAT2A 
knockdown CD34+ cells in mixed-lineage differentiation cultures revealed the 
relative loss of differentiated erythroid cells (Fig. 3.3F). This was evident by reduced 
percentage of CD235+ cells in KAT2Ash cells after seven days in culture, compatible 
with a defect in specification, differentiation, or survival of the red blood cell lineage. 
2. Isolation of  
    CD34+ cells 
3. Lentiviral shRNA 
    transduction 
4. FACS 1. CB processing 


































FIGURE 3.2   Progenitor activity of KAT2A knockdown CB CD34+ cells. (A) Western 
blot analysis showing KAT2A (95KDa) knockdown efficiency in erythroid-
affiliated K562 cells. ACTB (42KDa) was used as loading control. (B) 
Photographs of representative colony morphologies from transduced human 
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CB HSC and progenitors. BFU-E: Boost-forming unit – erythrocyte colony. 
CFU-GM: Colony-forming unit - granulocyte monocyte colony; CFU-GEMM or 
mixed: Colony-forming unit – granulocyte erythrocyte monocyte 
megakaryocyte colony. (C) Relative representation of colony-forming cells 
present in total CB CD34+ cells transduced with KAT2Ash. Mean ± SEM of 3 
individual CB samples. Paired two-tailed t-test for significance *p<0.05. (D) 
Relative representation of colony-forming cells present in total CB CD34+ cells 
transduced with CCDC101sh. Mean ± SEM of 3 individual CB samples. Paired 
two-tailed t-test for significance *p<0.05. (E) Western blot analysis showing 
CCDC101 (36KDa) knockdown efficiency in erythroid-affiliated K562 cells. 
ACTB (42KDa) was used as loading control. (F) Flow cytometry analysis of CB 
HSC transduced with CTRLsh (top) or KAT2Ash (bottom) after 7 days of liquid 
culture in erythroid differentiation conditions. Cells plotted were gated as live 





When investigating the CFC capacity of HSC and the different progenitor 
compartments upon KAT2A knockdown, at the point of sorting (Fig. 3.3A), I observed 
a significant decrease in the proportion of KAT2A-depleted MEP in total CD34+ CB 
cells (Fig. 3.3B), suggesting a defect in the specification, differentiation or survival 
of progenitors committed to the erythroid lineage, in agreement with the re-analysis 
of BM from the KAT2A KO mouse model. Moreover, I verified that loss of KAT2A 
affected erythroid lineage output from both HSC and MEP (Fig. 3.3, top). CFC ability 
of progenitors affiliated to the granulocyte-monocyte and lymphoid lineages, in turn, 








































FIGURE 3.3 CFC-efficiency of KAT2A lentiviral transduced, sorted, human stem 
(HSC/MPP) and progenitor (MEP, GMP, MLP) CB cell populations. (A) 
Representative sorting plot for transduced HSC and progenitor cells from CB 
CD34+ cells. (B) Proportion of KAT2Ash transduced CB HSC and progenitors. 
Mean ± SEM of >7 individual sorting experiments. Two-tailed paired t-test for 
significance; *p<0.05, **p<0.01. (C) Frequency of CFC efficiency in the 
HSC/MPP, MEP (top), GMP and MLP (bottom) compartments transduced with 
KAT2Ash. Mean ± SEM of 7 individual CB samples. Two-tailed paired t-test for 
significance; *p<0.05, **p<0.01. 
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CFC assays, however, are end-point experiments that do not permit a detailed 
dissection of mechanisms of cell specification or differentiation. As an attempt to 
overcome this limitation, a liquid culture system was used over the course of 9 days. 
Differentiation of HSC/MPP transduced with CTRLsh in the presence of 
hydrocortisone, SCF, TPO and EPO resulted in progressive loss of stemness marker 
CD34 and accumulation of cells expressing glycophorin A (CD235a), a marker 
characteristic of late erythroid maturation stages. In turn, the level of CD71+ (early 
erythroid marker) cells remained relatively constant (Fig. 3.4A). This result indicated 
effective progression of erythroid differentiation. When analysing the results of 
KAT2Ash cultures, it was possible to observe a highly similar trend (Fig. 3.4B), which 
culminated in a low proportion of CD34+ cells and high proportion of CD235a+ cells 
at Day9. Furthermore, cultures initiated from KAT2A-depleted HSC cells were 
severely restricted in their expansion (Fig. 3.4C) compared to control, with relative 
preservation of GFP positivity in both conditions, at least in the experiment were GFP 
% was assessed (Fig. 3.4D). However, the achievement of similar end-point levels of 
CD235a-positivity in (A) and (B), suggests that erythroid differentiation can progress 




































































































FIGURE 3.4   Erythroid cell differentiation in human CB HSCs progresses independently 
of KAT2A absence. (A) Erythroid differentiation of HSC/MPP sorted from 
CD34+ cells of individual CB samples transduced with CTRLsh in liquid 
cultures. (B) Erythroid differentiation of HSC/MPP sorted from CD34+ 
cells of individual CB samples transduced with KAT2Ash in liquid 
cultures. CD34 marks HSC and progenitors; CD71 and CD235a mark 
early and late differentiated erythroid cells, respectively. Data 
summarise mean ± SEM of 4 independent differentiation experiments. 
(C) Expansion of CTRLsh and KAT2Ash HSC in erythroid differentiation 
cultures in (A). (D) GFP+ percentage in CTRLsh and KAT2Ash HSC in 
in a representative erythroid differentiation culture experiment. 
 
 
Together, the data suggests that cells that commit to the erythroid lineage can 
progress unrestricted in their differentiation. However, most KAT2Ash cells don’t 
seem to get to that stage, in agreement of my earlier observations of impaired 
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Quantitative RT-PCR analysis of KAT2A-knockdown HSC showed downregulation of 
early erythroid regulatory genes including GATA2, EPOR and ID2 (Fig. 3.5A). 
Assessing for any unbiased differences in gene expression through RNA-sequencing 
in order to better characterise which transcriptional programmes were being 
subverted by loss of KAT2A, indicated a global reduction of erythroid and 
megakaryocytic programmes (Fig. 3.5B). This was in line with the outcome of CFC 
assays, portraying an erythroid defect. Indeed, amongst the down-regulated genes 
were erythroid-affiliated factors EPOR, HBB, ID2, GFI1B, HBG1 and HBG2. Examples 
of up-regulated genes are MPO and ERG. The full list of differentially expressed genes 
is given in Appendix A - RNA-seq differentially expressed genes in CTRLsh vs 
KAT2Ash HSCs (10% FDR).  
 
Furthermore, gene ontology (GO) associations as calculated by GOrilla analysis, 
identified gas transport and blood coagulation as enriched biological processes (Fig. 
3.5C). Likewise, gene Set Enrichment Analysis of down-regulated genes in KAT2Ash 
HSC revealed an enrichment for erythroid differentiation (Fig. 3.5D, left) and platelet 
biology (Fig. 3.5D, right), thus confirming a novel role for KAT2A in 
erythroid/megakaryocytic biology. The genes up-regulated upon KAT2A knockdown, 
in turn, did not capture any enriched GO categories. However, considering for 
example the case of MPO, it is possible that its upregulation is a consequence of 










































*** *** ** * p=0.06
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FIGURE 3.5 Transcriptional analysis of CTRLsh vs KAT2Ash CB HSCs. (A) Quantitative 
RT-PCR analysis of expression of erythroid-associated genes in KAT2Ash 
transduced HSC from individual CB samples. N³3 independent experiments, 
mean ± SEM of gene expression relative to CTRLsh, normalised to HPRT1 
housekeeping gene. Two-tailed paired t-test for significance *p<0.05, **p<0.01, 
***p<0.001. (B) MA plot of RNA-seq gene expression analysis of differentially-
expressed (DE) genes (red) in CTRLsh vs KAT2Ash transduced HSC/MPP cells 
at a false discovery rate of 10%. The average value of logCMP (counts per million) 
is plotted against the logFC (fold change). (C) Top Gene Ontology (GO) 
associations of KAT2A DE genes on biological processes as calculated by the 
GOrilla tool. (D) Gene Set Enrichment Analysis (GSEA) plot for erythroid 
differentiation (right) and platelet signature (left) in the RNA-seq data in (D). 
Gene signature identifiers are ADDYA Erythroid Differentiation by HEMIN and 
GNATENKO Platelet signature, respectively, as obtained from the UC San Diego 
and BROAD Institute Molecular Signatures Database (MSigDB).  
 
 
To further understand the erythroid defect observed, I conducted cellular 
investigation by analysing the apoptosis and cell cycle status of KAT2A sorted, 
transduced (GFP+) stem and progenitor populations. Quantification of apoptotic cells 
revealed specific increases in apoptotic HSC and MEP, suggestive of putative effects 
on cell survival peri-erythroid commitment, and which did not extend to other 
lineages (Fig. 3.6A). This is in line with a reduction in erythroid and megakaryocytic-
associated gene signatures in KAT2A-knockdown HSC (Fig. 3.5). There were no 
changes in cell cycle (Fig. 3.6B).  
D E 





























FIGURE 3.6 Analysis of apoptosis and cell cycle status of human CB stem and 
progenitor cells upon depletion of KAT2A. (A) Flow cytometry analysis of 
apoptosis by Annexin-V staining. N=3 individual cord blood samples; mean ± 
SEM. Two-tailed paired t-test for significance; *p<0.05. (B) Flow cytometry 
analysis of cell cycle in HSC/MPP, MEP, GMP and MLP transduced cells with 
KAT2Ash vs CTRLsh. N=3 individual cord blood samples; mean ± SEM. Two-
tailed paired t-test not significant.  
B 
A 
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Altogether, these observations support a function of KAT2A in human CB red blood 
cell specification and/or survival, with no impact on lymphoid or myeloid potential, 
sustaining a shared erythroid and platelet transcriptional programme.  
 
Given that KAT2A is present in two distinct macromolecular complexes, it leaves 
open the possibility of ATAC or SAGA being specifically required in erythroid 
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3.3.2 The ATAC complex is selectively required for erythroid 
specification from CB HSC, while SAGA facilitates erythroid 
differentiation post-commitment  
 
To dissect KAT2A-complex dependencies in normal haematopoiesis, I transduced 
CD34+ CB cells with ATAC and SAGA specific shRNA constructs, ZZZ3sh and 
SUPT20Hsh, respectively. CD34+ CB cells transduced (GFP+) with ZZZ3 or SUPT20H 
shRNAs (Fig. 3.7A) were flow-sorted into stem and multipotent progenitor cells (HSC) 
and lineage-restricted myelo-lymphoid (MLP), megakaryocytic-erythroid (MEP) and 
granulocytic-monocytic (GMP) progenitors as described (Fig. 3.3A). Upon sorting, no 
differences in the proportion of stem and progenitor cells were observed in CB CD34+ 





















FIGURE 3.7   ZZZ3 (ATAC) and SUPT20H (SAGA) depletion in human CB CD34+ cells. 
(A) Quantitative RT-PCR validation of SUPT20H and ZZZ3 knockdown in 
human cord blood HSC. Representative experiment for SUPT20H; mean ± SEM 
of 2 individual experiments for ZZZ3; gene expression relative to CTRLsh, 
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significance *p<0.05. (B) Proportion of ZZZ3sh transduced CB HSC and 
progenitors. Mean ± SEM of >3 individual sorting experiments. Two-tailed 
paired t-test for significance; no significant differences. (C) Proportion of 
SUPT20Hsh transduced CB HSC and progenitors. Mean ± SEM of >3 individual 




In contrast, CFC assay output revealed a unique defect in erythroid specification 
from HSC upon ZZZ3 loss (Fig. 3.8A), with no changes to generation of mixed-lineage 
(Mix) or GM colonies. Colony formation from downstream lineage-restricted 
progenitors was not affected, suggesting a unique requirement of ZZZ3 in early 
erythroid commitment, and a dispensable role for the ATAC component post-
erythroid commitment, as well as in the myelo-monocytic lineages. SUPT20H 
expression knockdown, on the other hand, did not result in significant changes in 




























































































































































FIGURE 3.8  CFC-efficiency of human stem and progenitor CB cells transduced with 
ATAC (ZZZ3) and SAGA (SUPT20H) specific subunits. (A) Frequency of 
colony forming efficiency (CFC) in the HSC/MPP, MEP (top), GMP and MLP 
compartments (bottom) transduced with ZZZ3sh. Mean ± SEM of 5 individual 
CB samples (4 for GMP, MLP). Two-tailed paired t-test for significance; 
*p<0.05, **p<0.01. (B) Frequency of CFC efficiency in the HSC/MPP, MEP, 
GMP and MLP compartments transduced with SUPT20Hsh. Mean ± SEM of 4 
individual CB samples. Two-tailed paired t-test for significance; no significant 
differences.  
 
nspection of a detailed single-cell profiling of erythroid lineage development by Tusi 
et al. (2018) captured Kat2a and Zzz3 enrichment, but no elements of the SAGA 
complex, at the transition of multipotent progenitors to the erythroid and 
megakaryocytic lineages (Fig. 3.9; Appendix B - Enriched genes in erythroid-
basophil-megakaryocyte-biased progenitors (EBMP) as per detailed single-cell 
profiling of erythroid development by Tusi et al. (2018).  
 
































































































































FIGURE 3.9   Gene expression (selected region) pattern of Kat2a and Zzz3 in erythroid 
development. Visualisation obtained using SPRING tool 
(https://kleintools.hms.harvard.edu/paper_websites/tusi_et_al/). As per 
Appendix B, other genes in this region include regulators of E/Meg cell fate 
commitment including Gata2, Zfpm1 and Myb. MPP: multipotent progenitors. 
EBMP: erythroid-basophil-megakaryocyte-biased progenitors. Meg: 
megakaryocyte. Ba: basophil. CEP: committed erythroid progenitors. ETD: 
erythroid terminal differentiation. 
 
 
This result supports the notion that KAT2A regulation of human early erythroid 
specification is likely dependent on ATAC activity.  
 
 
Interestingly, examination of the expression pattern of SAGA-specific elements 
during in vitro maturation of committed erythroid progenitors from human CB [274], 
showed that several elements associate with late differentiation, including members 
of the SAGA Core (TAF5L and SUPT7L), but also the SAGA-specific HAT subunit 
TADA2B and the H2B de-ubiquitinase, USP22 (Fig. 3.10; Appendix C – Erythroid 















FIGURE 3.10  Expression pattern of SAGA-specific elements during in vitro maturation 
of committed erythroid progenitors from human CB. SAGA-specific 
elements peak at the Intermediate (IntE) phase of late erythroid 
differentiation. Representation of SAGA-specific TADA2B (left) and USP22 
(right) within Cluster 17 extracted from visualisation database: 




In light of these data, I investigated if loss of SAGA DUB module-USP22 would mimic 
the defect observed in colony-formation at later E maturation (MEP stage) verified 
upon KAT2A knockdown in human CB (Fig. 3.3). As before, CB CD34+ cells were 
transduced with a lentiviral-delivered USP22 targeting shRNA and HSC, MLP, GMP 
and MEP sorted for downstream analysis. USP22 depletion was verified by both qRT-
PCR (Fig. 3.11A) and WB in haematopoietic cells (Fig. 3.11B). There was no 
detectable difference in the relative proportion of stem and progenitor GFP+ cells post-
transduction with USP22sh (Fig. 3.11C). However, unlike SUPT20H loss, knockdown 
of USP22 did result in loss of erythroid colony formation from committed MEP (Fig. 
3.11D). It did not significantly affect erythroid output from HSC and multipotent 
progenitors (Fig. 3.11C), suggesting that the MEP loss observed upon KAT2A 
knockdown may be due to synergistic effects of KAT2A participation in ATAC (early-
stage roles) and SAGA (post-erythroid commitment). Colony output from MLP and 
GMP, and indeed mixed-lineage or GM colony formation from HSC, were not affected 
(Fig. 3.11C), indicating a unique contribution of USP22 to expansion, differentiation, 
or survival of MEP.  
 
 


























FIGURE 3.11 Depletion of SAGA-DUB module USP22 subunit in human CB CD34+ cells. 
(A) Quantitative RT-PCR validation of USP22 knockdown in CB HSCs. Mean ± 
SEM of 3 individual experiments; gene expression relative to CTRLsh, 
normalised to HPRT1 housekeeping gene. Paired two-tailed t-test for 
significance **p<0.01. (B) Western blot analysis showing USP22 (60KDa) 
knockdown efficiency in K562 cells. ACTB (42KDa) was used as loading 
control. (C) Proportion of USP22sh transduced CB HSC and progenitors. Mean 
± SEM of >4 individual sorting experiments. Two-tailed paired t-test for 
significance; no significant differences. (D) Frequency of CFC efficiency in the 
HSC/MPP, MEP (top), GMP and MLP (bottom) compartments transduced with 
USP22sh. Mean ± SEM of 4 individual CB samples. Two- tailed paired t-test for 
significance; *p<0.05.  
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Altogether, colony-forming progenitor assays of CB CD34+ cells aligned loss of 
KAT2A-containing ATAC complexes with impairment of early erythroid and 
megakaryocytic specification. It also suggested that KAT2A-containing SAGA 
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3.3.3 KAT2A-containing ATAC and SAGA complexes have unique 
targets in haematopoietic cells  
 
In order to characterise KAT2A complex-specific roles in the blood system, chromatin 
immunoprecipitation followed by next-generation sequencing (ChIP-seq) of ATAC and 
SAGA-specific subunits was performed in self-renewing K562 cells. Specific sera 
against human ZZZ3 (ATAC-specific) and SPT20 (SAGA-specific) prepared in the Tora 
Lab [245], was used for ChIP-seq experiments, performed in duplicate.  
 
As in previous reports, there was limited overlap between ATAC and SAGA targets 
(Fig. 3.12A; Appendix D – ChIP-seq targets in human K562 cells). Bound peaks 
were preferentially found in the vicinity of the transcriptional start site (TSS) (Fig. 
3.12B) and were robustly enriched for known ZZZ3 and SPT20 targets, respectively 
(Fig. 3.12C-D). Interestingly, ZZZ3 peaks were more proximal than SPT20, contrary 
to the previously described enhancer association of ATAC complexes in lymphoblast 
and HeLa cells [245]. However, consistent with these results, a distinct ZZZ3 ChIP-
seq experiment in human NSCLC cells revealed that ZZZ3 peaks were strongly 
enriched at regions ±1 kb of TSS [235]. This suggests that ATAC-complex enhancer 
region occupancy may be cell type or context dependent. ENCODE experimental 
enrichment [275] of sequence-specific transcription factors within ZZZ3 and SPT20 
peaks was clearly distinct (Fig. 3.12C-D), highlighting unique complex biologies. 
These were reflected in distinct GO categories associated with complex-specific 
peaks, which encompass RNA and ribosomal metabolism in the case of ATAC (Fig. 







































FIGURE 3.12  ChIP-seq analysis of KAT2A-containing ATAC and SAGA complexes in 
K562 cells. (A) Venn-diagram of consensus ZZZ3 and SPT20 ChIP-seq 
binding from 2 independent experiments. (B) Genomic location of ZZZ3 (left) 
and SPT20 (right) ChIP-seq binding in K562 cells. Summary of consensus 
peaks from 2 independent ChIP-seq experiments is shown. (C) Specificity of 
ATAC (ZZZ3) and SAGA (SPT20) ChIP-seq targets against ENCODE; data as 
retrieved by EnrichR online annotation tool [275] (C,D). Specificity of ATAC 
(ZZZ3) and SAGA (SPT20) ChIP-seq targets against ENCODE; data as 
retrieved by EnrichR online annotation tool [275] (E,F). Top Gene Ontology 
(GO) associations of ZZZ3 and SPT20 ChIP-seq targets on biological processes 
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Moreover, SAGA specifically binds red blood cell-associated genes such as HBB (Fig. 
3.13A), which may indicate a unique role in erythroid differentiation or identity. 
ZZZ3, on the other hand, binds ribosomal protein genes such as RPS7 (Fig. 3.13A). 
Inspection of publicly available K562 ChIP-seq datasets in the ENCODE database 
confirmed that SPT20 and ZZZ3-bound regions coincided with H3K9ac peaks, a 
hallmark of KAT2A enzymatic activity [177] (Fig. 3.13B). Accordingly, loss of H3K9ac 
was observed at gene promoters upon SPT20 or ZZZ3 shRNA-mediated knockdown 
(Fig. 3.13C). Locus-specific loss of H3K9ac coincided with down-regulation of gene 
expression, which on the selected genes, was unique to loss of SAGA or ATAC 
complex elements (Fig. 3.13D). In other words, downregulation of ATAC function 
had no effect on SAGA-bound genes and vice versa. Gene expression changes could 
be partially recapitulated by KAT2A gene expression knockdown (Fig. 3.13E-F), 
particularly in respect of ZZZ3-bound elements, which could reflect differential 
dependence and/or redundance of histone acetyltransferase activity in either 
complex. Indeed, K562 cells were more clearly dependent on ZZZ3 than on SPT20 
for propagation in culture (Fig. 313F), which could potentially explain the greater 
number of target genes (Fig. 3.12A), and loss of KAT2A had an intermediate effect 
(Fig. 3.13F) which did not involve changes in cell cycle (Fig. 3.13G) or apoptosis 
(Fig. 3.13H). Finally, I also looked at H3K9ac changes at EPOR which was 
downregulated up KAT2A knockdown in CB, but did not observe significant changes, 
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FIGURE 3.13  KAT2A-containing ATAC and SAGA complexes have unique functional   
associations in K562 cells. (A) Representative ChIP-seq peak for ZZZ3 
target in K562 cells (RPS7) and representative ChIP-seq peak for SPT20 target 
in K562 cells (HBB). (B)  Publicly-available ChIP-seq tracks for H3K9ac 
(ENCFF257CLC) and ZZZ3 (ENCFF856KCV) in K562 cells at the RPS7 and 
HBB loci retrieved from the ENCODE project portal (www.encodeproject.org). 
The RPS7 and HBB loci in (A) are represented confirming the presence of 
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H3K9ac peaks and reproducing the selective ZZZ3 binding at RPS7 also 
observed in our data. (C) H3K9ac ChIP-qPCR analysis of representative 
SPT20 and ZZZ3 targets upon knockdown in K562 cells. N³3 independent 
experiments. Mean ± SEM of enrichment relative to rabbit-IgG, with 
normalisation to control intergenic region with no significant H3K9ac 
enrichment. Two-tailed t-test for significance *p<0.05. (D) Quantitative RT-
PCR analysis of expression of ATAC and SAGA complex targets in K562 cells. 
N³3 independent experiments, mean ± SEM of gene expression relative to 
CTRLsh, normalised to HPRT1 housekeeping gene. Two-tailed t-test for 
significance *p<0.05, **p<0.01, ***p<0.001. (E) Quantitative RT-PCR 
validation of KAT2A knockdown in K562 cells. Mean ± SEM of 8 individual 
experiments; gene expression relative to CTRLsh, normalised to HPRT1 
housekeeping gene. Paired two-tailed t-test for significance ***p<0.001.  (F) 
Growth curve of K562 cells transduced with shRNA constructs against ZZZ3, 
SUPT20H and KAT2A.  Mean ± SEM of 3 independent experiments. ANOVA 
for mixed effects analysis - Tukey’s multiple comparisons test significance 
*p<0.05, **p<0.01, ***p<0.001. (G) Flow cytometry analysis of cell cycle in 
K562 cells transduced with CTRLsh and KAT2Ash. Mean ± SEM of N=3 
independent experiments. Two-tailed t-test for significance; no significant 
changes. (H) Quantification of Annexin V+ apoptotic cells in K562 cultures 
transduced with CTRLsh and KAT2Ash. Mean ± SEM of N=3 independent 
experiments. Two-tailed t-test for significance. No significant difference. (I) 
H3K9ac ChIP-qPCR analysis of representative EPOR, and SPT20 targets MYC 
and JARID2 upon knockdown in K562 cells. N³3 independent experiments 
for EPOR; N=2 independent experiments for EPOR for MYC and JARID2. 
Mean ± SEM of enrichment relative to rabbit-IgG, with normalisation to 




Together, in line with independent activities of each complexes in hematopoietic cell 







 108  
As in primary CB cultures, I inspected the progression of erythroid differentiation in 
K562 cells upon depletion of ATAC and SAGA members ZZZ3 and SPT20. Erythroid 
differentiation is indicated by the gain of CD235a and loss of CD71 surface 
expression. Exposure of K562-CTRLsh (GFP+) cells to 1.5% DMSO resulted in 
accumulation of CD235a+ cells and progressive loss of the early erythroid-expressing 
CD71+ cells over a 6-day time-course (Fig. 3.14A). Moreover, it was accompanied by 
downregulation of early erythroid regulator GATA2 from Day 0 to Day6, with up-
regulation of EPOR and TAL1 (Fig. 3.14B). Thus, these results suggest that DMSO 
treatment effectively promotes erythroid differentiation programs. DMSO-induced 
differentiation cultures initiated by KAT2A or ZZZ3 knockdown cells followed a 
similar progression to control, as demonstrated by molecular analysis. As shown in 
Fig. 3.14C, ZZZ3 knockdown resulted in decreased GATA2 expression from Day 0 
to Day6, whereas TAL1 expression augmented from Day 0 to Day6. The same was 
verified upon KAT2A depletion, for which a change in EPOR was also detected, its 
expression increasing in the last day. This is compatible with unhindered erythroid 
differentiation post commitment. In contrast, SUPT20H depletion significantly 
perturbed erythroid differentiation of K562 cells, which abnormally retained 
expression of GATA2, and failed to consistently up-regulate EPOR and TAL1, 







































FIGURE 3.14  KAT2A-containing SAGA complex facilitates erythroid cell differentiation 
in hematopoietic K562 cells. (A) Time course of erythroid marker 
profiling by flow cytometry in K562 cells transduced with CTRLsh 
treated with 1.5% DMSO to induce erythroid differentiation. Proportion 
of cells expressing early (CD71) and late (CD235a) differentiation 
markers is shown at each time-point.  Data summarise mean ± SD of 6 
independent experiments. (B) Quantitative RT-PCR analysis of erythroid 
gene expression of CTRLsh-transduced K562 cells at the start (day 0) and day 
6 of 1.5% DMSO-induced erythroid differentiation. Mean ± SD of N>3 
independent experiments; data are represented relative to day 0 normalised to 
HPRT1 housekeeping gene. Two-tailed paired t-test for significance *p<0.05, 
**p<0.01, ***p<0.001. (C) Quantitative RT-PCR analysis of erythroid gene 
expression in K562 cells transduced with KAT2Ash, SUPT20Hsh and ZZZ3sh 
at day 6 of 1.5% DMSO-induced erythroid differentiation. Mean ± SD of N>3 
independent experiments, mean ± SEM of gene expression relative to day 0, 
normalised to HPRT1 housekeeping gene. Two-tailed paired t-test for 
significance *p<0.05, **p<0.01. 





































































* *** ** ** ****




























day 0 day 6
** ** ***
 110  
Overall, this result is compatible with a role for SAGA in facilitating late erythroid 
differentiation programmes, which supports the requirement for KAT2A and USP22 
in erythroid colony-formation from CB MEP. ATAC, on the other hand, is dispensable 
for this process, despite being required for maintenance of undifferentiated K562 
cells. The stage-specific requirement of either complex is broadly compatible with my 
observations in CB.  
 
 
3.4 Conclusions and future work  
 
The work herein, set out to investigate KAT2A functions in normal human 
haematopoiesis, demonstrated that KAT2A depletion resulted in loss of erythroid 
cell-containing colony types from both HSC and MEP CB compartments. This 
indicates that KAT2A is specifically required for appropriate specification and/or 
survival of erythroid/platelet committed progenitors, as well as in differentiation of 
red cell and platelet lineages. The removal of KAT2A had no impact on lymphoid and 
myeloid lineage potential from CB. It had been previously demonstrated that loss of 
Kat2a promoted terminal granulocytic differentiation in vitro, in the mouse blood 
system [196]. Whilst I failed to see an increase in GM colony formation upon KAT2A-
depletion, this could be due to differences between mouse and human 
haematopoietic systems. It should be said that CB-derived colonies were 
counted/scored visually under the microscope not-blindly. As such, it is arguable 
that this constitutes a limitation when compared to blind non-biased scoring, as well 
as more automated methods and/or the scoring by multiple operators. Any possible 
bias associated would have been excluded if the plates had been scored blindly. No 
defects in cell proliferation were noted upon KAT2A knockdown in any of the CB 
populations studied, discarding cell cycle as a prevailing mechanism by which 
KAT2A fosters erythroid development. In contrary, KAT2A-depletion resulted in 
increased apoptosis of HSC and MEP fractions, suggesting a role for KAT2A in 
survival of these cell populations. The results from CFC assays were matched by 
transcriptomic analysis of stem/multipotent CB cells in which KAT2A expression 
had been knocked down. Indeed, there was evident downregulation of erythroid (e.g.: 
HBB, GFI1B, HBG1 or HBG2) and platelet (e.g.: VWF, ITGB3) associated genes upon 
KAT2A-depletion in CB HSC, indicating that KAT2A regulates a shared erythroid and 
megakaryocytic transcriptional programme. Moreover, GSEA identified ‘erythroid 
differentiation’ and ‘platelet biology’ as enriched signatures of the RNA-seq data. In 
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future, it would be valuable to test some of the genes downregulated upon KAT2A 
depletion e.g.: EPOR, HBB, ID2 or TAL1, in phenocopy and rescue experiments to see 
(1) if the erythroid defect is indeed mimicked at the expected developmental stage (2) 
if the erythroid defect can be rescued by enforced expression of the candidate(s) 
downregulated gene(s). This would be a better indication that KAT2A directly 
regulates these genes, and it would be carried out by shRNA and overexpression 
constructs attempting to elicit or rescue phenotypes in CFC or other functional 
assays. Whereas the erythroid lineage is more obvious to track in CFC-assays, 
detection of megakaryocyte-only colonies would require adding TPO to the media. 
Still, megakaryocyte colonies may be difficult to detect morphologically, as they may 
contain very few cells. It would have been interesting, however, to follow 
megakaryocytic/platelet cell fate more thoroughly, for example by performing 
specialised CFU-Mk colony assays which relies on immunostaining for the 
megakaryocyte marker CD41.  
 
Given that KAT2A exerts its function via two distinct transcriptional co-activator 
complexes, ATAC and SAGA, I explored their contribution to normal blood 
development. Whilst I found that loss of ATAC (ZZZ3) resulted in a specific defect in 
erythroid colony-formation exclusively from HSC, no effects in lineage specification 
were noted when depleting SAGA (SUPT20H) from CB. This result points to a unique 
role of ATAC in human erythroid specification and align KAT2A early requirement in 
HSC with its participation in ATAC-complexes. Moreover, this seems to be the case 
not only at the level of lineage specification, but potentially also in survival of the 
erythroid lineage. Indeed, by examining the single-cell profiling of erythroid 
development by Tusi and colleagues, I found that both Kat2a and Zzz3 were enriched 
at the transition of multipotent progenitors to the erythroid and megakaryocytic 
lineages, where no elements of the SAGA complex were found [276]. Additionally, in 
the same study, gene set enrichment on dynamic gene clusters in early erythroid 
differentiation revealed cell essential biosynthetic pathways (RNA processing factors 
and ribosomal proteins) as early developmental events, which one could speculate is 
how ATAC-mediated KAT2A activities participate in cell survival [276]. This is 
speculative, and it would have been further understood by looking at apoptosis in 
CB compartments upon specific ATAC and SAGA- subunit depletion. Interestingly, 
when investigating the role of SAGA DUB module by downmodulating USP22 in 
human CB, I verified loss of erythroid colonies exclusively from MEP, bringing SAGA 
activities back into play. This same phenotype had also been noted upon KAT2A-
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depeletion. Two hypotheses can be raised to try and explain this result. On one hand, 
it is possible that both SAGA enzymatic modules - HAT (KAT2A) and DUB (USP22) – 
cooperate to regulate erythroid development post-commitment, in which SAGA Core 
(SPT20) roles may be dispensable. In other words, regulation of fully committed 
erythroid progenitors could involve the combinatory action of both histone/protein 
acetylation and deubiquitination. USP22 catalyses the deubiquitination of histone 
H2B and H2A, thereby acting as a transcriptional coactivator [277–278]. It is 
recruited to specific gene promoters by activators such as MYC and p53 [277]. As a 
result of USP22 loss, the level of H2B/A deubiquitination is lowered, leading to 
decreased transcription at target gene loci. As mentioned in the previous Chapter, 
transcriptionally repressive states can involve the action of PRC1 and PRC2 
complexes, which catalyse H2A ubiquitination and H3K27me3, respectively. It is 
possible that late erythroid-affiliated TFs would recruit SAGA to remove 
ubiquitination marks deposited by PRC complexes at histones via USP22. In turn, 
upon relief of repressive chromatin status, this would allow other epigenetic players, 
for example MLL complexes to promote SAGA-dependent acetylation, maintaining 
gene expression programmes relevant to erythroid development. Moreover, USP22 
deubiquitinates and stabilises SIRT1, likely within the context of SAGA [261], a 
histone deacetylase with specificity for a number of proteins including histone H3. 
Once deubiquitinated, SIRT1 is not targeted to proteosome degradation, in turn, 
supressing transcriptional programmes [261]. Further investigation is certainly 
needed to understand the potential crosstalk between these chromatin-remodelling 
complexes and their implications to transcription of erythroid genes. As a second 
possibility, KAT2A and USP22 roles are not strictly dependent on the association 
with the SAGA Core. Accordingly, it was previously demonstrated that SAGA HAT 
module can exist as a separate complex, at least in Drosophila [232], which may 
explain some level of independence from the Core module containing SPT20, and the 
differential role in late erythropoiesis in CB.  Likewise, USP22 does not seem to 
require SAGA incorporation in order to be directed to target genes [278]. Also, the 
recent elucidation of the structure of yeast SAGA suggests that upon binding of a 
nucleosome, SAGA displaces the HAT and DUB modules from the Core module [214], 
again suggesting some degree of independence that could be conserved from yeast 
to human.  
 
The fact that SAGA did not impact lineage fate commitment from HSC but was shown 
to regulate progression of erythroid differentiation post-commitment (via USP22), 
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suggests a role in controlling, rather than establishing transcriptional programmes 
and cell identity. In agreement, USP22 functions have been associated with lineage-
specific differentiation programmes [226]. Yet SAGA requirements may be 
contributory, rather than absolute, given that the same was not verified with the 
other SAGA element investigated, SPT20. To investigate this further, it would be of 
interest to assess what happens to the expression of late erythroid regulators upon 
USP22 knockdown and see if it correlates with the loss of H2B deubiquitination. 
Testing additional specific elements of Core or DUB modules, for example SUPT3H, 
that binds TATA-binding protein, and ATXN7, respectively would also be informative.  
 
This interpretation from the CB experiments, suggesting that ATAC, but not SAGA, 
is relevant for the cell fate decision towards erythropoiesis and not to terminal 
differentiation, would have been further supported if the GFP+ levels had been 
assessed at the end point of CFC-assays to confirm whether the shRNA expression 
was, in fact, silenced. The GFP+ levels had, however, been evaluated in the erythroid 
differentiation experiment in CB upon KAT2A depletion (Fig. 3.4), confirming gene 
silencing throughout the differentiation. Moreover, from a 2-day erythroid 
differentiation experiment performed in K562 cells in which KAT2A and ZZZ3 had 
been knocked down (data not presented in this thesis), the percentage of GFP+ cells 











FIGURE 3.15 GFP+ percentage in CTRLsh, KAT2Ash and ZZZ3sh K562 cells in a 
2-day erythroid differentiation culture experiment.  
 
In addressing the genome binding pattern of the two human KAT2A-containing 
complexes in haematopoietic K562 cells, the results showed that ATAC and SAGA 
have distinct chromatin substrates. Specifically, ATAC (ZZZ3) binds RNA metabolism 
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and ribosomal protein genes, while SAGA (SPT20) associates with DNA-binding and 
transcription related loci. First, this was interesting because, in previous work, 
namely in yeast, SAGA was found to be recruited mainly to stress regulated genes 
[279–280], which was not verified in this, as well as another study in human cell 
lines [245]. Thus, the data suggests diversification of SAGA complexes, or of KAT2A 
function itself, from yeast to human. Furthermore, it was demonstrated that both 
ATAC and SAGA have a narrow subset of target genes, 1088 and 165 bound-peaks, 
respectively. This, particularly in the case of SAGA, alludes to the possibility that it 
functions as coactivator for specific gene expression programmes, contrary to 
previously reported global acetylation functions [281]. This is supported by analysis 
of SAGA-bound genes, which associate with DNA-binding and regulation of 
transcription, as examples: MYC, E2F4, MLL1, STAT1, STAT3, MBD3 and RELA. The 
fact that K562 cell line was used to perform the ChIP-seq experiment to investigate 
normal haematopoiesis could pose some limitations, particularly if we aim to 
compare with the RNA-seq datasets, which derive from experiments performed in 
primary cells. As previously mentioned, K562 are a chronic myelogenous leukaemia 
cell line with multilineage potential [271]. These cells display aspects of molecular 
differentiation into erythroid, megakaryocytic and macrophage identities under 
defined cytokine conditions; in steady state, K562 cells represent immature 
leukaemia blasts with self-renewal properties. K562 cells have, however, been 
repeatedly used in past research as a model for understanding molecular 
mechanisms of normal erythroid, and malignant blood specification [282–285].  
 
The highly specific binding sites likely reflect different modes of recruitment of the 
two complexes, which could in principle associate with a stage specific 
TF/chromatin-complex relationship. In human CB, both ATAC and SAGA co-
activator complexes were found to be required in regulation of developmental stages 
in erythropoiesis - ATAC acting early, at the lineage specification level, and SAGA 
facilitating late differentiation, a phase devoid of ATAC function. In self-renewal K562 
cells, SPT20 (but not ZZZ3) was found to bind late erythroid-loci including HBB, for 
which expression was exclusively down-regulated upon SUPT20H knockdown. 
Indeed, knockdown of ATAC ZZZ3 or SAGA SUPT20H clearly affected the specific 
genes predicted to be bound by the respective complexes, which associated with loss 
of H3K9ac in both cases, suggesting that the expression of the regulated genes is 
dependent on HAT activity. If the limited number or target genes was to be a technical 
limitation of the ChIP experiment, functional qPCR (RT and CHIP-) analysis wouldn’t 
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have shown a correlation between knockdown of ATAC (ZZZ3) or SAGA (SUPT20H) 
and downregulation of the specific predicted bound genes by either complex. 
Interestingly though, knockdown of shared ATAC and SAGA - KAT2A in K562s, lead 
to reduced expression of ATAC target genes, but not of SAGA, at least the selected 
HBB locus. This may be due to the need for additional SAGA subunits in regulation 
of the HBB locus, for example its DUB module as suggested in erythroid maturation 
from CB. On the other hand, the fact that SPT20-bound peaks are less close to the 
TSS than ATAC, could suggest that SAGA is recruited to tissue stage-specific/ 
proximal enhancers. Although, reports suggest that the action of HAT complexes is 
more specific at enhancers, but more redundant at promoters [286], in which case 
maybe SAGA relies on KAT2B, and not KAT2A in final erythroid maturation stages. 
Notably, SUPT20H specifically interferes with the establishment of late differentiation 
programmes, a role that apparently exceeds KAT2A itself, since in its absence K562 
and CB cells reach a similar CD235a+ levels as control cells. Again, it is possible that 
SAGA complexes in late erythroid differentiation utilise the orthologue KAT2B thus 
compensating for KAT2A loss. Increased KAT2B expression in late erythroid 
differentiation (Appendix C) is compatible with this view, but this hypothesis needs 
examination. Another line of evidence to suggest redundancy by KAT2B in late 
erythroid development is that it was shown to interact with, and acetylate, TAL1, 
promoting erythroid differentiation in murine erythroleukemia (MEL) cells [287]. 
TAL1 associates with complexes containing master erythroid regulators, such as 
GATA2. The fact that progression of erythroid differentiation in K562 cells was 
uniquely impaired upon deletion of SUPT20H through failure in downregulating 
GATA2, could suggest redundancy by KAT2B, potentially involving prior TAL1-
acetylation.  Investigating combined requirements of subunits from both Core / DUB 
modules, Core / HAT or HAT / DUB modules would help elucidate the exact 
epigenetic and transcriptional mechanisms at place.  
 
Overall, analysis of normal human haematopoietic development indicates that 
KAT2A plays stage-specific roles in erythropoiesis, which are unique to the complexes 
it integrates. On the one hand, KAT2A regulates specification and survival of 
erythroid/ megakaryocytic progenitors likely through participation in the ATAC 
complex, which associates with biosynthetic activity pathways. On the other hand, 
KAT2A fine-tunes progression of erythroid differentiation through participation in 
SAGA, which is only required in fully committed progenitors and may play a 
contributory rather than an absolute role. This investigation emphasises the 
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importance of detailed analysis to unambiguously understand the biological roles of 
epigenetic complexes sharing the same enzyme in healthy, as well as malignant 






































Chapter 4  
Cellular investigation of KAT2A-complex 
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4.1 Introduction  
 
Having established differential requirements for ATAC and SAGA activity in normal 
blood and in the multipotent K562 line, I went on to investigate their contribution to 
AML biology, where our lab has previously established a role for KAT2A through a 
CRISPR drop-out screen (Fig. 4.1) [260]. In more detail, the authors studied five 
commonly used AML cell lines (MOLM-13, MV4-11, HL-60, OCI-AML2 and OCI-
AML3) in which they generated Cas9-expressing cells, which were then transfected 
with a lentiviral gRNA library to induce gene knockouts genome-wide. Following a 
period of continued culture, cells with diminished survival upon the loss in ‘essential 
genes’ were eventually outgrown by the larger number of cells whose survival was 
unaffected. The remaining cells were then harvested to determine stably integrated 
gRNA content by PCR amplification, thus allowing the identification of the ‘drop-out’ 

















FIGURE 4.1 KAT2A is a genetic vulnerability in AML. Table generated based on our lab’s 
CRISPR drop-out screen in AML cell lines across different genetic backgrounds 
[260]. Genes depleted in one or more AML lines are considered genetic 
vulnerabilities.  MOLM-13 (FLT3-ITD, MLL-AF9); MV4-11 (FLT3-ITD, MLL-AF4); 
HL-60 (NRAS p.Q61L); OCI-AML2 (hyperdiploidy and DNMT3A R635W); OCI-
AML3 (NRAS p.Q61L, NPM1 p.W288fs*12, BAX p.E41fs*33, DNMT3A). 
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Thus, human cell lines derived from AML bearing recurrent genetic abnormalities 
represent important in vitro models for the identification of novel genetic 
vulnerabilities of this disease. In order to investigate the cellular requirements of the 
two KAT2A complexes in human AML, I selected a panel of five AML cell lines ranging 
from MLL-rearranged leukaemia such as MOLM-13, MV4-11 (included in the original 
screen) and THP-1, as well as less commonly studied models, KG1a and Kasumi-1. 
MOLM-13 is a human AML cell line established from the peripheral blood of a 20-
year-old male at relapse, which had evolved from myelodysplastic syndrome (MDS). It 
harbours MLL-AF9 and FLT3-ITD fusion genes [288], and, phenotypically, 
corresponds to a myelomonocyte type leukaemia. THP-1 designates a monocyte-like 
cell line, derived from the peripheral blood of a childhood case of AML, also carrying 
an MLL-AF9 translocation [289], which occurs in approximately 20% of acute 
leukaemias. Model cell line MV4-11 was established from blasts cells of 10-year-old 
male with B-myelomonocytic leukaemia, harbouring a MLL-AF4 fusion gene and 
a FLT3-ITD mutation [290]. In turn, Kasumi-1 represents a less differentiated type 
of AML. It was established from peripheral blast cells from a 7-year-old Japanese 
male carrying a 8; 21 chromosome translocation, which gives rise to the fusion gene 
AML1-ETO or RUNX1-RUNX1T1, and an associated KIT mutation [291]. KG1a, a 
subline of KG1, is a promyeloblast type cell line [292]. KG1 was established from a 
59-year-old patient in whom AML had developed following an earlier phase of 
erythroleukaemia. Its derivative, KG1a, has the same karyotype abnormalities, 
including FGFR1OP2-FGFR1 fusion, but appears undifferentiated, failing to express 
the myeloid characteristics of the parent line KG1. Thus, the KG1a line represents a 
very immature type AML.  Whereas MOLM-13 and MV4-11 were used in the CRISPR 
screen that established KAT2A as a vulnerability in AML, none of the remainder cell 
lines were investigated, and its dependencies on elements of ATAC and SAGA 
complexes is currently unknown. AML remains a lethal disease for the majority of 
patients. A block of cellular differentiation is a hallmark of this disease, in which 
myeloid blasts fail to differentiate into fully functional mature myeloid cells. 
Preservation of the typical undifferentiated leukaemic cell identity and/or function 
depends on cellular mechanisms balancing cell death and cell proliferation. As such, 
cell processes including apoptosis, proliferation and differentiation are key 
mechanisms shaping leukaemogenesis. Here, I aimed to investigate how they are 
regulated by KAT2A and its complexes in the AML cell lines described above.  
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4.2 Chapter overview  
In this Chapter, I describe the results of functional in vitro experiments aimed at 
dissecting the contributions of ATAC and SAGA-KAT2A complexes to human AML. I 
used a panel of five human AML cell lines and a shRNA-mediated gene knockdown 
approach throughout. I targeted ATAC specific components ZZZ3, TADA2A and 
YEATS2, as well as SUPT20H and TADA2B, unique SAGA subunits. I demonstrate 
that both ATAC and SAGA functions are required to sustain AML cells in culture, 
but with separate effects on the leukaemia biology. Specifically, ATAC regulates 
biosynthetic activity necessary to maintain proliferating cells. On the other hand, 
SAGA mediates preservation of the characteristic undifferentiated identity of AML 
blasts, its loss promoting leukaemic differentiation. The unique roles of both 
complexes were observed across the different AML cell lines, independently of their 
molecular background. Together, these results explain the requirement of KAT2A in 
AML, which participates in one or the other complex to mediate distinct activities.  
 
4.3 Results and discussion   
 
In order to investigate KAT2A complex-specific requirements to AML, I knocked down 
the expression of unique ATAC (ZZZ3, TADA2A and YEATS2) and SAGA (SUPT20H, 
TADA2B) subunits in a panel of five AML cell lines. I explored the phenotypic 
consequences of depleting the ATAC and SAGA elements by conducting, cell cycle 
differentiation and apoptosis assays, complemented by gene expression analysis 
(Fig. 4.2). 
 
FIGURE 4.2 Schematic of the adopted experimental strategy. 
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4.3.1 KAT2A complexes uniquely maintain proliferation and 




I started by investigating the model AML cell line MOLM-13, previously shown to be 
dependent on KAT2A expression and activity [260]. Knockdown of ATAC (ZZZ3 and 
TADA2A), and of SAGA (SUPT20H and TADA2B) specific elements was verified by RT-
qPCR (Fig. 4.3A), together with the shared HAT KAT2A. Knockdown of KAT2A and 
of the subunits of its containing chromatin complexes restricted expansion of MOLM-
13 cultures as shown in Fig. 4.3B-C. Moreover, loss of KAT2A, at least when 
examined in parallel with ZZZ3sh and SUPT20Hsh transduced lines, seems to have 
a more profound effect than that of ATAC (ZZZ3sh) and SAGA (SUPT20Hsh) 
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FIGURE 4.3 Knockdown of ATAC and SAGA-specific components hinders expansion of 
MOLM-13 cells. (A) Quantitative RT-PCR validation of KAT2A, SUPT20H and 
TADA2B (SAGA-specific subunits) and ZZZ3 and TADA2A (ATAC-specific 
subunits) knockdown in MOLM-13 cells. N³3 independent experiments, mean ± 
SEM of gene expression relative to CTRLsh, normalised to HPRT1 housekeeping 
gene. Two-tailed t-test for significance *p<0.05, **p<0.01, ***p<0.001. (B) 
Growth curve of MOLM-13 cells transduced with shRNA constructs against 
KAT2A, SUPT20H and ZZZ3.  Mean ± SEM of 3 independent experiments. ANOVA 
for mixed effects analysis - Tukey’s multiple comparisons test significance 
*p<0.05, **p<0.01, ***p<0.001. (C) Growth curve of MOLM-13 cells transduced 
with shRNA constructs against TADA2B and TADA2A. Because two of the 
replicates from the CTRLsh group were lost due to technical failure, statistical 
analysis could not be performed.  
 
At a molecular level, depletion of KAT2A and ATAC components ZZZ3 and TADA2A, 
but not of SAGA elements (SUPT20H and TADA2B), led to reduced expression of 
ribosomal protein genes, RLP13 and RPS7 (Fig. 4.4A). This result in line with a 
pervasive control of protein biosynthetic activity by the ATAC complex suggested in 
the previous Chapter. The same function was also reported in lung cancer cell lines 
depleted of ZZZ3 and YEATS2 (ATAC complex) [235]. As shown in Fig. 4.4B, 
expression of MOLM-13 self-renewal signature genes HOXA9 and HOXA10, showed 
a more extensive association with ATAC elements. This was evidenced by reduced 
expression of HOXA9 upon depletion of ZZZ3 and TADA2A, and of HOXA10 following 
ZZZ3 knockdown (Fig. 4.4B). KAT2A loss in turn, had no impact on the expression 
of the tested HOXA genes (Fig. 4.4B). In accordance, inspection of our lab’s Kat2a 
KO leukaemia mouse model [197], carrying a similar MLL-AF9 leukaemia fusion 
oncogene, showed that progressive depletion of leukaemia stem-like cells does not 
strictly depend on the typical Hoxa gene signature.  
B C 








FIGURE 4.4 Analysis of MOLM-13 metabolism and self-renewal gene signature upon   
depletion of KAT2A, SAGA-specific SUPT20H and TADA2Bsh ATAC-specific 
ZZZ3 and TADA2A subunits. (A) Quantitative RT-PCR analysis of ribosomal 
protein gene expression in MOLM-13 cells transduced with KAT2Ash, SAGA-
specific SUPT20Hsh and TADA2Bsh and ATAC-specific ZZZ3sh and TADA2Ash. 
N³3 independent experiments, mean ± SEM of gene expression relative to 
CTRLsh, normalised to HPRT1 housekeeping gene. Two-tailed t-test for 
significance *p<0.05, **p<0.01, ***p<0.001. (B) Quantitative RT-PCR analysis of 
self-renewal gene signature in MOLM-13 transduced with KAT2Ash, SAGA-
specific SUPT20Hsh and TADA2Bsh and ATAC-specific ZZZ3sh and TADA2Ash. 
N=2 biological replicates, each run as 2 or 3 technical repeats; mean ± SEM of 
relative gene expression relative to CTRLsh, normalised to HPRT1 housekeeping 
gene. Two-tailed nested t-test for significance *p<0.05, **p<0.01, ***p<0.001.  
 
 
Given that KAT2A mediates H3K9 acetylation activity through either ATAC or SAGA 
complexes, to facilitate transcriptional activation, the next step was to assess 
differences in H3K9ac changes at the promoters of the genes analysed earlier. Loss 
of ZZZ3 resulted in decreased levels of H3K9ac in ribosomal protein genes and HOXA 
genes (Fig. 4.5) in line with the reduced gene expression (Fig. 4.4), which now can 
be attributed to KAT2A histone acetylation activity. Surprisingly, despite the selective 
impact of ATAC elements on gene expression, this analysis also showed reduced 
H3K9ac at ribosomal protein genes, HOXA genes and MEIS1 promoters upon loss of 
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FIGURE 4.5 H3K9ac ChIP-qPCR analysis of ribosomal protein genes and self-renewal 
genes in MOLM-13 cells upon knockdown of SAGA (SUPT20H) and ATAC 
(ZZZ3) elements. N³3 independent experiments. Mean ± SEM of enrichment 
relative to rabbit-IgG, with normalisation to control region in KRT5 locus with 
no significant H3K9ac enrichment. Two-tailed t-test for significance *p<0.05, 
**p<0.01, ***p<0.001 
 
HOX genes are highly expressed in stem cells, and their expression decreases with 
differentiation [293]. Whilst a reduced expression of HOXA9 and HOXA10 genes was 
verified predominantly upon loss of ATAC elements (Fig. 4.4, right), H3K9ac levels 
were reduced at their promoter following loss of both elements of ATAC (ZZZ3) and 
SAGA (SUPT20H). This suggests that although promoter occupancy may be more 
promiscuous than observed, for example, in K562 cells (Chapter 3), loss of H3K9ac 
per se is insufficient to decrease gene expression upon knockdown of SAGA.  
 
 
Analysis of the cellular consequences of gene knockdown, however, suggest that 
ATAC and SAGA act on distinct aspects on the biology of MOLM-13 cells. As shown 
in Fig. 4.6A-B, loss of ATAC ZZZ3 and TADA2A specifically arrested cell cycle 
progression in G0/G1, whereas depletion of KAT2A or SAGA-specific components 
allows normal progression through the cell cycle. In agreement with this finding, 




























































FIGURE 4.6 Cell cycle analysis of MOLM-13 cells upon knockdown of SAGA (SUPT20H, 
TADA2B) and ATAC (ZZZ3, TADA2A) elements. (A) Quantification of flow 
cytometry analysis of cell cycle in MOLM-13 cells transduced with KAT2Ash, 
SAGA-specific SUPT20Hsh and TADA2Bsh and ATAC-specific ZZZ3sh and 
TADA2Ash. Mean ± SEM of 3 independent experiments. Two-tailed t-test for 
significance *p<0.05, **p<0.01. (B) Representative flow cytometry plots of cell 
cycle analysis of MOLM-13 cells transduced with CTRLsh, KAT2Ash, SAGA-
specific SUPT20Hsh and TADA2Bsh, and ATAC-specific ZZZ3sh and TADA2Ash.  
 
 
To clarify the proliferation defect upon ATAC loss, I went on to perform cell divisional 
tracking following downmodulation of ZZZ3 and SUPT20H. In agreement with the 
lack of proliferation induced upon loss ATAC elements (Fig. 4.6), I observed a 
reduced number of ZZZ3 knockdown cells entering cell division (Fig. 4.7A-B) over a 





























FIGURE 4.7 Cell divisional tracking of MOLM-13 cells upon knockdown of SAGA 
(SUPT20H) and ATAC (ZZZ3) elements. (A) Representative flow cytometry 
plots of divisional tracking of MOLM-13 cells transduced with CTRLsh, 
SUPT20Hsh and ZZZ3sh and loaded with the Tag-IT violet dye after 3 days of 
culture. Regions 0, 1 and 2 represent the number of cell divisions relative to 
initial loading control. (B) Quantification of results in (B) representing the 
distribution of MOLM-13 cells transduced with CTRLsh, SUPT20Hsh and 
ZZZ3sh undergone 0-2 cell divisions after 3 days in culture. Mean ± SEM of 3 
independent experiments. Two-tailed t-test for significance *p<0.05. (C) Growth 
curve of MOLM-13 cells transduced with CTRLsh and shRNA constructs 
against SUPT20H and ZZZ3 and stained with Tag-it Violet cell tracking dye.  
Mean ± SEM of 3 individual experiments. ANOVA for mixed effects analysis - 
Tukey’s multiple comparisons test significance *p<0.05, **p<0.01, ***p<0.001. 
(D) Flow cytometry analysis of median fluorescence intensity of MOLM-13 cells 
stained with Tag-it Violet proliferation and cell tracking dye. As expected, the 
fluorescence is halved at each division.   
 
The data thus far positions the ATAC complex as an important regulator of self-
propagation of MOLM-13 AML cells. It is in agreement with previous observations 
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In contrast, loss of SAGA SUPT20H resulted in extensive differentiation of MOLM-13 
cells as observed morphologically (see methods section) (Fig. 4.8A-B). Similarly, loss 
of KAT2A also promoted cell differentiation (Fig. 4.8A-B), thus likely through its 













FIGURE 4.8 Differentiation analysis of MOLM-13 cells upon depletion of KAT2A, SAGA-
specific SUPT20H and ATAC-specific ZZZ3 subunits. (A) Quantification of 
blast-like and differentiated cells in MOLM-13 cultures transduced with 
CTRLsh, KAT2Ash, SUPT20Hsh and ZZZ3sh. Scoring of 3 randomly selected 
fields of >100 cells; Two-tailed t-test for significance; *p<0.05, **p<0.01, 
****p<0.0001. (B) Representative photographs of MOLM-13 cytospins. White 
arrow heads denote blast-like cells; black arrow heads denote differentiated 
cells. Scale 50 µm.  
 
 
This result points to a possible role of SAGA in preservation of cell identity as the 
blast cells are prompted into differentiation following loss of SUPT20H, and indeed of 
KAT2A. Interestingly, SAGA-mediated impact on MOLM-13 cell identify may not be 
exclusively exerted through the typical self-renewal HOXA gene signature, as 
suggested in Fig 4.4, where I observed loss of H3K9ac at HOXA9, HOXA10 and 
MEIS1 promoters followed ZZZ3 (ATAC) knockdown. This could suggest possible 
cooperation from other regulators, such as MYC in this AML, thus differentiation 
changes observed at cellular level may not be depended on H3K9ac. On the other 
hand, KAT2A activity in MOLM13 may involve H3K79 succinylation or other yet 
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When analysing apoptosis, there was no consistent apoptotic response to knockdown 
of any of the SAGA (SUPT20H and TADA2B), or ATAC (ZZZ3 and TADA2A) specific 
elements (Fig. 4.9A-B). This suggests that control of cell survival is not central to 
KAT2A complex-mediated maintenance of MOLM-13 AML cells. As for depletion of 
KAT2A itself, there is a trend towards enhanced apoptosis, which could be an end-























FIGURE 4.9 Apoptosis analysis of MOLM-13 cells upon depletion of KAT2A, SAGA- 
                     specific SUPT20H and ATAC-specific ZZZ3 subunits. (A) Quantification of 
Annexin V+ apoptotic cells in MOLM-13 cultures analysed by flow cytometry. 
Mean ± SEM of N>3 independent experiments; 2 biological replicates; 3 
technical replicates for KAT2Ash, TADA2Bsh, and ZZZ3sh groups; 6 technical 
replicates for SUPT20Hsh) Two-tailed t-test for significance.  (B) Representative 
flow cytometry analysis of apoptosis by Annexin V staining in MOLM-13 cells 
transduced with CTRLsh, KAT2Ash, SUPT20Hsh, ZZZ3sh (top) and CTRLsh, 
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staining allows for a distinction between viable cells (double negative), cells in 
early apoptosis (Annexin V positive), cells in late apoptosis (double positive) 
and dead cells (DAPI positive). N ³3 individual samples; mean ± SEM. Two-
tailed t-test for significance; no significant differences.  
 
 
Analysis of an additional ATAC-subunit, YEATS2 (Fig. 4.10A), also resulted in 
defects in cell cycle progression (Fig. 4.10B). Consistent with this observation, a 
compelling study showed dysregulation of cell cycle genes in human cancer cell lines 
upon shRNA-mediated depletion of YEATS2 [235]. No changes on cellular apoptosis 





































































FIGURE 4.10 Quantification of flow cytometry analysis of cell cycle and apoptosis in 
MOLM-13 cells transduced with shRNA construct against ATAC YEATS2 
component. (A) Quantitative RT-PCR validation of YEATS2 (ATAC-specific 
subunit) knockdown in MOLM-13 cells. N³3 independent experiments, mean 
± SEM of gene expression relative to CTRLsh, normalised to HPRT1 
housekeeping gene. Two-tailed t-test for significance *p<0.05, **p<0.01. (B) 
Flow cytometry analysis of cell cycle in KG1a cells transduced with ATAC-
specific YEATS2sh. Mean ± SEM of 3 independent experiments. Two-tailed t-
test for significance; no significant changes. (C) Flow cytometry analysis of 
apoptosis in KG1a cells transduced with shRNA constructs against ATAC-
YEATS2.  Mean ± SEM of % Annexin V positive cells in 3 independent 
experiments. Two-tailed t-test for significance *p<0.05. 
 
 
Overall, the data supports distinct roles for ATAC and SAGA in the model AML cell 
line MOLM-13. ATAC regulates proliferation/cell division likely through molecular 
control of biosynthetic machinery. SAGA, on the other hand, preserves the 
undifferentiated status of AML cells, its loss promoting differentiation. In light of the 
CRISPR screen, these results unveil previously uncharacterised dependencies of 
ATAC and SAGA elements in MOLM-13, serving to illustrate the importance of 







Annexin V  
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THP-1 
 
I next investigated cellular consequences of perturbing ATAC and SAGA elements in 
another MLL-AF9 cell line model, THP-1. Analysis of cell cycle revealed abnormalities 




















FIGURE 4.11 Cell cycle analysis of THP-1 cells upon knockdown of KAT2A and SAGA 
(SUPT20H, TADA2B) and ATAC (ZZZ3, YEATS2) elements. Quantification 
of flow cytometry analysis of cell cycle in THP-1 cells transduced with 
KAT2Ash, SAGA-specific SUPT20Hsh and TADA2Bsh and ATAC-specific 
ZZZ3sh and YEATS2sh. Mean ± SEM of 3 independent experiments. Two-tailed 
t-test for significance *p<0.05, **p<0.01, ***p<0.001.  
 
 
Although the effects of SUPT20H and ZZZ3 knockdown are similar to those observed 
in MOLM-13 (Fig. 4.6), the cell cycle changes do not seem to be captured by other 
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On the other hand, analysis of differentiation (see methods section) is consistent with 
observations in MOLM-13 (Fig. 4.8), whereby depletion of SAGA complex subunits, 
SUPT20H and TADA2B, promotes cell differentiation (Fig. 4.12), which is not visible 

















FIGURE 4.12 Representative photographs of THP-1 cytospins upon depletion of SAGA-
specific SUPT20H and TADA2B, and ATAC-specific YEATS2 subunits. 
White arrow heads denote blast-like cells; black arrow heads denote 
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Figure Fig. 4.13A-B shows analysis apoptosis in THP-1 cells, for which no significant 



























FIGURE 4.13 Apoptosis analysis of THP-1 cells upon depletion of KAT2A, SAGA-specific 
SUPT20H and TADA2B ATAC-specific ZZZ3 and YEATS2 subunits. (A) 
Quantification of Annexin V+ apoptotic cells in THP-1 cultures analysed by 
flow cytometry. Mean ± SEM of N>3 independent experiments; 2 biological 
replicates for SUPT20Hsh; 3 technical replicates KAT2Ash, TADA2Bsh (1 
replicate was lost due to technical failure), and the ZZZ3sh and the YEATS2sh 
groups. Two-tailed t-test for significance.  (B) Representative flow cytometry 
analysis of apoptosis by Annexin V staining in THP-1 cells transduced with 
CTRLsh, KAT2Ash, SUPT20Hsh, ZZZ3sh (top) and CTRLsh, TADA2Bsh and 
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In summary, these data suggests that THP-1 survival is not dependent on the 
function of KAT2A and its complexes, although it is arguable that as this analysis 
was performed shortly after transduction, the cells may not have been kept in culture 
for a sufficient period of time to observe differences. Moreover, whilst depletion of 
ATAC ZZZ3 lead to cell cycle arrest as previously observed in MOLM-13, the same 
effect was not observed upon knockdown of a second ATAC element, YEATS2. The 
effects in cell differentiation, on the other hand, are consistent with a role of SAGA 
elements in promoting differentiation of cultured cells upon its knockdown. Given 
that differentiated cells eventually exit the cell cycle [295], it is possible that the 
increase in cell differentiation shown in THP-1 followed by loss of TADA2B, reflects 
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MV4-11  
 
MV4-11 is another mix-lineage leukaemia, carrying a MLL-AF4 translocation. In 
addition, it has a FLT3-ITD mutation, one of the most common gain-of-function 
mutations in AML, occurring in nearly 30% cases. With the caveat that this 
experiment was only performed once, knockdown of KAT2A did not seem to impact 
cell apoptosis (Fig. 4.14 A-B) nor cell cycle progression (Fig. 4.14 C-D). Despite an 
absolute need for repeating, this experiment matched the result of the AML CRISPR 




















FIGURE 4.14 Apoptosis and cell cycle analysis of MV4-11 cell line upon KAT2A 
depletion. (A) Flow cytometry analysis of apoptosis in MV4-11 cells 
transduced with KAT2Ash; representative experiment. (B) Representative 
flow cytometry plots of apoptosis analysis in (A). (C) Flow cytometry analysis 
of cell cycle in MV4-11 cells transduced with KAT2Ash; representative 
experiment. (D) Representative flow cytometry overlays of cell cycle analysis 
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Yet, I proceeded to dissecting complex specific essentialities by looking at the cellular 
consequences of depletion of TADA2B (SAGA) and TADA2A and YEATS2 (ATAC). 
Surprisingly, cell proliferation analysis revealed a G0/G1 defect upon loss the two 
ATAC elements, TADA2A and YEATS2 (Fig. 4.15 A-B). It was somewhat unexpected 
to see changes associated with depletion of members of the complexes, given that 

















FIGURE 4.15 Cell cycle assay in MV4-11 cell line upon knockdown of SAGA-specific 
SUPT20H and TADA2B and ATAC-specific TADA2A and YEATS2 subunits. 
(A) Flow cytometry analysis of cell cycle in THP-1 cells transduced with SAGA-
specific TADA2Bsh, and ATAC-specific TADA2Ash and YEATS2sh. Mean ± SEM 
of 3 independent experiments. Two-tailed t-test for significance; no significant 
changes. (B) Representative flow cytometry overlays of cell cycle analysis in 
MV4-11 cells transduced with shRNA constructs against TADA2B, TADA2A 
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I next assessed differentiation changes, by staining the cells with a CD13 antibody, 
and looking at its expression by flow cytometry in MV4-11 cells transduced with 
SUPT20Hsh (SAGA) and YEATS2sh (ATAC). It was possible to observe a mild increase 
in the percentage of cells expressing CD13 uniquely upon SUPT20H knockdown, 
which might be indicative to induced differentiation. In a similar vein, SUPT20Hsh 
resulted in increased cell differentiation in both MOLM-13 (Fig. 4.8) and MV4-11 










FIGURE 4.16 Flow cytometry analysis of CD13 expression in MV4-11 cells 
transduced with CTRLsh, SAGA-specific SUPT20Hsh and ATAC-
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No significant changes were noted in cell survival (Fig. 4.17A-B) followed by 
















FIGURE 4.17  Apoptosis analysis of MV4-11 cells upon knockdown of SAGA-specific 
SUPT20H and TADA2B and ATAC-specific TADA2A and YEATS2 
subunits. (A) Flow cytometry analysis of apoptosis in MV4-11 cells 
transduced with shRNA constructs against SAGA-TADA2B, and ATAC-
TADA2A and YEATS2.  Mean ± SEM of % Annexin V positive cells in 3 
independent experiments. Two-tailed t-test for significance; no significant 
changes. (B) Representative flow cytometry plots of apoptosis analysis of 
MV4-11 cells transduced with CTRLsh, TADA2Bsh, TADA2Ash and 
YEATS2sh. N=2 biological replicates; 3 technical replicates for TADA2Ash, 
TADA2Bsh and YEATS2sh.  
 
These results implicate the ATAC complex in regulation of the cell cycle, as observed 
in MOLM-13, and a potential role for SAGA in keeping MV4-11 phenotype. Whilst a 
role for KAT2A itself in MV4-11 biology cannot be excluded, and needs further 
assessment, the experiment performed here and the result of the CRISPR screen do 
not indicate a dependency on KAT2A.  
 
I then went on to extend the cellular analysis of KAT2A and its complexes in CD34+ 
leukaemia, making use of KG1a and Kasumi-1 cell lines.  
A 
B 
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4.3.2 KAT2A complexes have distinct contributions to proliferation 




KG1a carry a FGFR1OP2-FGFR1 fusion, involving fibroblast growth factor receptor 1 
(FGFR1) gene, and represent a very undifferentiated AML type. As shown in Fig. 
4.18, depletion of TADA2A (ATAC), resulted in cell cycle arrest in G0/G1, which I 
had also observed in MOLM-13 and MV4-11 cell lines. Thus, ATAC control of cell 
proliferation seems to be a consist feature, despite differences in genetic background 




















FIGURE 4.18 Quantification of flow cytometry analysis of cell cycle in KG1a AML cells 
transduced cells with shRNA constructs against KAT2A, SAGA (SUPT20H, 
TADA2B) and ATAC (ZZZ3, TADA2A) elements. N=3 individual experiments; 
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Also consist with observation in the previous AML models, no changes in apoptosis 











FIGURE 4.19 Quantification of flow cytometry analysis of apoptosis by Annexin V 
staining in KG1a cells transduced cells with shRNA constructs against 
KAT2A, SAGA (SUPT20H, TADA2B) and ATAC (ZZZ3, TADA2A) elements. 
N³3 individual samples mean ± SEM; 2 biological replicates for SUPT20Hsh, 
TADA2Bsh and ZZZ3sh groups (6 technical replicates each); 3 technical 
replicates for KAT2Ash and 4 technical replicates for TADA2Ash. Two-tailed 
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Furthermore, when investigating shRNA-mediated knockdown of YEATS2 (ATAC 
complex), I observed a trend towards G0/G1 arrest (p=0.06), suggesting reduced cell 












FIGURE 4.20 Quantification of flow cytometry analysis of cell cycle and apoptosis in 
KG1a cells transduced with shRNA construct against ATAC YEATS2 
component. (A) Flow cytometry analysis of cell cycle in KG1a cells transduced 
with ATAC-specific YEATS2sh. Mean ± SEM of 3 independent experiments. 
Two-tailed t-test for significance; no significant changes. (B) Flow cytometry 
analysis of apoptosis in KG1a cells transduced with shRNA construct against 
ATAC-YEATS2.  Mean ± SEM of % Annexin V positive cells in 3 independent 
experiments. Two-tailed t-test for significance; no significant changes. 
 
 
When assessing differentiation consequences of loss of ATAC or SAGA components, 
and I observed downregulation of the CD34 marker by flow cytometry upon loss of 
both SUPT20H (SAGA) and ZZZ3 (ATAC) (Fig. 4.21A-B). However, morphological 
differentiation along the monocytic lineage (see methods section) (Fig. 4.21C-D) was 




































































FIGURE 4.21 Analysis of differentiation status of KG1a cells upon knockdown of ATAC 
specific ZZZ3 and SAGA specific SUPT20H elements. (A) Representative 
analysis of undifferentiated marker CD34 in KG1a cells transduced with 
CTRLsh, SUPT20Hsh and ZZZ3sh. (B) Quantification of CD34+ cells in 
transduced KG1a cells in (A). N=3 independent experiments. Two-tailed t-test 
for significance *p<0.05, **p<0.01. (C) Quantification of blast-like and 
differentiated cells in KG1a cultures transduced with CTRLsh, SUPT20Hsh and 
ZZZ3sh. Scoring of 3 randomly selected fields of >100 cells; Two-tailed t-test 
for significance; *p<0.05. (D) Representative photographs of KG1a cytospins. 
White arrow heads denote blast-like cells; black arrow heads denote 
differentiated cells. Scale 50 µm. 
 
 
Differentiation following depletion of SUPT20H was apparent also in the previously 
investigated cell line models, supporting a predominant role for SAGA activities in 
sustaining the characteristic undifferentiated state/identity of AML cells. On the 
other hand, the data points to a pervasive role for ATAC elements in cell cycle control 
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Kasumi-1 
 
Lastly, I sought out to investigate Kasumi1 which like KG1a represents a minimally 
differentiated AML. Kasumi-1 harbour a RUNX1-RUNX1T1 fusion, one of the most 
frequent chromosomal rearrangements in AML, and an associated KIT mutation 
[296]. Similar to what had been observed in MOLM-13 and THP-1, loss of ZZZ3, 





















FIGURE 4.22 Cell cycle analysis of Kasumi-1 cells upon knockdown of KAT2A, SAGA-
specific SUPT20H and ATAC-specific ZZZ3. Quantification and 
representative of flow cytometry plots of cell cycle in Kasumi-1 cells transduced 
with CTRLsh, KAT2Ash, SAGA-specific SUPT20Hsh and ATAC-specific ZZZ3sh. 
Mean ± SEM of 3 independent experiments. Two-tailed t-test for significance 
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When assessing the differentiation status of Kasumi-1cells following knockdown of 
SAGA (SUPT20H and TADA2B) or ATAC (ZZZ3 and TADA2A), no differences in CD34 





















FIGURE 4.23 Analysis of differentiation status of Kasumi-1 cells upon knockdown of 
SAGA specific SUPT20H and TADA2B and ATAC specific ZZZ3 and 
TADA2A elements. Representative analysis of undifferentiated marker CD34 
in Kasumi-1 cells transduced with CTRLsh, SUPT20Hsh, TADA2Bsh, ZZZ3sh 
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As in previous cell lines, Kasumi-1 did not display changes in cell apoptosis in 











FIGURE 4.24 Apoptosis analysis of Kasumi-1 cells transduced with KAT2Ash, SAGA-
specific SUPT20Hsh and TADA2Bsh and ATAC-specific ZZZ3sh and 
TADA2Ash. (A) Quantification of Annexin V+ apoptotic cells in Kasumi-1 
cultures analysed by flow cytometry. Mean ± SEM of N>3 independent 
experiments. N=2 biological replicates; 3 technical replicates for KAT2Ash, 
SUPT20Hsh, TADA2Bsh, TADA2Ash and ZZZ3sh. Two-tailed t-test for 
significance; no significant differences. (B) Representative flow cytometry 
analysis of apoptosis by Annexin V staining in Kasumi-1 cells transduced with 
CTRLsh, KAT2Ash, SUPT20Hsh, ZZZ3sh (top) and CTRLsh, TADA2Ash and 
TADA2Bsh (bottom). The combination of Annexin V and DAPI staining allows 
for a distinction between viable cells (double negative), cells in early apoptosis 
(Annexin V positive), cells in late apoptosis (double positive) and dead cells 
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Altogether, these cellular analyses show some discrepancies in regulation of Kasumi 
biology by the two chromatin complexes. Whereas cell cycle regulation seems 
dependent on ATAC (ZZZ3) thus likely to mediate proliferation, as previously 




4.4 Conclusions and future work  
 
In this Chapter, I performed cellular characterisation of the roles of KAT2A 
complexes, ATAC and SAGA, in cultured AML cell lines, describing the phenotypic 
readouts of knocking down specifc elements of either complex. The deliberate use of 
five different AML cell lines, each with markedly different mutations, and which 
clinically associate with a range from good to poor prognosis, allowed for a better 
experimental representation of the considerable human AML heterogeneity. Both 
complexes were found to contribute to AML biology, although mediating different 
cellular activities. Results are summarised in Table 4.1.  
 
Table 4.1 Summary of KAT2A-complex cellular effects in the AML cell lines studied.  
 
It became apparent that removing elements of the ATAC complex including ZZZ3, 
YEATS2 and TADA2A limited cell proliferation capacity in different AML cell lines. In 
the case of MOLM-13, the most extensively characterised cell line here, it was further 
demonstrated by cell divisional tracking that less cells enter cell division, uniquely 
when depleting ZZZ3. Although, the exact mechanism by which ATAC causes the cell 
cycle phenotype, remains to be understood. For example, it was previously shown 
that KAT2A plays roles in cell cycle progression through direct acetylation of CDC6 
[297] and cyclin A (G1/S cell cycle transition) the latter, within its participation in 
the ATAC complex [294]. On the other hand, as demonstrated in MOLM-13, ATAC- 
ZZZ3 depleted cells had lost H3K9ac at promoters of ribosomal protein genes, RPS7 
and RPL13, which associated with a decrease in their gene expression. This is in 
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agreement with a role for ATAC-mediated H3K9ac activity in controlling ribosomal 
protein and translation associated genes, which are essential pathways to cell 
survival and proliferation. Signer and colleagues have previously shown that AML 
stem-like cells are highly dependent on control of translational activity [298]. Thus, 
it is possible that the increased fraction in G0/G1 observed across AML cell lines 
followed by ATAC loss, reflects downregulation of the biosynthetic/ribosomal protein 
machinery targeted by the ATAC complex. Indeed, ATAC histone acetylation activity 
has also been associated with regulation of biosynthetic pathways in other cancer 
types beyond leukaemia such as NSCLC [235–236]. Thus, ATAC likely contributes to 
AML through preservation of metabolism required to maintain leukaemia stem-like 
cells (LSC). Given that the cell cycle experiments performed here did not distinguish 
between G0 and G1 phases, this is something that could be looked at in future 
experiments to investigate regulation of LSC quiescence.  One possible approach 
would be to enforce cells into G0 quiescence by serum deprivation and see if cells in 
which ATAC elements have been knockdown down accumulated at that stage or 
could progress to G1. It would also be interesting to measure protein synthesis 
activity in the absence of ATAC and SAGA, to understand if leukaemia cells are 
indeed less translationally active when removing ATAC members. This could be 
achieved by an OP-puro incorporation assay.  
 
On the other hand, the cellular events observed upon knockdown of SAGA-specific 
elements associated with enhanced AML differentiation. This was verified both in 
differentiated/monocytic-type leukaemic cell lines, such as MOLM-13 and THP-1, 
but also in a more immature or less differentiated AML, KG1a. While this suggests 
that SAGA contributions to the characteristic AML differentiation block are 
irrespective of the exact cell differentiation state, which could be an indication that 
SAGA makes use of the transcriptional machinery available on specific cell types 
rather than having a fix set of target genes. An exception to the pro-differentiative 
effects of SAGA shRNA treatment was Kasumi-1, for which no changes were noted 
upon depletion of SAGA elements. Again, this discrepancy could be an indication 
that SAGA operates in a cell-type/context manner to favour the AML maturation 
arrest. In other words, maybe the genes targeted/regulated by SAGA are less likely 
to be shared between leukaemia types. Mechanistic studies are essential to 
understand this. SUPT20H loss of function, in particular, showed minimal 
consequences to normal haematopoiesis, which may suggest potential therapeutic 
targeting of SAGA Core module for differentiation-based therapies in AML. However, 
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based on its role in erythropoiesis (K562), the context in which its inhibition for 
therapeutic benefit is proposed is clearly of significant importance. This warrants 
further studies to rule out the possibility that dynamic interactions with subunits of 
other SAGA modules would have detrimental consequences in normal blood. 
 
Considering the molecular results in MOLM-13, loss of H3K9ac had a more profound 
effect at promoters of both ribosomal protein and MLL-AF9 HOXA target genes, than 
their relative mRNA levels followed by loss of ZZZ3 or SUPT20H. Two interpretations 
can be draw for this observation: (1) regulation by KAT2A complexes may be cell type 
specific, as this was not observed in K562 cells; (2) this may suggest that specific 
functions on transcription regulation by SAGA or ATAC at a given promoter region, 
may require additional enzymatic activities of their neighbouring subunits (H2B 
deubiquitination by USP22) and (H4 acetylation by KAT14), respectively. In a similar 
way, they could also involve regulation by the non-catalytic elements. For example, 
in the case of disruption of ATAC complexes in the absence of ZZZ3, this may affect 
H3K27ac recognition by YEATS2 and/or, interaction with MLL complexes via WDR5, 
resulting in a more dramatic transcriptional effect. Alternatively, KAT2A activity in 
MOLM13 may involve H3K79 succinylation [180] or other yet uncharacterised 
acetylation marks. Furthermore, it is possible that full activity requires protein-
protein interaction and/or acetylation, which may be different between complexes. 
This emphasises the intricacy of multi-modular chromatin complexes to regulation 
of transcription and further studies investigating combined knockdowns of these 
subunits in AML would help understanding how they drive the leukaemic potential.  
 
Our lab has previously shown a requirement for Kat2a in sustaining leukaemia stem-
like cells (LSC) in a MLL-AF9 mouse model [197]. In that context, it was demonstrated 
that loss of Kat2a led to reduction in LSCs in a manner associated with increased 
transcriptional variability (stochasticity in gene expression). Genes regulated by 
Kat2a through promoter H3K9ac, and which had lost the chromatin mark upon 
kat2a KO with increased transcriptional variability, specifically associated with 
ribosomal /translation activity, which in this thesis I show to be targets of the ATAC 
complex. Also interesting, is the fact that one TF prevented from binding at its target 
gene promoters in Kat2a KO cells, was GABPA, which is bound by ATAC in K562 
(Appendix D). Additionally, Gabpa has previously been reported as a regulator of 
CML self-renewal [299–300], which is potentially related with ATAC functions 
described here. Thus, it is possible that Kat2a control of transcriptional variability 
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in AML is exerted through ATAC, and it would be interesting to test this hypothesis 
in the future. On the other hand, control of transcriptional variability by Kat2a is 
well recognised in yeast, which contains SAGA but not ATAC complexes. Indeed, in 
our mouse kat2a KO model, TF Myc, which is bound by SAGA in K562s (Appendix 
D), is prevented of binding in promoters that lost H3K9ac in kat2a KO cells [197]. 
Myc is a known partner of Kat2a [301], and has been implicated in different AML 
subtypes, including MLL-driven leukaemia [302]. As such, both complexes may in 
principle make contributions to transcription stability and variability control to 
regulate the self-renewal and differentiation activities in AML. Future studies 
investigating this hypothesis could be done by single cell RNA-seq or by single 
molecule RNA FISH (a method for detecting individual RNA molecules within cells by 
fluorescence microscopy) in response to parallel ATAC and SAGA-specific 
knockdowns in the same AML type and across different AMLs.  
 
None of the cell lines studied here showed cell survival defects when knocking down 
KAT2A, or specific ATAC or SAGA members. Except MOLM-13, where most extensive 
characterisation was carried out, this comes with the caveat that cells may not have 
been cultured for a sufficient period of time in order for me to observe differences in 
apoptosis, since the experiments were performed shortly after transduction.  
 
Together, this work offers functional assessment of the ATAC and SAGA complexes 
in AML biology. The data implicates SAGA in the AML differentiation block, whereas 
ATAC plays a role in maintaining leukaemia propagation. Functional investigation of 
KAT2A, SAGA and ATAC requirements in human AML patient cells is presented in 






















Chapter 5  
Functional characterisation of the role of 
KAT2A and ATAC and SAGA complexes 
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5.1 Introduction 
 
Having assessed the sensitivity of human AML cell lines to downmodulation of KAT2A 
and specific ATAC and SAGA members, I aimed to investigate their roles in human 
AML primary cells, which better reflect in vivo circumstances.  
 
Whereas cell lines are relatively easy to manipulate, maintaining primary AML cells 
in culture is more difficult, particularly without an adequate supportive niche, as 
AML blasts rapidly differentiate and enter apoptosis ex vivo. Moreover, while cell lines 
are reasonably homogenous (unless cultured for prolonged periods, in which they 
can acquire mutations), patient samples have an inherent clonal and heterogeneous 
nature, adding a degree of unpredictability when trying to investigate. Culturing 
primary AML cells ex vivo has been made possible mainly from adapting standard 
protocols for normal HSCs [266]. In 1977, Dexter et al. established a ‘niche-like’ 
methodology using BM stromal cells obtained from femurs of mice [303]. This co-
culture method has been refined and currently involves the use of immortalised 
feeder layers, such as murine MS-5, osteoblast derived SaOs-2 and human umbilical 
vein endothelial (HUVEC) cells [266–304–307]. The choice of the supportive stromal 
cell type selects for a range of different secreted cytokynes (reviewed in [308]), needed 
for stimulating the growth of AML cells. Interestingly, a cross-comparison between 
stromal layers showed MS-5 to be the most supportive for AML blasts [266]. 
Additionally, MS-5 are advantageous because they display contact-inhibition and do 
not require irradiation [308]. More recently, patient-derived BM stromal cells have 
also been used in co-culture assays with patient samples [309]. Others investigated 
co-culture systems using mesenchymal stromal cells (MSC) from healthy human 
donors [310]. In the same study, by comparing the supportive capacity of normal 
MSC with those of AML patients, Azadniv and colleagues showed that patient derived 
cells better supported survival of leukaemic blasts [310].  
 
AML arises from the transformation of a single cell and it is maintained by a rare 
population of leukaemia stem-like cells [106]. These have been found to reside in the 
CD34+ compartment [106], and particularly in CD38+ and CD45RA+ population, 
resembling GMP-like progenitors [112], and more rarely, in CD34− compartment 
[311].  
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Ex vivo co-culture systems work as a surrogate for animal transplantation 
experiments in which these populations are normally investigated due to their ability 
to recapitulate disease. Importantly, they more closely approximate with in vivo 
human biology, allowing the investigation of leukaemic stem like/initiating cells for 




5.2 Chapter overview  
This Chapter details the results of experiments aimed at testing KAT2A requirements 
in primary human AML cells, as well as an attempt to validate ATAC and SAGA 
complex dependencies. I tested a small array of AML patient samples directly 
obtained from the AML clinic, with the aim to capture diverse genetic backgrounds 
and reflect the heterogeneous nature of the disease. I used an adaptation of the MS-
5 stromal co-culture system by Schuringa and Schepers  to validate the functions of 
KAT2A and its complexes in the AML patient samples obtained. I showed that the 
MS-5 AML co-culture system preserves expansion of leukaemic cells for up to 3 
weeks. As the assay proved suitable, I performed KAT2A inhibition studies with a 
small molecule inhibitor, MB-3, in the co-culture system, and demonstrate that the 
drug supresses growth of leukaemic blasts and results in a reduction of primitive 
leukemic CD34+ marker over time. Furthermore, genetic ablation of KAT2A 
reproduced the results obtained by chemical inhibition. Lastly, I was able to 
transduce one patient sample with lentiviral shRNAs against ATAC - ZZZ3 and SAGA 
– SUPT20H, in which knockdown of ZZZ3 uniquely reduced expansion of AML cells, 
a finding compatible with a role of the ATAC complex in maintaining leukaemic 
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5.3 Results and discussion  
 
 
I started by obtaining a small cohort of seven human AML patient samples 
representative of different genetic backgrounds. Patient sample characteristics can 
be found in Table 5.1.  
 
 
As detailed in the methods section (Chapter 2), samples were thawed, pre-stimulated 
with cytokines and either transduced with lentiviral-delivering shRNAs against 
KAT2A or complex-specific elements, or treated with KAT2A catalytic inhibitor, MB-
3. Patient cells where then either tested for colony-forming activity in 
methylcellulose-based assays or seeded and maintained onto MS-5 layers for a few 
weeks, with hemi population twice a week (Fig. 5.1). 
 
 
FIGURE 5.1 Experimental strategy adopted for investigating the role of KAT2A and its 
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5.3.1 Clonogenic growth of AML patient samples is hindered by 
treatment with MB-3, the KAT2A small molecule inhibitor  
 
In a first set of experiments, I tested the effects of inhibiting KAT2A by treating AML 
patient samples with 100mM MB-3. Three out of four samples shown reduced CFC-
capacity compared to vehicle DMSO (Fig. 5.2A-B). In line with these results, our lab 
has previously demonstrated that pharmacological ablation of KAT2A with MB-3 















FIGURE 5.2 KAT2A small molecule inhibitor, MB-3, reduces CFC-capacity of human 
primary AML cells. (A) CFC-assay of 4 primary AMLs treated with 100 mM 
MB-3 and vehicle DMSO. AML1, AML2 and AML3 are responsive to MB-3 
treatment. (B) Mean values of CFC-assays in (A). Two-tailed unpaired t-test for 
significance; *p<0.05.  
 
As per Table 5.1, the inhibitory effect on clonogenic potential was observed across 
AML samples of different genotypes, and appeared independent of sex, age and 
cytogenetic abnormality. Short-term methylcellulose-based assays, however, do not 
necessarily capture the most primitive candidate leukaemic stem cells, and medium-
to-long term cultures would help identify these rare populations and their ability to 
sustain the leukaemia over longer periods. With this in mind, next I aimed to test a 
co-culture system that would allow maintenance of AML primitive cells for longer, in 
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5.3.2 MS-5 co-culture system preserves growth, CFC-capacity and 
phenotype of human primary AML cells  
 
When testing of the MS-5 co-culture system (Schuringa and Schepers, 2009), it was 
found that growth of AML patient cells (AML5) was sustained for up to 3 weeks (Fig. 
5.3A). In parallel, I also tested the sample for colony initiation capacity, which was 
preserved for up to three weeks, suggesting maintenance of progenitor-like 
leukaemic cells (Fig. 5.3B). Moreover, co-culture on MS-5 layers broadly supports 


















FIGURE 5.3  MS-5 co-culture system preserves growth, expansion and moderate cell 
surface phenotype of primary AML cells for up to 3 weeks. (A) Growth curve 
of human primary AML cells in the MS-5 co-culture system. (B) CFC-capacity 
of primary human AML cells is preserved in the MS-5 co-culture system for up 
to 3 weeks. (C) Maintenance of cell surface phenotype of AML patient cells for 
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Having validated the suitability of the co-culture method to experiment on primary 
human AML cells, I then tested the effects of inhibiting KAT2A activity using MB-3 
in the culture system. Drug treatment led to reduced growth of CD34+ AML cells 
when compared to vehicle, DMSO (Fig. 5.4A), impacting the proportion of candidate 

























FIGURE 5.4 KAT2A chemical inhibition with MB-3 suppresses growth and expansion of 
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primary CD34+ AML cells treated with KAT2A inhibitor MB-3 vs vehicle DMSO 
in the MS-5 coculture system for up to 3 weeks.  Individual CD34+ patient 
samples (AML3, AML4 and AML5) and one CD34- sample (AML6) are shown. (B) 
Percentage of L-GMPs at week 2 of MS-5 co-culture for AML2 cells treated with 
KAT2A inhibitor MB-3 vs vehicle DMSO. (C) Representative flow cytometry plot 
of data in (B).  
 
 
Overall, these data indicate that medium-term survival of primary AML cells can be 
supported by the MS-5 co-culture method, which mimics the tumour 
microenvironment.  Though, not all samples perform equally, with some expanding 
better than others, which likely reflects the heterogeneous nature of AML. 
Significantly, small-molecule inhibition of KAT2A resulted in decreased growth of 
CD34+ AML blasts over the of 2-3 weeks period. Impairment of L-GMP compartment, 
representative of leukaemia initiating /stem-like cells, was also verified for one of the 
patient samples upon treatment of MB-3, suggesting a role for KAT2A in the 
maintenance of primitive human AML.  
 
Next, I tested whether KAT2A genetic inhibition reproduced the results observed with 
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5.3.3 KAT2A lentiviral-mediated knockdown mimics its chemical 
inhibition, reducing leukaemic expansion in the MS-5 co-culture 
system 
 
When attempting to transduce human AML cells with shRNAs against KAT2A, few 
samples were able to transduce and I could observe GFP+ cells (transduced cells) in 
33% of the samples tested, all of them were CD34+. Successfully transduced samples 
were kept in culture for 2-3 weeks in the presence of MS-5 stroma, while monitoring 
their expansion as well as the preservation of total GFP, CD34+ and L-GMP 















FIGURE 5.5 Flow cytometry gating strategy used for analysis of primitive AML CD34+ 
and GMP-like (L-GMPs) cell populations. Cells gated for live cells (SSC-A vs 
FSC-A), and singlets considered (SSC-A vs SSC-H). Singlets were then gated for 
GFP+ to establish the global level of GFP against which individual sub-
populations were analysed. Sub-populations analysed were CD34+ (left), and L-
GMPs (right), gated as CD34+CD38+CD123+CD45RA+ cells. GFP levels within 
CD34+ cells and L-GMP were obtained and compared with global GFP levels for 
each construct to determine relative preservation of each sub-population upon 
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KAT2A knockdown (Fig.5.6) resulted in reduction in growth of transduced AML cells 
overtime (Fig.5.7A-B), as elicited by pharmacological inhibition with MB-3, thus 
validating the drug’s specificity. Moreover, expansion of primitive CD34+ and L-GMP 




FIGURE 5.6   Flow cytometry profiling of KAT2A transduced (GFP+) cells over a 2-week 











































FIGURE 5.7 KAT2A knockdown reduces expansion of human primary AML cells in the 
MS-5 co-culture system. (A-B) Growth of human primary AML cells (CD34+ 
samples) transduced with CTRLsh and KAT2Ash and maintained in the MS-5 
co-culture system for 2-weeks. (C) Percentage of GFP+ CD34+ cells in AML 
samples in (A-B) analysed at week 2 of the MS-5 co-culture. Analysis gates are 
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unequal GFP transduction levels. Data are normalized to global GFP levels, to 
correct for unequal GFP transduction levels. (D) Percentage of GFP+ GMP-like 
(L-GMP) cells at week 2 of the MS-5 co-culture system in AML samples in (A-B). 
GFP transduction correction as in (C). (E) Representative flow cytometry plot of 
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5.3.4 KAT2A complex activity maintains propagation of human 
primary AML cells in MS-5 co-culture  
 
Finally, I attempted to transduce (Fig. 5.8) primary CD34+ AML patient blasts with 
the lentiviral vectors delivering shRNAs SUPT20H or ZZZ3. 
 
 
FIGURE 5.8  Flow cytometry profiling of shRNA-transduced AML7 sample – gating of 
total GFP+ cells in the whole sample over a 3-week co-culture period. 
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In the sample analysed (AML7), downregulation of ZZZ3, but not of SUPT20H, 
resulted in reduced expansion of transduced AML blasts (Fig. 5.9A), which 
specifically affected CD34+ (Fig. 5.9B) and/or L-GMP (Fig. 5.9C), suggesting a loss 



























FIGURE 5.9 ATAC-ZZZ3 knockdown reduces expansion of human primary AML cells in 
the MS-5 co-culture system. (A) Growth of human CD34+ primary AML cells 
(AML7) transduced with CTRLsh, SUPT20Hsh or ZZZ3sh and maintained in the 
MS-5 co-culture system for 3 weeks. (B) Percentage of GFP+ CD34+ cells in 
AML7 (A) analysed at week 2 of the MS-5 co-culture. Analysis gates are 
presented in Fig. 5.5. Data are normalized to global GFP level, to correct for 
unequal GFP transduction levels. (C) Percentage of GFP+ GMP-like (L-GMP) cells 
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5.4 Conclusions and future work  
 
KAT2A has histone acetyltransferase activity through its catalytic HAT domain, 
exerted within SAGA or ATAC complexes, and which is druggable with a small 
molecule inhibitor, MB-3. These data shows that pharmacological inhibition of 
KAT2A with MB-3 is effective in reducing colony-initiation capacity of primary human 
leukaemias, confirming the disease’s dependence on KAT2A function.  
 
The MS-5 co-culture assay employed in this study, proved robust in maintaining 
AML cells for a few weeks, with leukaemic blast survival and proliferation benefiting 
from the culture on MS-5 layers. The main advantage of these assays to investigate 
stem/progenitor leukaemic cells is their accessibility when compared to mice 
xenotransplantation experiments, which typically take place over 8-20 weeks prior 
analysis. In turn, gene-perturbation analysis in candidate leukaemic stem cells can 
be performed on MS-5 stroma while regularly monitoring phenotypes. Similarly, with 
the development of new target therapies, this method seems an appropriate and 
predictive preclinical model to screen AML inhibitory compounds. By using the MS5-
co culture strategy, I showed that as a result of both KAT2A loss or MB-3 inhibition, 
leukaemic cell expansion was decreased over a period of 2-3 weeks, and it was 
accompanied by a reduction of CD34+ and L-GMP phenotypic compartments.  
 
Although I could only successfully transduce one patient sample with the ATAC and 
SAGA-delivering shRNAs, downmodulation of ZZZ3 delayed AML cell expansion 
considerably, which was not observed with loss of SAGA-SUPT20H. This is 
compatible with a role for ATAC in sustaining leukaemic self-renewing properties as 
suggested in the previous Chapter in AML cell lines. It would have been meaningful 
to test by qRT-PCR if ribosomal protein genes were being downregulated upon loss 
of ATAC as observed in the context of cell line models. However, as the cell numbers 
were limiting and the population was being lost overtime time, this was not assessed. 
Furthermore, a more direct measure of self-renewal would be to harvest ZZZ3sh and 
SUPT20Hsh cultures and serial-replate onto new stroma. Indeed, a particular 
characteristic of MS-5 co-cultures is the formation of cobblestones, which are 
thought to correspond to leukaemic stem and progenitor cells [307], that when 
replated for a number of weeks would maintain the disease. Although, during the 
time frame of these experiments I failed to observe such structures, which may 
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require more than 3-weeks to form. Ideally, this would be done in parallel with 
xenotransplantation assessment in which the prediction would be that ZZZ3-
depleted cultures would fail to re-capitulate the disease. In future, testing AML ATAC 
and SAGA dependencies in a larger cohort of AML patient samples is of considerable 
interest and requires further characterisation. Thus, it would be of great value to 
obtain information of a larger number of primary AMLs.  
 
One other future aim would be to make use of the co-culture system to functionally 
validate plausible downstream effectors of KAT2A loss, yield by both RNA/ChIP-seq. 
Likewise, to validate unique targets of ATAC and SAGA complexes from our ChIP 
dataset, that could specifically act on leukaemic maintenance or differentiation.   
 
Although the cohort of samples analysed was small, the capacity for medium-term 
ex vivo proliferation did not seem dependent on the genetic characteristics, as 
suggested by others [312]. However, it is recognised in the field that more aggressive 
leukaemias are more resistant to inhibitory compounds (and indeed engraft better 
into mice) [313]. Knowing this, it is possible to imagine that this could impose a bias 
towards more aggressive AML samples to self-propagate better in this co-culture ex 
vivo assays, than low risk leukaemias.  
 
It has become apparent that malignant haematopoietic cells and their niche cells and 
their niche cells can affect each other in a bidirectional way [314]. However, little is 
known on how murine stromal cells stimulate human cell proliferation or mimic the 
BM microenvironment ex vivo [307]. One way, it has been shown, is that stromal 
cells prevent apoptosis of leukaemic blasts by up-regulating anti-apoptotic proteins 
in the AML cells [315]. In future, it would be interesting to characterise the phenotype 
of the blasts that are in direct contact with the feeder layer, for instance by 
immunostaining, and to investigate whether/how KAT2A and its complexes mediate 
AML-stromal cell interaction, as well as its potential niche dependencies across 
different types of AML. Also, it was not tested whether MB-3 treatment affected the 
viability and function of the MS-5 stromal cells themselves, a possibility that cannot 
be ignored.  
 
 
In summary, while these experiments need reproduction using larger sample sizes, 
the co-culture experimental approach represents a good model for dissecting the 
differences in molecular mechanisms exerted by ATAC and SAGA complexes in AML. 
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It provided further evidence to suggest that KAT2A-mediated ATAC roles govern 
proliferation of human leukaemia. On the other hand, SAGA functions need to be 
better studied in primary AMLs. A recent study reported that MB-3, in combination 
with all-trans retinoic acid (ATRA), reduced the capacity of patient blasts to form 
colonies in non-APL AML [316]. This would be interesting to explore, particularly in 
the context of SUPT20H knockdown, as an attempt to enhance its pro-differentiation 
effects via targeting the Core module of SAGA. This is in keeping with the mild 
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The unifying message of the work detailed in this thesis is the unique, differential 
contribution, of KAT2A chromatin complexes ATAC and SAGA, to normal and 
malignant haematopoiesis. 
 
Both normal and leukaemic haematopoiesis are regulated by cytokines, lineage-
specific Tfs, and epigenetic modifiers. The latter include ‘readers’, ‘writers’ or 
‘erasers’, which all facilitate changes in chromatin state, influencing transcriptional 
programmes in both healthy and aberrant developmental scenarios. Indeed, 
epigenetic dysregulation is a widely recognised feature of AML, which remains a 
lethal disease for most patients. Therefore, examination of its chromatin 
susceptibilities is essential to gain a better understanding of the disease. Histone 
modifiers, central components of the epigenetic machinery, are often found in 
multiprotein complexes. Critically, while their enzymatic functions have been more 
extensively characterised and exploited as targets in AML therapeutics [120], little is 
known about the molecular context in which they function. KAT2A encodes for a 
HAT that is present within two multiprotein complexes, ATAC and SAGA, and which 
has been identified as a vulnerability in AML by our lab, but for which roles in normal 
blood were less well defined.  
 
In this thesis, I investigated the roles of KAT2A in normal and malignant human 
haematopoiesis through analysis of the two co-activator complexes in which it exerts 
its HAT activity. Specific ATAC subunits ZZZ3, TADA2A and YEATS2, and SAGA-
specific SPT20, TADA2B and USP22 were used surrogates of one or the other 
complex. Through the use of CB, AML cell lines and primary samples and a shRNA-
treatment approach, functional data addressing specificity of the two KAT2A 
complexes has been presented.  
 
In normal blood, KAT2A was found to regulate erythroid progenitor specification and 
survival. While not required for granulocytic or lymphoid lineage development, the 
erythroid lineage was specifically dependent on KAT2A. RNA-seq in KAT2A-depleted 
CB cells provided a better understanding of the specific transcriptional programmes 
repressed in its absence. Those associated with oxygen transport and platelet 
function, agreeing with the defect in erythroid (and/or megakaryocytic) lineage 
development when removing KAT2A. Significantly, the defect along the erythropoietic 
lineage involved the contribution of ATAC and SAGA complexes, which were required 
in early and late developmental stages, respectively. Specifically, it was possible to 
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reconcile loss of the ATAC complex with a defect in fate commitment towards the 
erythroid lineage, suggesting that it is required for erythroid specification from CB. 
Conversely, while depletion of SAGA Core SPT20, did not affect normal blood cell 
function overall, SAGA DUB module USP22 was shown to impair erythroid 
maturation post-commitment. This suggested a role for SAGA in preservation – 
rather than initiation – of erythroid cell fate. Interestingly, the realisation that one 
other SAGA element with a different enzymatic activity than KAT2A regulates late 
erythroid fate could indicate combined activities of HAT and DUB modules, 
potentially explaining the more pronounced effect that seems to exceed loss of 
SUPT20H. On the other hand, there is also evidence in the literature for KAT2A-
independent functions of the DUB module, which could potentially explain this 
disparity [278]. Similarly, Wang and colleagues recently elucidated the structure of 
yeast SAGA and reported a conformational change upon complex binding to DNA, in 
which the DUB module physically detaches from the Core [214], a mechanism 
potentially conserved in human SAGA complexes. It may also be possible that in late 
erythroid maturation, SAGA complexes rely on KAT2B, the KAT2A orthologue, 
mutually exclusive with KAT2A in ATAC and SAGA. In support of this hypothesis, 
expression of KAT2B increases in late erythroid differentiation (Appendix C). All 
these speculations need further investigation and could partially be answered by 
examining the effects of combined depletion of HAT and DUB subunits.  
 
Regarding ATAC roles, its specific requirement in commitment to the erythroid 
lineage may relate to its association with protein synthesis and translation-affiliated 
genes, as revealed by the chromatin binding profile of ZZZ3 in haematopoietic cells 
(Appendix D). In line with this view, studies of protein synthesis rates during 
hematopoiesis have indicated that dramatic changes occur during the early stages 
of lineage commitment [298]. More specifically, it has been shown that defects in the 
ribosome and in translation can selectively impact commitment to the erythroid, but 
not other hematopoietic lineages [317]. It would be intersting to consider this in the 
future with further investigation. It would also be important to investigate additional 
ATAC subunits, such as YEATS2. For example, MLLT3, which contains a YEATS 
domain, has previously been implicated in erythroid specification [318], and there is 
the possibility that the reader domain can play a role in the recruitment of this and 
other YEATS-containing proteins, such as ATAC-YEATS2, to promoters of erythroid 
regulators.  
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When addressing the transcriptional significance of unique ATAC and SAGA binding 
peaks in eryhtroid-affiliated K562 upon ZZZ3 or SUPT20H knockdown, I observed 
loss of H3K9ac at unique ATAC-bound, as well as SAGA-bound genes - ribosomal 
protein genes and HBB, respectively. This was complex dependent and site specific. 
In other words, loss of H3K9ac at specific ATAC bound promoters coincided with 
down-regulation of its target genes, without affecting SAGA-bound regions, and vice 
versa. Given the identified KAT2A role in erythropoiesis, further assessment of 
H3K9ac status at other eryhtroid regulators, identified by the RNA/ChIP-seq 
datasets would provide better mechanistic insight into the exact maturation stages 
of erythroid development governed by the activities of either complex. I examined 
H3K9ac levels at EPOR, which expression was significantly reduced following KAT2A 
knockdown in CB HSCs, and which initially was thought to explain the defect in 
development of the eryhtroid lineage. In this experiment, however, I did not find 
H3K9ac levels to change in K562-SUPT20Hsh cells. Interestingly, in K562 cells, 
failure in downregulating GATA2 upon loss of SUPT20H uniquely prevented erythroid 
differentiation. However, the exact mechanism is not clear at present. It has 
previously been shown that KAT2B interacts with, and directly acetylates TAL1, 
promoting erythroid differentiation in MEL cells [287]. One possibility is that failure 
of KAT2B in acetylation and activation of TAL1-dependent programmes (if SAGA 
indeed relies on KAT2B instead), would reflect the persistence of GATA2 and 
differentiation arrest, which could be an indirect effect from an upstream 
dysregulation via KAT2B acetylation of TAL1. Given the observations the CB, it would 
be interesting to perform a similar time course of erythroid differentiation in K562s 
upon loss of SAGA DUB module USP22, to obtain more mechanistic insight on the 
SAGA contributions to erythroid differentiation.  
 
I extended the investigation of ATAC and SAGA functions to malignant 
haematopoiesis, where the disparity in roles between the two KAT2A-containing 
complexes was also functionally observed. I made use of a panel of AML cell lines 
containing markedly different genetic mutations, allowing for a better representation 
of the disease. In investigating the functions of the two KAT2A complexes, I found 
that SAGA participates in preservation of the characteristic AML differentiation 
block, irrespectively of the leukaemic subtype, which may suggest general control of 
cell state/identity in line with its roles in normal haematopoiesis post-commitment. 
ATAC, on the other hand, regulates cell biosynthetic activities, via control of 
ribosomal protein and translation-associated genes. This molecular information, 
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together with the pervasive G1/G0 cell cycle arrest observed in most AML lines, 
indicates that the ATAC complex fulfils an essential role in maintaining leukaemic 
cells. Notably, the phenotypic changes associated with depletion of SAGA or ATAC 
elements were somewhat consistent across the different AML cell models, 
independently of their genetic background. Lack of cellular differentiation is a 
hallmark of AML. In addition, LSCs cells are dependent on tight translational activity 
[298], thus justifying a dependence on the activities of both complexes in the 
leukaemia biology. The data suggest that the pro-differentiation effects of KAT2A-
inhibition are likely to be exerted through SAGA. From this point of view, one may 
think of targeting SAGA Core as an anti-leukaemic strategy as its effects in normal 
haematopoietic were minimal. This could, for example, be done in combination with 
chemotherapy, or ATRA which has recently been shown to have synergistic effects 
with KAT2A inhibitor MB-3, beyond APL leukaemias [316].  
 
Mechanistically, in K562s, ChIP-qPCR analysis of H3K9ac, at self-renewal and 
ribosomal protein genes, showed reduction of the specific histone activating mark at 
these loci, upon knockdown of SUPT20H (SAGA) and ZZZ3 (ATAC) elements. 
Nevertheless, ATAC and SAGA control of gene transcription may be more specific 
than its role as H3K9 acetyltransferase at gene promoters. In the leukaemic setting, 
loss of both SAGA and ATAC were accompanied by loss of H3K9ac at Hoxa genes as 
well as ribosomal protein-coding genes, suggesting a more complex epigenetic 
regulation at gene promoters, potentially involving additional complex enzymatic 
activities, as could also be the case in normal blood. Future studies investigating 
single and combined requirements of ATAC (for example ZZZ3 and KAT14) and SAGA 
(HAT and DUB) enzymatic subunits in locus and cellular regulation will enhance our 
understanding of the ‘crosstalk’ between different chromatin marks and of their 
effects on transcriptional control in leukaemia and the normal blood system. 
Similarly, this work focused on the HAT activity of KAT2A, and does not address if 
other histone modifications catalysed by KAT2A such as histone succinylation of 
H3K79 [180], are involved normal or leukaemic processes. To my knowledge this 
newly described enzymatic function has not been linked to neither SAGA nor ATAC 
complexes, but speculation as to if this is the case requires investigation.  
 
On a more fundamental level, the data suggests diversification of SAGA complexes, 
or of KAT2A function itself, from yeast to human. In yeast, KAT2A had been found 
to promote global acetylation genome-wide. On the contrary, the ChIP data indicates 
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a relatively low number of SAGA-specific and ATAC-specific targets. This suggests a 
more restricted use in mammalian cells as compared to yeast. Although it is also 
arguable that precise identification of KAT2A complex targets may be limited by the 
tools available. When comparing between the categories of genes bound SAGA and 
ATAC, it seems that SAGA regulation may involve control of other transcriptional 
regulators (e.g. MYC, STAT, ERG). ATAC, in contrast, appears to control a more 
unique set of genes, which encompass the translational machinery, and are 
ubiquitous across multiple cell types. This was verified in context of haematopoiesis, 
in this work, but also by others in other cancer types [235–236]. In line with this 
view, and because different cell types and states (for example at different stages of 
lineage differentiation), may be differentially sensitive to loss of ‘identity’ control vs 
biosynthetic pathways, it is conceivable that the differential requirement would 
determine the cells’ relative dependency on ATAC or SAGA complexes. Similarly, the 
dependency on the roles - rather than the roles themselves – could direct the extent 
to which loss of KAT2A equates with loss of one or both complex activities. In the 
case of normal haematopoiesis, the fact that the requirement of either complex is 
restricted to erythropoiesis may reflect the distinctive nature of 
erythroid/megakaryocytic commitment and differentiation, which segregate from the 
stem cell root upstream of myeloid and lymphoid lineages [319–320] with de novo 
establishment of transcription programs  [52]. In normal hematopoiesis, 
maintenance dominates pre-commitment, and identity post-commitment, with ATAC 
required early and SAGA late in lineage development. In light of this, a proposed 








































FIGURE 6.1 Working model of cell dependence on ATAC and SAGA complexes in normal 
and leukemic hematopoiesis. ATAC regulates leukaemia maintenance and 
SAGA cell identity/ state. In normal hematopoiesis, maintenance dominates 
pre-commitment, and identity post-commitment, with a stronger role of ATAC 
required early, and of SAGA in later stages of lineage development. 
 
Overall, while mechanistic investigation is needed to understand exactly how KAT2A 
participation in individual ATAC or SAGA complexes balance cell fates in normal and 
malignant settings, KAT2A-containing complexes may operate in order to preserve 
the cellular status quo. This would be compatible with the role of KAT2A in 
sustaining, rather than initiating, gene transcription [179]. Similarly, it aligns with 
its function in stabilising promoter activity and minimising variability in 
transcriptional output as recently described by our lab in embryonic stem cells [187] 
and leukaemia [197]. In leukaemia, our lab demonstrated that Kat2a sustains LSCs 
in a MLL-AF9 mouse model [197], and linked Kat2a loss to promoter dysregulation 
and enhanced transcriptional variability. In respect of control of transcriptional 
variability, Kat2a-dependent promoters that respond to Kat2a KO with loss of 
H3K9ac and increased transcriptional variability, were enriched in ATAC-dependent 
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in the context of its complexes [249], and this would be an interesting question to 
explore in future studies in response to ATAC and SAGA-specific depletions, using 
single-cell analysis.  
 
Genetic and pharmacological perturbations have been performed to address the role 
of KAT2A and its complexes in human AML primary samples, as presented. By using 
the MS5 co-culture system, I showed that KAT2A loss or chemical inhibition reduced 
leukaemic cell expansion over a period of 2-3 weeks, confirming KAT2A roles in 
primary leukaemias. More significantly, there was reduction in CD34+ and L-GMP 
primitive leukaemic compartments. Though only a single patient sample was 
successfully transduced with the ATAC and SAGA-delivering shRNAs, down-
modulation of ZZZ3 impaired AML cell expansion, which was not verified upon loss 
of SUPT20H. While this warrant further investigation in larger patient cohorts and 
potentially optimisation of shRNA transduction conditions in primary AML cells, the 
result is compatible with a role for ATAC in sustaining leukaemic self-renewing 
properties. In future, the AML-MS-5 co-culture system could be used to functionally 
validate KAT2A downstream targets (yield by both RNA/ ATAC and SAGA ChIP 
datasets) that specifically act on leukaemic maintenance or differentiation. With this 
in mind, I have validated a CRISPR epigenetic-editing tool to directly deliver KAT2A 
activity to its putative target genes (Appendix E). In future this would involve: (a) re-
design a more robust CRISPR-tool containing a fluorescent marker, thus avoiding 
the use of antibiotic selection on human samples; (b) design and test fusions between 
dCas9 and specific components of the KAT2A-containing complexes. The most 
obvious candidates would be DNA-binding ZZZ3 in the case of ATAC, and for example 
DUB, in the case of SAGA.  
 
To date no other knockouts of ATAC and SAGA subunits have been investigated in 
the hematopoietic system, at the exception of Usp22, which did not affect stem and 
progenitor compartments or normal myeloid differentiation [259], but had a 
surprising tumour suppressor effect in Kras-driven transformation. However, a 
recent screen of deubiquitinating enzymes required for 4-week bone marrow 
engraftment which identified Usp15 as a regulator of HSC activity in vitro and in vivo 
[321], also identified Usp22 as a possible hit, re-enforcing the notion that additional 
analysis of ATAC and SAGA-mediated roles in mouse haematopoiesis is necessary. 
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In summary, the data presented in this thesis provided functional in vitro assessment 
of ATAC and SAGA complexes in both normal and malignant blood development. It 
identified unique roles for ATAC and SAGA complexes which associate with 
maintenance of biosynthetic activity in the case of ATAC, and cell status/ identity in 
the case of SAGA [322]. It also prompted new questions that would be important to 
answer with future experiments: 
 
-Is KAT2B the preferential HAT in SAGA complexes at late stages of erythroid 
differentiation?   
 
-What are the consequences of combined knockdowns of SAGA-specific versus 
ATAC-specific depletions to normal and malignant haematopoiesis?  
 
-Through which pathways/mechanisms does SUPT20H loss enforce cell 
differentiation?  
 
-Is KAT2A control of transcriptional variability complex dependent, and if so, do both 
complexes play a role, or does it act uniquely through one of them? 
 
-Would Cas9-fusions with molecules involved in large chromatin complexes pose a 
challenge to efficient epigenetic editing? Would this approach fail potentially because 
of inability of assembly of endogenous complexes?  
 
Investigating these questions would further this work and shed new light into ATAC 
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Appendix A  
RNA-seq differentially expressed genes in CTRLsh vs KAT2Ash 
HSCs (10% FDR).   
FC- log fold change; CPM- log counts per million; FDR- false discovery rate  
 
Gene ID logFC logCPM F PValue FDR 
FAM178B -2.7919339 4.57662182 209.804103 6.36E-08 0.00055831 
NDUFA7 -10.65197 1.56035749 273.732958 6.52E-08 0.00055831 
RP11.442H21.2 -10.718431 1.59202772 240.327631 1.13E-07 0.00055831 
AC026703.1 7.97918721 1.91624787 182.503811 1.22E-07 0.00055831 
ITGB3.1 -3.3532307 3.66336714 176.048598 1.44E-07 0.00055831 
GATS -9.8349675 0.76338795 168.500593 5.06E-07 0.00163249 
PPBP -2.3129192 4.47036984 129.031556 6.04E-07 0.00167001 
IGFBP4 -2.0176159 3.9944502 107.138753 1.41E-06 0.00339818 
PKHD1L1 -2.1180676 5.62881016 96.497307 2.25E-06 0.00483162 
CCND1 -1.5451196 4.9786278 91.951013 2.79E-06 0.00539332 
AC068831.15 -9.2135714 0.21358427 107.191964 3.29E-06 0.00563785 
SELP -2.3323822 5.01591171 87.3775137 3.50E-06 0.00563785 
VWF -1.5753351 6.29388924 84.4974527 4.06E-06 0.00603634 
RP11.1415C14.2 7.12949796 1.12423216 81.0659378 4.87E-06 0.00626421 
RP11.1415C14.1 7.12949796 1.12423216 81.0659378 4.87E-06 0.00626421 
SYP 2.25769994 3.15817232 78.3308404 5.66E-06 0.00626421 
CD36 -1.326918 7.01035101 78.0046359 5.77E-06 0.00626421 
GRAP2 -1.2923771 5.2741455 76.9619779 6.12E-06 0.00626421 
HBB -1.6668311 5.87745836 75.25629 6.75E-06 0.00626421 
FOXJ1 -1.5969441 4.42706646 74.5606195 7.03E-06 0.00626421 
CDH1 -1.8230216 3.76533043 74.4864825 7.06E-06 0.00626421 
YWHAB -1.2845636 6.9949001 74.0013034 7.26E-06 0.00626421 
CTTN -1.822755 4.0674422 73.5734519 7.45E-06 0.00626421 
ABCC3 -2.394305 3.25978991 71.3241095 8.52E-06 0.00680041 
PRG2 -1.9734162 7.53643255 70.8261119 8.79E-06 0.00680041 
PKLR -1.4229324 4.42151634 70.154519 9.16E-06 0.00681476 
GABRE -2.1886179 4.24873927 68.8742229 9.92E-06 0.0071073 
ITM2B -1.557922 6.61457459 66.8155077 1.13E-05 0.0078133 
GNG4 2.95563226 1.24601719 64.9897665 1.27E-05 0.00849883 
YBX3 -1.4253536 6.6826618 64.4799722 1.32E-05 0.00849883 
SLC2A14 -2.1432289 2.8145318 63.1737887 1.44E-05 0.00897912 
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BSN 1.91960277 3.42469595 60.9870835 1.67E-05 0.01011188 
RAB39A 3.35323633 0.69731341 60.0074013 1.79E-05 0.01050583 
RHAG -1.3504209 4.35702225 59.2009561 1.90E-05 0.0108007 
CTAGE4 8.6059153 -0.3081708 64.0312481 2.58E-05 0.01426574 
CA2 -2.1260744 2.12866322 53.3948398 2.93E-05 0.01576866 
TOP1MT -1.307755 4.38732688 51.9844273 3.28E-05 0.0170132 
F2R -1.5511334 6.09105276 51.7597565 3.34E-05 0.0170132 
NSMAF -0.9951983 6.01800862 50.1991702 3.80E-05 0.0188299 
RIC3 2.02759409 2.18867936 49.6014567 3.99E-05 0.01901569 
LTBP1 -1.6018366 7.41311926 49.4804437 4.03E-05 0.01901569 
C5orf15 -1.0839755 4.76990089 49.0924172 4.16E-05 0.01917822 
GDAP1 1.30514176 4.07378424 48.4088614 4.41E-05 0.01985042 
ATPAF1 -1.1499677 4.48521769 48.0974605 4.53E-05 0.0199231 
ZDHHC9 -1.1517861 4.47687887 47.3933614 4.81E-05 0.02025234 
VWA5A -0.9983599 5.11952474 47.392728 4.82E-05 0.02025234 
UBXN10 -2.4949024 1.30463104 46.9555644 5.00E-05 0.02059178 
SLC25A1 -0.9251074 5.84309404 45.8367069 5.52E-05 0.02214392 
EPX -1.2447312 4.18530108 45.6648631 5.61E-05 0.02214392 
CBLL1 -1.0071338 6.56940098 45.3804639 5.75E-05 0.02225436 
LEPR -1.038541 5.00235499 44.9792063 5.97E-05 0.02225436 
AHSP -2.3857605 1.26399934 44.5915816 6.18E-05 0.02225436 
AC107982.4 8.31512407 -0.5415332 50.7194788 6.33E-05 0.02225436 
GOLGA7B 4.04593555 0.3217727 44.284004 6.36E-05 0.02225436 
CERS6 -0.9272692 6.41153102 44.2112845 6.40E-05 0.02225436 
SLC38A5 -0.9433713 5.52936971 44.1414792 6.44E-05 0.02225436 
NAA50 -0.9482909 6.7311562 43.7335918 6.69E-05 0.02270539 
ARHGEF40 0.94868749 5.65523475 43.361784 6.93E-05 0.02310135 
TNS4 -5.2103863 -0.0832531 43.1433841 7.07E-05 0.02317986 
NEO1 -2.0606482 3.74001808 42.0458542 7.85E-05 0.02495992 
PF4 -1.8572984 3.42942765 42.0141851 7.87E-05 0.02495992 
RP11.676J12.4 -5.8285494 -0.720811 41.7191008 8.10E-05 0.02498902 
PROS1 -0.9298074 5.26689604 41.6675479 8.14E-05 0.02498902 
PTGER3 -1.2232757 4.45593947 41.3488967 8.39E-05 0.02537133 
PTGDR2 1.13971918 4.79593733 40.3128622 9.29E-05 0.02766214 
LRRC32 -1.7191298 3.16815555 39.9482605 9.64E-05 0.02779905 
TRIM29 -2.6631628 0.62281202 39.8853808 9.70E-05 0.02779905 
ASIC4 1.09577074 4.48802608 39.8120555 9.77E-05 0.02779905 
ITGB3 -1.1972307 7.40461172 39.3024809 0.00010286 0.02866704 
RAD51L3.RFFL -8.1705926 -0.7568719 44.1904411 0.00010628 0.02866704 
APOE -1.9903519 1.98727918 38.3016778 0.00011399 0.02866704 
RNU1.28P 0.88579753 6.24989788 38.1689679 0.00011557 0.02866704 
RNU1.27P 0.88579753 6.24989788 38.1689679 0.00011557 0.02866704 
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RNU1.1 0.88579753 6.24989788 38.1689679 0.00011557 0.02866704 
RNVU1.18 0.88579753 6.24989788 38.1689679 0.00011557 0.02866704 
RNU1.2 0.88579753 6.24989788 38.1689679 0.00011557 0.02866704 
RNU1.4 0.88579753 6.24989788 38.1689679 0.00011557 0.02866704 
RNU1.3 0.88579753 6.24989788 38.1689679 0.00011557 0.02866704 
CD9 -1.9467042 3.64928251 37.3473395 0.00012597 0.03007184 
ARL6IP5 -0.8337588 5.8761186 37.3375136 0.00012611 0.03007184 
MGAT5B 1.73447744 2.37236315 37.3222539 0.00012631 0.03007184 
TMEM56 -1.6718854 2.69502293 37.2374884 0.00012745 0.03007184 
HBG2 -0.8282934 5.94648663 36.7330561 0.0001345 0.03135243 
TMCO3 -0.9437675 4.80969303 36.5031394 0.00013787 0.03175491 
GHITM -0.9183674 6.01344833 36.3460458 0.00014022 0.03191844 
MANEAL 1.96595002 1.48162798 35.8582543 0.00014787 0.03281923 
TRAP1 -0.8838828 6.13952359 35.8115418 0.00014863 0.03281923 
PDE3A -0.9356703 4.77743718 35.4844034 0.00015407 0.03281923 
LGMN -1.77024 2.12904195 35.4594272 0.00015449 0.03281923 
UCA1 -2.0350359 1.93501915 35.3996797 0.00015552 0.03281923 
CHKB.CPT1B 1.99840445 2.10248956 35.3847193 0.00015577 0.03281923 
SARM1 1.24214122 4.35948296 35.3684057 0.00015606 0.03281923 
ID2 -1.0669651 4.39141285 35.1214586 0.00016039 0.03336809 
PCSK9 -1.3372199 3.97783467 34.8629172 0.00016508 0.03397938 
SLC2A3 -1.0086984 6.7553463 34.5535491 0.00017092 0.03481049 
BLVRB -0.8682192 5.41037738 34.3484159 0.00017493 0.03525562 
TUBB2A -1.7278508 2.24568264 33.8049665 0.00018611 0.03712182 
ADD2 -0.8998515 4.75469628 33.657413 0.00018929 0.03737134 
AC087392.1 7.97840136 -0.8923142 37.3754379 0.00019667 0.03843671 
AK4 -0.795312 5.74617402 33.2172086 0.00019918 0.03845034 
NPDC1 1.13703402 4.24048107 33.0978855 0.00020197 0.03845034 
CANX -1.1322802 8.74190948 33.0296228 0.00020359 0.03845034 
STXBP6 1.39834956 3.03612252 32.9832994 0.00020469 0.03845034 
PVRIG2P -1.78422 1.66888481 32.7054642 0.00021148 0.03933609 
CLN3.1 -7.9868634 -0.9843453 36.5381172 0.00021347 0.03933609 
TPSB2 -1.2373947 7.08879588 32.0307471 0.00022912 0.04153233 
CSF3R 0.78123683 5.55651326 32.0100722 0.00022969 0.04153233 
BNIP3 -0.8138449 5.1524408 31.8735765 0.00023348 0.04182725 
TP53RK -0.7768699 6.3211129 31.6150208 0.00024087 0.04275594 
STC2 -2.2428256 0.94733728 31.3566473 0.00024854 0.04371677 
FAM43A 1.18372714 4.15838417 31.2073312 0.00025311 0.04411922 
TPSAB1 -1.2030019 8.19963128 30.9484953 0.00026127 0.04449602 
EPCAM -1.5339833 2.76771534 30.8414242 0.00026474 0.04449602 
C3orf58 -0.7969384 6.23164933 30.7944966 0.00026628 0.04449602 
RP11.407N17.3 -4.1358966 0.70791621 30.78418 0.00026662 0.04449602 
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C3orf14 1.95600349 1.57611997 30.7795367 0.00026677 0.04449602 
ENPP3 -0.9862373 4.32312895 30.6248766 0.00027193 0.04483512 
EMP2 -1.7056126 1.73977288 30.5379116 0.00027488 0.04483512 
SERP1 -0.7894917 6.71876662 30.5123182 0.00027576 0.04483512 
AMMECR1 -0.8031819 5.82654732 30.4408996 0.00027822 0.04485859 
ARPP21 -1.6987374 2.71608016 30.2255962 0.00028581 0.04542714 
PHLDA3 2.04345096 1.05355279 30.2078871 0.00028644 0.04542714 
CFH 1.04028486 4.04377359 30.0904145 0.0002907 0.04572731 
MAT2B -0.8163782 5.42627552 29.9404309 0.00029625 0.046085 
EPOR -0.8176704 5.16392446 29.9006506 0.00029774 0.046085 
PRAM1 1.24923531 3.79806198 29.7722213 0.00030262 0.04617265 
TPSD1 -1.2369253 4.26435643 29.6810532 0.00030614 0.04617265 
PMP22 -0.9559369 4.26586747 29.6706337 0.00030655 0.04617265 
BTF3L4 -0.7748487 5.21217322 29.6372609 0.00030785 0.04617265 
HLA.DOA 1.28331849 3.22561627 29.5707343 0.00031047 0.0462073 
SCAMP5 1.40545233 2.83120183 29.4633752 0.00031475 0.0463338 
BASP1 -0.8003496 5.63455362 29.3968746 0.00031744 0.0463338 
AP001266.1 2.21428311 1.14298939 29.3708237 0.0003185 0.0463338 
LRRC16B 2.08687342 0.85782887 29.1502071 0.00032766 0.04731052 
EIF5B -0.8287479 7.20088314 29.064146 0.00033132 0.04748447 
AKAP2 -0.9017449 7.8219992 28.9669432 0.00033551 0.04754467 
PVRL1 -0.7814922 5.41328982 28.9407013 0.00033666 0.04754467 
SDPR -0.8974509 6.92870613 28.7706565 0.00034418 0.04825438 
LTC4S 1.46920778 2.41047034 28.6794954 0.00034829 0.04829741 
RNF7 -1.0065562 4.02338962 28.6383457 0.00035017 0.04829741 
ALAS2 -1.3153514 3.42050156 28.5626644 0.00035365 0.04829741 
MAPK11 1.87368602 3.39885673 28.4521791 0.00035881 0.04829741 
MORF4L2 -0.7627965 6.49246579 28.4248837 0.0003601 0.04829741 
FAM175A -0.815534 4.81136455 28.4081103 0.00036089 0.04829741 
AC138123.2 -1.0987862 4.01386774 28.3759497 0.00036242 0.04829741 
SHPK.1 2.01459595 1.74908342 28.3179362 0.0003652 0.04829741 
PFKFB4 -0.7520225 5.50115389 28.2571484 0.00036814 0.04829741 
CTD.2031P19.4 -1.1367786 4.0513881 28.2304554 0.00036944 0.04829741 
EDA2R 1.7680313 1.62496642 28.0244169 0.00037967 0.04930088 
ANXA5 0.78343047 5.19469237 27.7668226 0.00039294 0.05047524 
FAM45A -0.7444832 5.47672151 27.7479327 0.00039393 0.05047524 
PRSS23 0.74256901 5.2823292 27.5410165 0.00040503 0.05155573 
MBOAT2 -0.7126237 6.04089307 26.9133373 0.00044108 0.05577731 
WSB2 -0.9982382 4.40503946 26.7451262 0.00045139 0.05671047 
ADAM28 0.7746216 4.88769837 26.6472454 0.00045752 0.05711019 
RPL13AP5 -0.7030387 6.07815373 26.5385448 0.00046445 0.05726508 
LDHA -1.0378328 8.5129856 26.5349582 0.00046468 0.05726508 
 209  
KRT13 -2.7745848 -0.0672338 26.4132031 0.0004726 0.05787218 
AL139819.1 -1.4321284 4.19845397 29.0921665 0.00047788 0.05815113 
RYR3 -0.8103062 7.47668867 26.1931394 0.00048732 0.05892968 
DISP2 1.48135078 2.18861542 25.7348167 0.00051981 0.06246813 
SCAMP1 -0.7362454 5.08817676 25.6082556 0.00052924 0.06287205 
GP6 -1.3526847 3.14022592 25.5241435 0.00053562 0.06287205 
CPNE2 -1.0194098 3.83230925 25.5203829 0.00053591 0.06287205 
FCGR2A -0.9061804 4.41477167 25.5169386 0.00053617 0.06287205 
ATP11C -0.6942706 5.54854695 25.4426789 0.00054189 0.06315968 
RP11.46D6.1 1.87153375 1.03619075 25.3348793 0.00055032 0.06375826 
SEMA3C -0.7469942 5.12045685 25.1482586 0.00056529 0.06483875 
EPAS1 1.60624714 1.8186077 25.0956176 0.00056961 0.06483875 
FST -1.0687936 3.57486032 25.0944674 0.0005697 0.06483875 
AP000350.10 7.6728791 -1.2001501 27.5795353 0.0005742 0.06494734 
SEL1L -0.7148802 6.54762541 24.991435 0.00057826 0.06494734 
WSCD2 -2.7346026 0.7409234 24.9620664 0.00058073 0.06494734 
LY6G6D -3.9627172 -0.5807463 24.7803104 0.00059628 0.06600066 
SLC18A2 -0.7128584 6.36427728 24.7724465 0.00059697 0.06600066 
STMN3 1.35399173 5.79589784 24.5132719 0.00062006 0.06789482 
EIF3J -0.7212653 5.71019568 24.4801888 0.00062309 0.06789482 
BMS1P1 0.96707672 3.8743946 24.4634103 0.00062463 0.06789482 
PTPRJ -1.7443619 3.28185298 24.3951825 0.00063094 0.06819794 
CECR1 0.86571777 4.57861688 24.3000011 0.00063988 0.06873636 
ARPC1A -0.7675712 4.79342371 24.2668375 0.00064303 0.06873636 
ODC1 -0.7008897 6.63176562 24.198468 0.00064958 0.06905527 
MTFP1 -1.1123866 3.35157625 23.9960313 0.00066946 0.07077971 
TSPAN7 1.3950794 2.10073699 23.798262 0.00068959 0.07229403 
PRKAA1 -0.7319216 5.76108611 23.7822533 0.00069125 0.07229403 
TOMM20 -0.7096446 6.86970144 23.7096101 0.00069886 0.07237508 
HPSE -1.4908599 3.3433987 23.7033881 0.00069951 0.07237508 
FN3K -0.8259704 4.41538903 23.4903277 0.00072242 0.07417593 
BLOC1S6 -0.6698255 5.72460557 23.4706108 0.00072458 0.07417593 
ANKRD36BP1 -0.9917558 3.7318181 23.3488568 0.00073813 0.07516495 
AP000295.9 -1.8267503 1.03520702 23.1695836 0.00075864 0.07668658 
ETV5 -0.7601633 4.70321533 23.149299 0.000761 0.07668658 
SLFN5 -1.1064563 3.91599488 23.0544978 0.00077216 0.07740839 
KRT19 -1.4654521 1.78739353 22.9773267 0.0007814 0.07793028 
TRIB2 -0.6801247 6.18045808 22.6833799 0.00081781 0.08114375 
CLEC1B -1.7555943 1.71975901 22.6497139 0.00082211 0.08115423 
SOS1 -0.9795413 8.45725912 22.5641488 0.00083316 0.08147846 
GEMIN5 -0.6496575 5.71098756 22.5076845 0.00084056 0.08147846 
RAB8B -0.6579424 5.87062131 22.4889479 0.00084303 0.08147846 
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SH3TC1 1.25077137 4.67893985 22.4595957 0.00084691 0.08147846 
AC011558.5 5.3271911 -0.7538758 22.4529686 0.0008478 0.08147846 
RGS6 -1.0646422 3.99516341 22.43144 0.00085066 0.08147846 
CHML -0.64272 5.82534996 22.3127432 0.00086669 0.08260478 
ANP32E -0.6822003 6.82690423 22.1963674 0.00088276 0.08274363 
FAM136A -0.7214768 5.16170751 22.1921695 0.00088335 0.08274363 
MICALL2 -0.7335035 4.81988097 22.1829178 0.00088464 0.08274363 
SELENBP1 -1.4292228 2.10522309 22.1785452 0.00088526 0.08274363 
ARHGAP18 -0.7174464 5.9672185 22.1099423 0.00089493 0.08301663 
SEZ6L 3.56941383 0.36849377 22.0970864 0.00089676 0.08301663 
RP11.512M8.5 1.38325472 3.02174272 22.0430399 0.00090449 0.0833336 
ZFPM2 -2.8317646 1.18586688 21.9652103 0.00091576 0.08397254 
HIF1A -0.7826863 6.36404852 21.884628 0.00092762 0.0846582 
HSP90AB1 -1.0449005 9.83087933 21.8105577 0.00093868 0.08505706 
RASGRP3 -0.9267197 5.05454515 21.7965861 0.00094078 0.08505706 
CYP1B1 0.68642082 5.23351094 21.7658897 0.00094542 0.0850792 
KCNE1 -1.7829089 0.99369599 21.6632025 0.00096115 0.08520657 
PRICKLE2 -1.8392286 1.22267361 21.6269857 0.00096678 0.08520657 
RASSF4 1.78838528 1.10412488 21.6260212 0.00096693 0.08520657 
ICK -0.8644244 4.13343114 21.5850528 0.00097334 0.08520657 
PLD4 1.21746499 4.32928614 21.553292 0.00097834 0.08520657 
FAM98A -0.7348393 4.99416749 21.5489105 0.00097904 0.08520657 
SERPINE2 -0.8448244 4.85528786 21.5386295 0.00098066 0.08520657 
LPXN 0.82316008 4.56609367 21.5207727 0.0009835 0.08520657 
ARHGEF17 0.65242592 5.36809812 21.5021234 0.00098647 0.08520657 
UBE2L5P -1.9673131 1.17867075 21.4152467 0.00100046 0.08603087 
SLC16A9 -1.5640968 1.28257914 21.2519576 0.00102741 0.08784995 
MPO 1.69480594 3.90681474 21.2091112 0.00103463 0.08784995 
KDELC1 -1.10165 3.07349912 21.1919322 0.00103754 0.08784995 
SLC6A8 -1.0328807 3.42313539 21.174008 0.00104058 0.08784995 
CACNA1I -1.7482538 1.27206738 21.1521196 0.00104432 0.08784995 
RP11.618P17.4 -1.3882373 1.97481629 21.1093208 0.00105167 0.08808536 
RPS17 -0.6573157 5.29603309 21.0797522 0.00105679 0.08810133 
KAZN -0.974455 3.61019998 21.0557045 0.00106097 0.08810133 
PDK1 -0.6870707 6.26762363 20.8205075 0.00110294 0.09074915 
EFCAB12 -1.4560328 1.46056569 20.8035261 0.00110605 0.09074915 
KLHL5 -0.6594703 5.11697821 20.7987653 0.00110693 0.09074915 
RAB11FIP4 1.03622119 3.43676387 20.7490204 0.0011161 0.09111513 
MCFD2 -0.6264449 5.86844186 20.7018124 0.00112489 0.09144692 
C10orf54 0.6731067 4.9702224 20.6355187 0.00113738 0.09178737 
IFITM2 -0.6844192 5.39916135 20.6292467 0.00113857 0.09178737 
TYW3 -0.7344454 4.6107657 20.512051 0.00116108 0.09321395 
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NPW -1.1658232 2.75862878 20.4812785 0.00116708 0.0933085 
TET1 -0.7882876 5.75960703 20.4421707 0.00117476 0.09353599 
PPAP2B -1.6064195 1.07058221 20.3876471 0.00118557 0.09400976 
BCL2L1 -0.6552427 6.07704532 20.3265286 0.00119783 0.09459421 
S100A4 0.62059892 5.83953456 20.2195066 0.00121967 0.09511883 
RP11.113K21.4 -7.3313967 -1.5568306 21.985637 0.00122237 0.09511883 
SMIM3 -2.6157678 -0.0636175 20.1996258 0.00122378 0.09511883 
ANKRD36B -0.6256711 5.85247061 20.1885333 0.00122608 0.09511883 
NCS1 -1.2608174 2.51106657 20.1659098 0.00123078 0.09511883 
RAC3 -0.9084007 3.90240005 20.1506621 0.00123397 0.09511883 
TMOD2 1.14626111 3.23821838 20.0829097 0.00124824 0.09583726 
UBE2Q2 -0.7216157 4.81964366 19.9643019 0.00127371 0.09690211 
ERG 0.63718607 6.28535264 19.9339021 0.00128034 0.09690211 
C1orf186 -0.7590097 4.71743077 19.9270683 0.00128184 0.09690211 
BIN1 0.95547765 4.22704575 19.925666 0.00128214 0.09690211 
CHD7 -0.6443556 6.68937852 19.886201 0.00129083 0.09717873 
RP11.1415C14.4 -1.4671649 4.48257937 19.8524624 0.00129831 0.09736295 
ACE 1.24420367 3.79514181 19.7865621 0.00131307 0.09808967 
SGPL1 0.96750681 3.60354119 19.7087999 0.00133075 0.09902798 
CHGB 2.83209038 -0.1141612 19.6182886 0.00135169 0.09970443 
VGF 1.95736732 0.58544287 19.5804203 0.00136057 0.09970443 
CTC.273B12.8 -1.9726701 0.38204147 19.5558751 0.00136636 0.09970443 
KCNH8 1.54689242 1.12519072 19.5485975 0.00136808 0.09970443 
GFI1B -0.7888666 6.9236806 19.5297529 0.00137256 0.09970443 
COX7A2L -0.7116701 4.93033386 19.5050119 0.00137846 0.09970443 
LINC01122 1.50532819 1.32053011 19.4976759 0.00138021 0.09970443 
SH3GL1P3 1.52428129 1.14383303 19.4941346 0.00138106 0.09970443 
HBG1 -1.0645057 3.12242422 19.4592863 0.00138945 0.09993677 
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Appendix B 
Enriched genes in erythroid-basophil-megakaryocyte-biased 
progenitors (EBMP) as per detailed single-cell profiling of 
erythroid development by Merryweather Clarke (2011).  
 












Apoe 1.638 Fermt3 0.334 Fam102a 0.269 Galnt6 0.233 
Ctla2a 1.391 Pla2g4a 0.333 Gm11114 0.269 Gns 0.232 
Muc13 1.112 Tbc1d14 0.333 Sptssa 0.269 Pkd1l3 0.232 
Gata2 1.101 mt-Atp6 0.332 Spock2 0.268 Tor4a 0.232 
H1fx 1.012 Mecom 0.332 Proser3 0.268 Rai1 0.232 
Ctla2b 1.012 Vwc2l 0.331 Serinc1 0.268 Mettl14 0.232 
Pbx1 0.994 Git2 0.331 Gm14735 0.268 Gm13552 0.232 
F2r 0.958 2610034B18Rik 0.331 Fam60a 0.268 Ndst1 0.232 
Nrgn 0.939 Bcr 0.33 Rhoh 0.268 Spint2 0.232 
Itga2b 0.921 Zmynd11 0.33 Bex1 0.267 Runx2 0.232 
Slc22a3 0.864 Rpl13a 0.33 Glul 0.267 Gna15 0.232 
Pafah2 0.852 Rps14 0.328 Ankef1 0.267 Gm8522 0.231 
Diap1 0.848 Pnisr 0.328 Jam3 0.266 Abcc3 0.231 
Adgrg1 0.845 Gnmt 0.328 Ski 0.266 Cep55 0.231 
Cdk6 0.835 Sfi1 0.327 Zfp13 0.266 Mtus2 0.231 
Meis1 0.766 Zdhhc24 0.327 Klk8 0.266 Gm14607 0.231 
H2-K1 0.764 Tnfrsf18 0.327 Heg1 0.266 Mbtps2 0.231 
Eef1a1 0.759 Tnrc18 0.327 Neurl1b 0.266 Ncor2 0.231 
Slc18a2 0.757 Zfp664 0.327 Nrxn1 0.266 Rhobtb3 0.231 
Zfp385a 0.756 Atf7ip 0.327 Usp40 0.265 Col1a2 0.231 
Mpl 0.751 Clec11a 0.326 Mzt1 0.265 Tet1 0.231 
Csgalnact1 0.748 Tjp2 0.326 Notch2 0.265 Ptprc 0.231 
Vezf1 0.746 Unk 0.326 Tmem59 0.265 Gm4613 0.231 
Txnip 0.744 Fam189b 0.326 Stxbp1 0.265 Gm355 0.231 
Fam65a 0.738 Tmem40 0.326 Gm14975 0.265 Gm13247 0.23 
Mdga1 0.729 Rbms3 0.325 Nr2e1 0.264 Fbxl19 0.23 
Angpt1 0.703 Dock8 0.324 Ddx52 0.264 Hsd3b2 0.23 
Spns2 0.703 Gm18291 0.324 Hoxa10 0.264 Tuba8 0.23 
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Serpina3g 0.701 Stat3 0.323 Dennd1c 0.264 Rpl17-ps8 0.23 
Rab37 0.698 Fam199x 0.323 Plgrkt 0.264 Creb1 0.23 
Itga6 0.691 Rftn2 0.323 Rps11-ps1 0.263 Clec4d 0.23 
Atp13a2 0.667 Trip6 0.323 Rps16 0.263 Tnip3 0.23 
Ptrf 0.663 Sesn3 0.321 Pgpep1 0.263 5430427O19Rik 0.23 
Sox4 0.663 Rps21 0.321 Trappc6a 0.263 Kat6a 0.23 
Ikzf2 0.652 Klc3 0.321 Bin1 0.263 Rpl23a-ps14 0.23 
Rgs18 0.643 Aplnr 0.32 Stbd1 0.263 Plbd2 0.23 
Dapp1 0.639 Usp11 0.319 Rbmx 0.263 Tmem47 0.229 
Slc7a8 0.634 Mrm1 0.319 4930555F03Ri 0.263 Ndn 0.229 
Rpl15 0.632 Rbms2 0.319 Laptm4a 0.262 Srrm2 0.229 
Ndrg1 0.628 Zfp82 0.318 Taok3 0.262 Oit3 0.229 
Gnb4 0.624 Plek 0.317 Fam64a 0.262 Cul7 0.229 
Vim 0.602 Gpr161 0.317 Nedd4 0.262 Rfc2 0.229 
Mycn 0.597 Glud1 0.317 Gm6368 0.262 Homer3 0.228 
Plec 0.59 Afap1l1 0.317 Gm5356 0.262 Prl8a8 0.228 
Gse1 0.59 Lgals1 0.317 Fnbp1l 0.262 Rpl26 0.228 
B2m 0.585 Smad5 0.317 Epsti1 0.261 Hint2 0.228 
Inafm1 0.581 Zxdc 0.316 Atp6v0a2 0.261 Dtx3 0.228 
Dach1 0.58 Neil1 0.316 Tap1 0.261 Rell2 0.228 
Bin2 0.58 Snx10 0.315 Psat1 0.261 Zfhx3 0.228 
Rps19 0.577 Ago1 0.315 Rplp2 0.261 Eef2 0.228 
H2-D1 0.577 Tctn3 0.315 Ctnnbip1 0.261 Ube2e1 0.228 
Tmem123 0.569 Slamf1 0.315 Rai14 0.261 Rtfdc1 0.227 
Zfp36l2 0.566 Pdcd4 0.315 Ier3 0.26 Kcnt1 0.227 
Tmem176b 0.565 Pold4 0.314 Eml2 0.26 Orai2 0.227 
S100a10 0.565 Socs7 0.314 4933415A04Ri 0.26 Rpl38 0.227 
Pitpnc1 0.564 Fam212a 0.314 Eml1 0.26 Aamdc 0.227 
Gcnt2 0.56 Cobll1 0.314 Zfp54 0.26 Arhgef18 0.227 
Rps15 0.555 Erg 0.313 Cpsf1 0.26 Gm38356 0.227 
Rps9 0.553 Fam222a 0.313 Cstf2t 0.259 A930004D18Rik 0.227 
Mef2c 0.551 Zbed3 0.312 Gm7329 0.259 Gm5493 0.227 
Myct1 0.547 Mme 0.311 Ubald2 0.259 Gtf2i 0.227 
H1f0 0.544 Fam3c 0.31 Cyp4f16 0.258 Fam65b 0.227 
Treml2 0.536 Tmco4 0.31 Nav1 0.258 Ltbr 0.226 
Rpl10a 0.535 AW551984 0.31 Sdr39u1 0.258 Ilf3 0.226 
Rps18 0.534 Hsd17b10 0.309 Nek9 0.258 Svil 0.226 
Plxnc1 0.527 Dag1 0.309 Arsk 0.257 Otos 0.226 
Stmn1 0.526 Pdcd2 0.309 Tfap4 0.257 Nlgn2 0.226 
Kit 0.526 Prkcq 0.309 Armc10 0.257 Best3 0.226 
Rps5 0.519 Gm8420 0.309 Smad4 0.257 Gm21092 0.226 
Cbfa2t3 0.518 Rps13 0.308 Cdk17 0.257 Ctr9 0.226 
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Lat 0.516 Ifitm1 0.308 Slc9b2 0.257 Gm38280 0.226 
Zyx 0.515 Il17ra 0.307 Kansl1 0.256 Rnf2 0.226 
Ccdc8 0.514 Utrn 0.307 Xlr4c 0.256 Phldb3 0.225 
Gnb2l1 0.513 Rpl18-ps1 0.306 Camk1 0.256 1810030O07Rik 0.225 
Tmem176a 0.513 Prkcdbp 0.306 Cd274 0.256 Rasip1 0.225 
Macf1 0.508 Slit1 0.306 Cep68 0.255 Arl6ip1 0.225 
Fbxl20 0.508 Crim1 0.306 RP24-461L18.3 0.255 Nap1l3 0.225 
Tmem98 0.504 Ctsk 0.305 Ldlr 0.255 Rpl27a 0.225 
Lgals9 0.503 Grb2 0.305 Ttc21b 0.254 Akt1 0.225 
Smarca2 0.5 Samd14 0.305 Kctd3 0.254 Gm16411 0.225 
Sfxn3 0.499 Itgb3 0.305 Prkar2b 0.254 Olfr132 0.225 
Esam 0.497 Mlph 0.304 Tmem240 0.254 Gm12268 0.225 
Soga1 0.495 Pcbp3 0.304 Lmo4 0.254 Gm12518 0.225 
Ankrd13a 0.494 Actg1 0.304 Map4k4 0.253 2410004B18Rik 0.225 
Tbxas1 0.491 Dcaf8 0.304 Gm14007 0.253 Echdc3 0.225 
Ifitm3 0.49 Ppif 0.304 Cirbp 0.253 Vmn2r106 0.225 
Numa1 0.489 Bahcc1 0.304 Clec4e 0.253 Gm26914 0.225 
Msi2 0.488 Zfp191 0.304 Eif2ak3 0.252 Gm13195 0.224 
Gp5 0.487 Dock2 0.304 Cuzd1 0.252 Acap1 0.224 
Mtfr2 0.484 Ctf2 0.303 Pon3 0.252 Gm6136 0.224 
H2-Q7 0.479 Bicd1 0.303 Hspb8 0.251 Lrrc4c 0.224 
Rpl18 0.478 Ttc28 0.302 Ccdc112 0.251 Setd2 0.224 
Ptms 0.476 Tbx20 0.302 D17H6S53E 0.251 Stx4a 0.224 
Rps3 0.474 Ttc3 0.301 Slit2 0.251 Vmn1r52 0.224 
Smim5 0.473 Rpl22 0.301 Myo1b 0.251 Spaca7 0.224 
Arid1b 0.472 Dgkz 0.301 Ino80b 0.251 Adamts15 0.224 
Rabgap1l 0.466 Rest 0.301 Gemin8 0.251 Kng1 0.224 
Arid1a 0.466 Tom1l2 0.301 Fam198b 0.251 Pcmtd2 0.224 
Tgfbr2 0.462 Acp5 0.3 Lypla1 0.251 Sord 0.224 
Por 0.459 Spry3 0.3 Calr3 0.25 Anks1 0.223 
Sgce 0.459 Ric8 0.3 Lrrc9 0.25 Dlx1 0.223 
Samsn1 0.458 Zer1 0.3 Ccdc121 0.25 Rbpj 0.223 
Hsd3b7 0.455 Nckap5l 0.3 Kat2a 0.25 Gm2308 0.223 
Tgfb1 0.454 Bcl2 0.3 Fhod1 0.25 Mlycd 0.223 
Kctd1 0.451 Map1lc3b 0.299 Phf14 0.25 Elk1 0.223 
Ms4a2 0.451 Ltc4s 0.299 Tnni3 0.25 Sptbn1 0.223 
Prkca 0.45 As3mt 0.299 Rsrc1 0.249 Wfikkn1 0.223 
Ehd3 0.449 Med12l 0.299 Olfr729 0.249 Npas3 0.223 
Ccng2 0.448 Cd84 0.299 RP23-183O3.1 0.249 Gm6829 0.223 
Csrp3 0.445 Cldn34-ps 0.298 Il10rb 0.249 Socs4 0.223 
Spn 0.445 Cbln2 0.298 Rps11 0.249 Gprasp2 0.223 
Crlf2 0.442 Grcc10 0.298 Odf3b 0.249 Gm7776 0.223 
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Fyn 0.441 Gm7206 0.298 Vsig10l 0.249 Gm28239 0.223 
Ptprcap 0.441 Atf7 0.298 Zfp282 0.249 Ttc41 0.222 
Dok2 0.439 Rtn4 0.297 Sncb 0.248 Col16a1 0.222 
Tgfbr3 0.439 Ankrd16 0.297 Zcchc11 0.248 Dxo 0.222 
Phf21a 0.433 Rapgef3 0.296 Gnpda2 0.248 Med15 0.222 
Cuedc1 0.432 Btbd8 0.296 Prkar1a 0.248 Foxo1 0.222 
Mprip 0.428 Dusp23 0.296 Zbtb9 0.248 RP24-188B2.2 0.222 
Vamp5 0.426 Ggcx 0.295 Col14a1 0.248 Wdr63 0.222 
Sigirr 0.426 Myl12b 0.295 Rcor2 0.248 Tle2 0.222 
Zbtb20 0.425 Adgrl1 0.295 Rpl34 0.247 Fam161b 0.221 
Pafah1b3 0.425 H2-T22 0.295 Kcnab2 0.247 Podxl2 0.221 
Cox14 0.424 Cnbp 0.295 Rpl37a 0.247 AI314180 0.221 
Myb 0.423 Gimap9 0.295 Mapk10 0.247 Pcdhb5 0.221 
Celf2 0.423 Glns-ps1 0.295 Ikbkb 0.247 Mt3 0.221 
Anxa5 0.421 Zfp831 0.295 Slc39a1 0.247 Vmn1r5 0.221 
Pear1 0.42 Ick 0.295 Gm2830 0.247 Gm6771 0.221 
Slc45a3 0.42 Tagln2 0.294 Anxa4 0.247 Gng2 0.221 
Rab27b 0.419 Nr1d1 0.294 Gm13478 0.247 Ankrd7 0.221 
St8sia6 0.418 Cenpb 0.293 Skp1a 0.247 Cdkn2c 0.22 
Cnot6l 0.413 Gem 0.293 Cyb5r4 0.246 RP24-335I21.2 0.22 
Csnk1e 0.412 Commd2 0.293 Gm8909 0.246 Adamts13 0.22 
Gmpr 0.411 Cbfb 0.293 Sapcd1 0.246 Ddx58 0.22 
Tsc22d1 0.409 Srgap3 0.293 Bcor 0.246 Vkorc1 0.22 
Rpl6 0.408 Calhm2 0.292 Cacul1 0.246 Gucy1b3 0.22 
Tnfsf12 0.407 Dhrs1 0.292 Wdpcp 0.246 Arhgap25 0.22 
Emp3 0.407 Polr3k 0.292 Gm11914 0.246 Cnpy4 0.22 
Sdsl 0.406 Lrba 0.292 Glb1 0.246 Itm2c 0.219 
Kifc3 0.405 Vsig10 0.292 Gprasp1 0.245 2810403A07Rik 0.219 
F2rl2 0.405 Ywhag 0.291 Hhex 0.245 Pip5k1c 0.219 
Vwa5a 0.405 Chd9 0.291 Ppp3r2 0.245 Mndal 0.219 
Pecr 0.404 Atxn7 0.29 mt-Co2 0.245 Htr2a 0.219 
Ctnnd1 0.403 Hnrnph1 0.29 Ncor1 0.245 Gm9795 0.219 
Pard3b 0.402 Zfp157 0.289 Dennd6a 0.245 Itgal 0.219 
Rpl23 0.401 Sepw1 0.289 Gm7142 0.245 Rnase6 0.219 
Trim47 0.4 Gna14 0.289 Runx1 0.245 Ajuba 0.219 
Abca2 0.4 Nynrin 0.289 Hic2 0.245 Gbas 0.219 
Ssbp2 0.4 Magi2 0.289 Ntrk2 0.245 Akr1b3 0.219 
Kcnj5 0.4 Pwwp2a 0.289 D430041D05Ri 0.244 1700021K19Rik 0.218 
Rps28 0.399 Casp2 0.289 Krba1 0.244 Ccdc94 0.218 
Clec4f 0.398 R3hdm4 0.288 Cers4 0.244 Mro 0.218 
Cux1 0.397 Map3k12 0.287 Pla2g4b 0.244 Qrfp 0.218 
H3f3b 0.397 Zfp113 0.287 Kctd10 0.244 Wdfy3 0.218 
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Tpt1 0.397 Akr1c13 0.287 Sik3 0.244 Uvssa 0.218 
Madd 0.395 Map7 0.287 Suv420h1 0.244 Olfr961 0.218 
Stx3 0.395 Olfr609 0.287 Btk 0.244 Copg1 0.218 
Bcl11a 0.394 Eif3h 0.287 Slc9a3r1 0.244 Lrrc3 0.218 
Ctdsp2 0.394 Stat5a 0.286 Fam180a 0.243 Mfap3 0.218 
Ankrd33b 0.394 Slc14a1 0.286 Zzz3 0.243 Zbtb12 0.218 
Tpst2 0.394 Ocrl 0.286 Cabp4 0.243 Tmem201 0.218 
Zfp358 0.392 Fgf13 0.285 4732471J01Ri
k 
0.243 Ldlrad4 0.217 
Serinc3 0.392 Pcbp4 0.285 Gm6472 0.243 Mapk14 0.217 
Rab38 0.391 Rhof 0.285 Prdx4 0.243 Panx3 0.217 
Morf4l1 0.391 Ilvbl 0.285 Ubr2 0.243 Ebpl 0.217 
Fgf3 0.389 Kmt2c 0.284 Znhit6 0.243 Ddit4l 0.217 
Sipa1l1 0.388 Ptov1 0.284 Pou5f2 0.243 Lrig3 0.217 
Pts 0.388 Gm15427 0.284 Gp9 0.243 Rpl32 0.217 
Clstn3 0.388 Gm10638 0.284 Ttc14 0.243 Smc5 0.217 
Gabarapl1 0.387 Rpl18a 0.284 Cep89 0.242 2010012O05Rik 0.217 
Klhl22 0.387 Adipor2 0.283 Hk1 0.242 Zfp580 0.217 
Mon1b 0.387 Chrnb4 0.283 Gm7589 0.242 Il6 0.217 
Ncoa1 0.386 Hoxa7 0.283 Bcl7c 0.242 C1ql2 0.217 
Phc1 0.386 Ccdc148 0.283 Cndp2 0.242 Sytl3 0.217 
Fam171a2 0.385 Dennd5a 0.283 Ift74 0.242 Pdgfb 0.216 
Samd13 0.383 Lim2 0.283 Best2 0.241 Gm13038 0.216 
Gramd1a 0.383 Copz2 0.283 Zfpm1 0.241 Gm14880 0.216 
Fut8 0.382 Hlf 0.282 Sulf1 0.241 Trhr2 0.216 
Psd3 0.38 Fut7 0.282 Msl3l2 0.241 Gm5224 0.216 
Rps15a 0.379 Polr3gl 0.282 Itga5 0.241 2810039B14Rik 0.216 
Zc4h2 0.379 Mink1 0.282 Mmrn1 0.241 Cggbp1 0.216 
Akap13 0.375 Dnmt3b 0.282 Rusc2 0.241 Ddx17 0.216 
Aipl1 0.374 Ube2d2a 0.281 Cdh16 0.241 Gm11197 0.216 
Jak3 0.372 Ap5z1 0.281 Trp53 0.241 Cd109 0.216 
Tnfsf10 0.371 Crebzf 0.281 Gm10123 0.241 Plscr3 0.215 
St3gal1 0.37 Tbc1d31 0.281 Ociad2 0.241 Fbxl8 0.215 
Prdx1 0.369 Tigd5 0.28 Ddx19b 0.241 Nomo1 0.215 
Rpl31 0.369 Tsc22d3 0.28 RP24-383C4.1 0.241 Tmem219 0.215 
Ptk2b 0.369 Cxxc5 0.28 Sp6 0.24 Fam159b 0.215 
Tia1 0.368 Gng11 0.28 Usp17la 0.24 Hnrnph3 0.215 
Ccnd2 0.368 Tm9sf3 0.28 Ahdc1 0.24 Acbd6 0.215 
Ifi47 0.368 Ptpn18 0.28 Rps18-ps1 0.24 Tmem57 0.215 
Cttn 0.368 Gm20699 0.28 Sumo3 0.24 Chst3 0.215 
Ecm2 0.367 Rps17 0.28 Ppp1r35 0.24 Hfe2 0.215 
Gm14805 0.366 Eri3 0.279 Rsf1 0.24 Zfp677 0.215 
Ormdl1 0.365 Map3k4 0.279 Rsbn1l 0.239 Fam168b 0.215 
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Dapk1 0.36 Tes 0.279 Sdr42e1 0.239 Gatad1 0.214 
Prkacb 0.359 Tspan14 0.279 Fam117a 0.239 Gstk1 0.214 
Sepp1 0.357 2610002J02Rik 0.279 Nat1 0.239 Tek 0.214 
Rpl7 0.355 Rsph3b 0.279 Snw1 0.239 Rps4x 0.214 
Tmod3 0.355 Tns1 0.278 Gtpbp10 0.239 Rps13-ps6 0.214 
Nfe2 0.354 Cys1 0.278 Wdr72 0.239 RP23-246L14.4 0.214 
H2-Q4 0.353 Fabp5 0.278 Pcp4l1 0.238 P2rx3 0.214 
Cox7a2l 0.353 Apaf1 0.278 Rps26 0.238 Mfsd6 0.214 
Fto 0.352 Ppfibp1 0.277 Oxct1 0.238 Dusp4 0.214 
Tbrg1 0.351 Sde2 0.277 Tubd1 0.238 Rbbp6 0.214 
Ddah2 0.351 Rps29 0.277 Pttg1ip 0.238 Atxn3 0.214 
Tmsb10 0.351 Parp12 0.277 Aebp2 0.238 Dyx1c1 0.214 
Hdac7 0.35 Rftn1 0.277 Nfya 0.238 Ermn 0.214 
Smim10l1 0.35 Aktip 0.277 Zfp764 0.238 Fpr-rs3 0.214 
Oplah 0.349 Iqgap1 0.276 Gm14931 0.238 Zdhhc9 0.214 
Deptor 0.349 Marcksl1 0.276 Cabin1 0.238 Mbd6 0.214 
Zeb2 0.347 Neto2 0.276 Klhdc9 0.238 Nmb 0.214 
Igf1r 0.347 Terf2 0.275 Gm9320 0.238 Gm14867 0.213 
Trappc9 0.346 3110062M04Rik 0.275 Nras 0.238 Rxrb 0.213 
Sdpr 0.346 Uba7 0.275 Abhd14a 0.237 Ldha 0.213 
Kmt2a 0.345 Psme1 0.275 Zfx 0.237 Serpina3i 0.213 
Zbtb17 0.345 Rnh1 0.275 Prrt2 0.237 Gm16210 0.213 
Eif4a2 0.345 Yap1 0.275 Gm10540 0.237 Trp53bp1 0.213 
Ak1 0.345 Rpl28 0.275 Csf2rb 0.237 Gm10300 0.213 
Emid1 0.345 Gm6546 0.275 Ifitm2 0.237 Ift46 0.213 
Srebf2 0.344 Gpatch8 0.274 Trim33 0.237 Trip10 0.213 
Spred2 0.343 Mex3b 0.274 Zfp949 0.237 Pnrc1 0.212 
Nfkb1 0.343 Ric8b 0.274 Nkain3 0.237 Cers2 0.212 
Acss2 0.343 Fzd6 0.274 Olfr389 0.237 Cnot4 0.212 
1500012F01Rik 0.343 Coro1b 0.273 Gltscr2 0.236 Klhl6 0.212 
Gbp2b 0.343 Prpf40b 0.273 Trim35 0.236 Gm15382 0.212 
Obsl1 0.342 Guca1a 0.273 Slc35b3 0.236 Pkd1 0.212 
Senp6 0.342 Prmt2 0.273 Tmem222 0.236 Gigyf2 0.212 
Renbp 0.342 Chd3 0.272 Gsap 0.236 Pik3cd 0.212 
Skor1 0.342 Prrc2c 0.272 Rassf3 0.236 Olig2 0.212 
Rpl7a 0.341 Dgkq 0.272 Flot1 0.236 Cage1 0.212 
Nucb1 0.34 Appbp2 0.271 Gm17727 0.235 Cib3 0.212 
Osbpl1a 0.34 Fkbp9 0.271 Obfc1 0.235 Zbtb33 0.211 
Arl6ip5 0.339 Ctcfl 0.271 Tsr2 0.235 2410089E03Rik 0.211 
Zfp457 0.339 Mfge8 0.271 Arap3 0.235 Ltbp3 0.211 
Gp1bb 0.338 Dynll2 0.271 Cacnb4 0.235 Vmn2r95 0.211 
Cd48 0.338 Pcdhb14 0.271 Zfyve21 0.235 Gm12302 0.211 
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PISD 0.338 Rpl13 0.27 Pnrc2 0.235 Fam49a 0.211 
Csrp1 0.338 Fam174b 0.27 Rpl10a-ps1 0.234 Pdp2 0.211 
Jsrp1 0.337 Fxyd5 0.27 Rabac1 0.234 Gm7593 0.211 
Cd47 0.337 Dnm3 0.27 Lrwd1 0.234 Gpx2 0.211 
Rpl14 0.337 Rpl37rt 0.27 Acvr1b 0.234 Pde4b 0.211 
Foxp1 0.337 Ptger3 0.269 1110037F02Ri 0.234 B930041F14Rik 0.211 
Timp2 0.337 Slc45a4 0.269 Add3 0.234 Bace2 0.211 
Eef1b2 0.336 Rab11b 0.269 Tef 0.233 Tbc1d22a 0.21 
Cpne2 0.336 Pomgnt1 0.269 Chrm3 0.233 Mterf1a 0.21 
Kmt2e 0.335 Emcn 0.269 Ccdc120 0.233 Ly6g6f 0.21 
Ptprs 0.334 Tcf25 0.269 Msn 0.233 Sash1 0.21 
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Appendix C  
Genes enriched in Intermediate Erythroblasts (IntE) as defined 
in a microarray study of human erythroid differentiation by 
Tusi et al. (2018).  
 
Cluster 17 obtained from the Human Erythroblast Maturation database: 
https://cellline.molbiol.ox.ac.uk/eryth/index.html 
 
Gene ID Probes Description 
ABI2 225112_at Entrez: 10152 
ACADM 202502_at Entrez: 34 
ACER3 227776_at, 222688_at, 222689_at Entrez: 55331 
ACSBG1 206466_at Entrez: 23205 
ACSL3 201660_at Entrez: 2181 
ACSL4 202422_s_at Entrez: 2182 
ADAL 239711_at Entrez: 161823 
ADCY7 203741_s_at Entrez: 113 
ADSSL1 226325_at Entrez: 122622 
AHCTF1 226115_at Entrez: 25909 
AK3 224655_at Entrez: 50808 
AKR1C3 209160_at Entrez: 8644 
ALKBH6 225969_at Entrez: 84964 
ALMS1 214221_at Entrez: 7840 
AMMECR1 204976_s_at Entrez: 9949 
AMPD3 207992_s_at Entrez: 272 
AMY2B 228023_x_at Entrez: 280 
ANGEL2 221825_at Entrez: 90806 
ANKRD10 223251_s_at Entrez: 55608 
ANKRD49 219069_at Entrez: 54851 
ANP32E 221505_at Entrez: 81611 
AP3M2 203410_at Entrez: 10947 
APOBEC3A 210873_x_at Entrez: 200315 
APOBEC3B 206632_s_at Entrez: 9582 
APOBEC3G 204205_at Entrez: 60489 
ARF6 224788_at Entrez: 382 
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ARGLU1 227448_at Entrez: 55082 
ARID2 1553349_at Entrez: 196528 
ARL6IP6 225711_at Entrez: 151188 
ASB3 224524_s_at Entrez: 51130 
ASPM 219918_s_at Entrez: 259266 
ATF7IP2 228381_at, 219870_at Entrez: 80063 
ATL3 224893_at Entrez: 25923 
ATP13A3 212297_at Entrez: 79572 
ATP2C1 211137_s_at Entrez: 27032 
AURKA 208079_s_at Entrez: 6790 
AURKB 239219_at, 209464_at Entrez: 9212 
AZI2 227904_at Entrez: 64343 
BCL2L2 209311_at Entrez: 599 
BIRC6 233093_s_at Entrez: 57448 
BLM 205733_at Entrez: 641 
BRCA1 204531_s_at, 211851_x_at Entrez: 672 
BRCA2 208368_s_at Entrez: 675 
BRWD2 229694_at, 218090_s_at Entrez: 55717 
BTAF1 209430_at Entrez: 9044 
BTF3L4 238675_x_at, 225976_at Entrez: 91408 
BUB1 209642_at Entrez: 699 
BUB3 209974_s_at Entrez: 9184 
C11orf30 242847_at, 222807_at, 222806_s_at Entrez: 56946 
C11orf80 238593_at Entrez: 79703 
C12orf69 237484_at Entrez: 440087 
C14orf106 241816_at Entrez: 55320 
C15orf15 222465_at Entrez:  
C16orf52 230296_at Entrez: 730094 
C17orf85 218896_s_at Entrez: 55421 
C18orf1 209574_s_at Entrez: 753 
C18orf18 229829_at Entrez: 147525 
C18orf54 244324_at, 229442_at Entrez: 162681 
C1orf25 223404_s_at Entrez: 81627 
C21orf66 218515_at Entrez: 94104 
C22orf30 1558097_at Entrez: 253143 
C2CD3 36552_at Entrez: 26005 
C2orf30 224628_at Entrez: 27248 
C2orf49 226951_at Entrez: 79074 
C2orf64 225409_at Entrez: 493753 
C3orf23 1555906_s_at Entrez: 285343 
C3orf38 229174_at Entrez: 285237 
C4orf41 218179_s_at Entrez: 60684 
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C5orf22 203738_at Entrez: 55322 
C5orf24 224876_at Entrez: 134553 
C5orf28 1557828_a_at Entrez: 64417 
C5orf34 229886_at Entrez: 375444 
C6orf153 235223_at Entrez: 88745 
C6orf89 1556359_at Entrez: 221477 
C8orf83 225603_s_at Entrez: 286144 
C9orf102 228211_at Entrez: 375748 
C9orf64 235940_at Entrez: 84267 
CAMSAP1 212710_at Entrez: 157922 
CARD8 204950_at Entrez: 22900 
CARHSP1 224910_at Entrez: 23589 
CASC4 224619_at Entrez: 113201 
CASC5 1552680_a_at, 228323_at Entrez: 57082 
CBX5 226085_at Entrez: 23468 
CCDC14 225017_at Entrez: 64770 
CCDC82 223300_s_at, 223301_s_at Entrez: 79780 
CCNE2 211814_s_at, 205034_at Entrez: 9134 
CD47 226016_at Entrez: 961 
CDAN1 228516_at Entrez: 146059 
CDC23 223651_x_at Entrez: 8697 
CDCA3 223307_at Entrez: 83461 
CDK2 204252_at Entrez: 1017 
CENPF 209172_s_at Entrez: 1063 
CENPM 218741_at Entrez: 79019 
CENPQ 219294_at Entrez: 55166 
CEP120 226449_at Entrez: 153241 
CEP152 238535_at Entrez: 22995 
CEP192 218827_s_at Entrez: 55125 
CEP72 219531_at Entrez: 55722 
CGGBP1 224599_at Entrez: 8545 
CHD1L 238070_at Entrez: 9557 
CHD6 225031_at Entrez: 84181 
CHMP2B 202536_at Entrez: 25978 
CHUK 209666_s_at Entrez: 1147 
CKAP2 1554264_at Entrez: 26586 
CNOT6 222476_at Entrez: 57472 
COMMD10 222637_at Entrez: 51397 
COPS8 202141_s_at Entrez: 10920 
COQ7 209745_at Entrez: 10229 
COX15 223281_s_at Entrez: 1355 
CP110 204662_at Entrez: 9738 
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CRLS1 237502_at, 225324_at Entrez: 54675 
CRYL1 220753_s_at Entrez: 51084 
CRYZL1 1552347_at Entrez: 9946 
CSE1L 210765_at Entrez: 1434 
CSNK1G1 231920_s_at, 226888_at Entrez: 53944 
CSTF2T 212905_at Entrez: 23283 
CTTN 201059_at Entrez: 2017 
CWF19L2 228916_at Entrez: 143884 
CYTL1 219837_s_at Entrez: 54360 
DCLRE1A 209804_at Entrez: 9937 
DCLRE1C 222233_s_at Entrez: 64421 
DCUN1D4 212855_at Entrez: 23142 
DDX59 228385_at Entrez: 83479 
DEK 200934_at Entrez: 7913 
DEPDC1B 226980_at Entrez: 55789 
DNAJC6 204720_s_at Entrez: 9829 
DNAJC9 213092_x_at Entrez: 23234 
DTL 222680_s_at Entrez: 51514 
DUT 208956_x_at Entrez: 1854 
DYNC1LI1 217976_s_at Entrez: 51143 
E2F7 228033_at Entrez: 144455 
E2F8 219990_at Entrez: 79733 
EFHC1 225656_at Entrez: 114327 
EID1 211698_at, 208670_s_at Entrez: 23741 
EIF2AK2 213294_at Entrez: 5610 
EIF3F 200023_s_at Entrez: 8665 
ELAVL1 244660_at Entrez: 1994 
ELL2 226982_at Entrez: 22936 
EME1 234465_at Entrez: 146956 
ENO2 201313_at Entrez: 2026 
EPC2 242960_at Entrez: 26122 
EPS15 217886_at Entrez: 2060 
ERAP1 214012_at Entrez: 51752 
ERCC4 235215_at Entrez: 2072 
ERGIC2 226422_at Entrez: 51290 
ERI2 240603_s_at Entrez: 112479 
ESCO2 235178_x_at Entrez: 157570 
EXOC4 224926_at Entrez: 60412 
EXOSC8 215136_s_at Entrez: 11340 
FAM119A 1553743_at Entrez: 151194 
FAM122B 222673_x_at Entrez: 159090 
FAM126A 227239_at Entrez: 84668 
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FAM178A 203482_at, 235590_at Entrez: 55719 
FAM29A 222685_at Entrez: 54801 
FAM40B 231880_at, 1555292_at Entrez: 57464 
FANCA 203805_s_at Entrez: 2175 
FANCB 1557218_s_at Entrez: 2187 
FANCD2 242560_at Entrez: 2177 
FANCI 213007_at, 213008_at Entrez: 55215 
FAR1 224866_at Entrez: 84188 
FBXO3 238686_at Entrez: 26273 
FBXO5 218875_s_at Entrez: 26271 
FBXW2 209630_s_at Entrez: 26190 
FEN1 204767_s_at Entrez: 2237 
FLJ11151 239135_at Entrez:  
FN3KRP 218210_at Entrez: 79672 
FUSIP1 204299_at Entrez: 10772 
GARNL1 214855_s_at, 213049_at Entrez: 253959 
GCOM1 212244_at Entrez: 145781 
GINS3 218719_s_at Entrez: 64785 
GINS4 1554356_at Entrez: 84296 
GLCCI1 225706_at Entrez: 113263 
GLTSCR2 217807_s_at Entrez: 29997 
GNA11 213766_x_at Entrez: 2767 
GNAI1 227692_at Entrez: 2770 
GNG10 201921_at Entrez: 2790 
GOLGA8E 222149_x_at Entrez: 390535 
GOLGA8F 222149_x_at Entrez: 100132565 
GOLGA8G 222149_x_at Entrez: 283768 
GOLT1B 222552_at Entrez: 51026 
GPR89A 222140_s_at Entrez: 653519 
GPR89B 222140_s_at Entrez: 51463 
GPR89C 222140_s_at Entrez: 728932 
GRINL1A 212244_at Entrez: 81488 
GTSE1 211040_x_at, 204318_s_at Entrez: 51512 
GUSBL2 232207_at Entrez: 375513 
GYPE 1561136_at Entrez: 2996 
H2AFV 212205_at Entrez: 94239 
HCCS 203745_at Entrez: 3052 
HCFC2 235264_at Entrez: 29915 
HCG4P6 215973_at Entrez: 80868 
HDAC4 228813_at Entrez: 9759 
HELLS 220085_at, 227350_at Entrez: 3070 
HIGD1A 221896_s_at, 217845_x_at Entrez: 25994 
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HINT1 1555960_at Entrez: 3094 
HIRIP3 204504_s_at Entrez: 8479 
HMGA2 208025_s_at Entrez: 8091 
HMGB1 224734_at Entrez: 3146 
HMGXB4 212596_s_at, 212597_s_at Entrez: 10042 
HNRNPA2B1 225107_at Entrez: 3181 
HNRNPA3 211929_at Entrez: 220988 
HNRNPD 213359_at Entrez: 3184 
HNRNPU 235603_at Entrez: 3192 
HSD17B6 37512_at Entrez: 8630 
IFFO1 36030_at Entrez: 25900 
IFI27L1 230172_at Entrez: 122509 
IKZF1 227344_at, 227346_at Entrez: 10320 
INPP5B 213804_at Entrez: 3633 
INPP5F 203607_at Entrez: 22876 
INSIG2 209566_at Entrez: 51141 
INTS7 218783_at Entrez: 25896 
IPO7 200994_at Entrez: 10527 
IPO9 213785_at Entrez: 55705 
IREB2 225892_at Entrez: 3658 
ITFG1 1556151_at Entrez: 81533 
ITGB3BP 205176_s_at Entrez: 23421 
ITPKB 203723_at Entrez: 3707 
JAZF1 225798_at Entrez: 221895 
KIAA0101 211713_x_at Entrez: 9768 
KIAA0841 213054_at, 36888_at Entrez: 23354 
KIAA1143 226816_s_at Entrez: 57456 
KIAA1429 243927_x_at Entrez: 25962 
KIAA1524 231855_at Entrez: 57650 
KIAA1704 226429_at Entrez: 55425 
KIAA1731 215018_at Entrez: 85459 
KIAA1841 243539_at Entrez: 84542 
KIF11 204444_at Entrez: 3832 
KIF21A 226003_at Entrez: 55605 
KIF9 231319_x_at, 228429_x_at Entrez: 64147 
KLHDC5 225961_at Entrez: 57542 
KLHL2 219157_at Entrez: 11275 
KPNA2 201088_at Entrez: 3838 
KRAS 204009_s_at Entrez: 3845 
LCORL 240592_at Entrez: 254251 
LGALS8 210731_s_at, 208933_s_at, 
208935_s_at 
Entrez: 3964 
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LIG1 202726_at Entrez: 3978 
LIMK2 202193_at Entrez: 3985 
LIN7C 221568_s_at Entrez: 55327 
LIN9 235039_x_at Entrez: 286826 
LOC100128661 230293_at Entrez: 100128661 
LOC149832 228456_s_at Entrez: 149832 
LOC158402 236769_at Entrez: 158402 
LOC284926 1556064_at Entrez: 284926 
LOC285147 236166_at Entrez: 285147 
LOC642558 204299_at Entrez: 642558 
LOC645030 232932_at Entrez: 645030 
LOC728179 234512_x_at Entrez:  
LOC728860 201088_at Entrez: 728860 
LOC729082 225225_at, 225332_at Entrez: 729082 
LOC91431 1565935_at Entrez: 91431 
LOC92270 228816_at Entrez:  
LRRCC1 231872_at Entrez: 85444 
LSM8 219119_at Entrez: 51691 
LYST 210943_s_at Entrez: 1130 
MAD2L1 203362_s_at Entrez: 4085 
MALT1 210017_at Entrez: 10892 
MANEA 222805_at, 219003_s_at Entrez: 79694 
MAP3K7 206853_s_at Entrez: 6885 
MAPK14 202530_at Entrez: 1432 
MASTL 228468_at Entrez: 84930 
MATR3 228012_at Entrez: 9782 
MDM1 213761_at Entrez: 56890 
MED4 222438_at Entrez: 29079 
MED6 207078_at Entrez: 10001 
MELK 204825_at Entrez: 9833 
METTL4 232194_at Entrez: 64863 
MGC21881 228040_at Entrez: 389741 
MIB1 224720_at Entrez: 57534 
MIER3 231975_s_at, 228961_at Entrez: 166968 
MIS12 221559_s_at Entrez: 79003 
MITF 226066_at Entrez: 4286 
MKLN1 235067_at, 1560145_at Entrez: 4289 
MOBKL3 202919_at Entrez: 25843 
MON2 212755_at Entrez: 23041 
MOSPD2 64883_at Entrez: 158747 
MPHOSPH9 215731_s_at Entrez: 10198 
MPPE1 213727_x_at Entrez: 65258 
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MRPL39 236910_at Entrez: 54148 
MSL3 236165_at Entrez: 10943 
MSTP9 213380_x_at Entrez: 11223 
MT1X 204326_x_at Entrez: 4501 
MTBP 233436_at Entrez: 27085 
MTERFD2 226486_at Entrez: 130916 
MTR 203774_at Entrez: 4548 
MUM1 221290_s_at Entrez: 84939 
MYEF2 229464_at Entrez: 50804 
N4BP2L1 229718_at Entrez: 90634 
N4BP2L2 202259_s_at Entrez: 10443 
NAF1 229757_at Entrez: 92345 
NAG 240579_at Entrez:  
NAP1L1 208752_x_at, 204528_s_at, 
212967_x_at 
Entrez: 4673 
NAPG 225448_at Entrez: 8774 
NCAPD3 212789_at Entrez: 23310 
NCAPG2 219588_s_at Entrez: 54892 
NCAPH 212949_at Entrez: 23397 
NCKAP1 207738_s_at Entrez: 10787 
NDC80 204162_at Entrez: 10403 
NDFIP2 224801_at, 224802_at Entrez: 54602 
NDUFA8 218160_at Entrez: 4702 
NEDD1 1560116_a_at Entrez: 121441 
NEK9 212299_at Entrez: 91754 
NFATC2IP 217527_s_at, 217526_at Entrez: 84901 
NIP30 217896_s_at Entrez: 80011 
NIPA1 225752_at Entrez: 123606 
NIPSNAP3A 224436_s_at Entrez: 25934 
NPAT 209798_at Entrez: 4863 
NR2C1 210530_s_at Entrez: 7181 
NRF1 204651_at Entrez: 4899 
NRIP1 202599_s_at Entrez: 8204 
NSL1 209484_s_at Entrez: 25936 
NUCKS1 217802_s_at, 224582_s_at Entrez: 64710 
NUDCD1 225438_at Entrez: 84955 
NUDT21 224830_at Entrez: 11051 
NXT2 209628_at Entrez: 55916 
OPA1 214306_at Entrez: 4976 
OSBP2 1569617_at Entrez: 23762 
OSBPL8 212582_at, 212585_at Entrez: 114882 
PBK 219148_at Entrez: 55872 
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PCBD2 223712_at, 240846_at Entrez: 84105 
PCGF3 212753_at Entrez: 10336 
PCM1 228905_at Entrez: 5108 
PCNA 201202_at Entrez: 5111 
PCSK7 232521_at Entrez: 9159 
PDCL 204449_at Entrez: 5082 
PDE7A 223358_s_at Entrez: 5150 
PDS5A 212140_at Entrez: 23244 
PDS5B 204742_s_at Entrez: 23047 
PGM2L1 229256_at Entrez: 283209 
PGRMC2 213227_at, 201701_s_at Entrez: 10424 
PHC3 226508_at Entrez: 80012 
PHF17 225816_at Entrez: 79960 
PHF2 212726_at Entrez: 5253 
PHF20L1 230098_at Entrez: 51105 
PIAS1 217863_at Entrez: 8554 
PIGK 227639_at, 209707_at Entrez: 10026 
PIGM 235532_at Entrez: 93183 
PJA2 201133_s_at Entrez: 9867 
PLK4 204886_at Entrez: 10733 
PLRG1 227246_at Entrez: 5356 
PNKD 225298_at Entrez: 25953 
POLH 231115_at Entrez: 5429 
POLI 238992_at Entrez: 11201 
POLQ 207746_at Entrez: 10721 
POLR3GL 223269_at Entrez: 84265 
POT1 204354_at Entrez: 25913 
POU2F1 227254_at Entrez: 5451 
PPP2R1B 202883_s_at Entrez: 5519 
PPP6C 225429_at Entrez: 5537 
PRKAA1 225985_at Entrez: 5562 
PRKX 204060_s_at, 204061_at Entrez: 5613 
PRKY 204060_s_at Entrez: 5616 
PROS1 207808_s_at Entrez: 5627 
PSIP1 205961_s_at Entrez: 11168 
PSMC2 201067_at Entrez: 5701 
PTBP2 218683_at Entrez: 58155 
PTK2 241453_at Entrez: 5747 
PTPLB 212640_at Entrez: 201562 
PTS 209694_at Entrez: 5805 
PURA 204020_at Entrez: 5813 
PYCR2 224855_at Entrez: 29920 
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PYROXD1 219802_at Entrez: 79912 
QKI 212265_at Entrez: 9444 
R3HDM2 203831_at Entrez: 22864 
RAB11FIP2 203884_s_at Entrez: 22841 
RAB3GAP2 202372_at Entrez: 25782 
RAB3IP 223471_at, 231399_at, 238526_at Entrez: 117177 
RAB6B 221792_at Entrez: 51560 
RAD51 205023_at Entrez: 5888 
RAD54B 219494_at Entrez: 25788 
RAD54L 204558_at Entrez: 8438 
RAI1 226143_at Entrez: 10743 
RAP1GDS1 237856_at Entrez: 5910 
RB1 203132_at Entrez: 5925 
RBBP4 244872_at, 210371_s_at, 225396_at Entrez: 5928 
RBL1 1555004_a_at Entrez: 5933 
RBL2 212331_at Entrez: 5934 
RBM17 224780_at Entrez: 84991 
RBM25 212033_at Entrez: 58517 
RBPJ 211974_x_at, 207785_s_at Entrez: 3516 
REEP5 208873_s_at Entrez: 7905 
RFC1 208021_s_at, 209085_x_at Entrez: 5981 
RFC3 204127_at Entrez: 5983 
RFC5 203209_at Entrez: 5985 
RFPL2 207227_x_at Entrez: 10739 
RFWD3 218564_at Entrez: 55159 
RMI1 218979_at Entrez: 80010 
RNASEH2B 219056_at Entrez: 79621 
RNF34 236288_at Entrez: 80196 
RNGTT 211387_x_at Entrez: 8732 
ROCK1 213044_at Entrez: 6093 
RPA1 201528_at Entrez: 6117 
RPL10 200725_x_at Entrez: 6134 
RPRD1A 225953_at Entrez: 55197 
RPS21 200834_s_at Entrez: 6227 
RPS3A 200099_s_at Entrez: 6189 
RPS4X 216342_x_at Entrez: 6191 
RRM1 201477_s_at Entrez: 6240 
RSPH10B2 1555272_at Entrez: 728194 
RSU1 201980_s_at Entrez: 6251 
S100PBP 218370_s_at Entrez: 64766 
SASS6 231895_at Entrez: 163786 
SCLT1 1569495_at, 236487_at Entrez: 132320 
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SCML2 206147_x_at Entrez: 10389 
SCYL3 205607_s_at Entrez: 57147 
SDCCAG1 218649_x_at Entrez: 9147 
SEC63 229969_at Entrez: 11231 
SENP1 226619_at Entrez: 29843 
39692 226627_at Entrez: 23176 
SESTD1 227041_at Entrez: 91404 
SFI1 36545_s_at Entrez: 9814 
SFRS1 227164_at Entrez: 6426 
SFRS11 200685_at Entrez: 9295 
SFRS12IP1 227288_at Entrez: 285672 
SFRS14 64371_at, 212000_at, 214092_x_at, 
213505_s_at 
Entrez: 10147 
SFRS15 233753_at Entrez: 57466 
SGPP1 223391_at Entrez: 81537 
SIK2 213221_s_at Entrez: 23235 
SLC11A2 210047_at Entrez: 4891 
SLC25A21 220474_at Entrez: 89874 
SLC25A40 227012_at Entrez: 55972 
SLC25A46 226831_at Entrez: 91137 
SLC2A13 227176_at Entrez: 114134 
SLC2A3P1 221751_at Entrez: 100128062 
SLC30A7 226601_at, 226217_at Entrez: 148867 
SLC30A9 202614_at Entrez: 10463 
SLC36A1 213119_at Entrez: 206358 
SLC39A10 225295_at Entrez: 57181 
SLC7A1 212295_s_at Entrez: 6541 
SLMO2 217851_s_at Entrez: 51012 
SMC1A 201589_at Entrez: 8243 
SMC2 204240_s_at Entrez: 10592 
SMC4 201664_at Entrez: 10051 
SMC5 212927_at Entrez: 23137 
SMCHD1 212569_at Entrez: 23347 
SMEK2 226230_at, 222270_at Entrez: 57223 
SMYD4 229175_at Entrez: 114826 
SNRNP200 200058_s_at Entrez: 23020 
SNRNP48 226263_at Entrez: 154007 
SPC24 235572_at Entrez: 147841 
SPC25 209891_at Entrez: 57405 
SRBD1 219055_at Entrez: 55133 
SS18L1 213140_s_at Entrez: 26039 
STAMBP 202811_at, 227515_at Entrez: 10617 
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STK11 231017_at Entrez: 6794 
STX16 221499_s_at Entrez: 8675 
STX7 212631_at Entrez: 8417 
STX8 204690_at Entrez: 9482 
SUDS3 224974_at Entrez: 64426 
SUMO1 208762_at Entrez: 7341 
SUMO2 213881_x_at, 200740_s_at Entrez: 6613 
SUMO3 200740_s_at Entrez: 6612 
SUPT7L 201838_s_at Entrez: 9913 
SVIP 230005_at Entrez: 258010 
TADA1L 225455_at Entrez: 117143 
TADA2B 236248_x_at Entrez: 93624 
TAF2 209523_at Entrez: 6873 
TAF5L 1554415_at Entrez: 27097 
TAL1 206283_s_at Entrez: 6886 
TAPT1 227407_at Entrez: 202018 
TBC1D1 227945_at Entrez: 23216 
TBC1D24 227632_at Entrez: 57465 
TBRG1 230320_at Entrez: 84897 
TCEB3 213604_at Entrez: 6924 
TCERG1 202396_at Entrez: 10915 
TCF19 223274_at Entrez: 6941 
TGOLN2 1554608_at Entrez: 10618 
TIA1 201449_at, 201448_at Entrez: 7072 
TIPRL 214773_x_at Entrez: 261726 
TLE3 212770_at Entrez: 7090 
TLK1 244389_at, 202606_s_at Entrez: 9874 
TMEM161B 238783_at Entrez: 153396 
TMEM167A 224702_at Entrez: 153339 
TMEM188 235812_at Entrez: 255919 
TMEM194A 212621_at Entrez: 23306 
TMEM41B 212623_at, 212622_at Entrez: 440026 
TMPO 203432_at Entrez: 7112 
TOP2A 237469_at Entrez: 7153 
TOP3A 214299_at Entrez: 7156 
TOPBP1 202633_at Entrez: 11073 
TPM1 210986_s_at Entrez: 7168 
TPR 228709_at Entrez: 7175 
TRA2A 213593_s_at Entrez: 29896 
TRIM10 56748_at Entrez: 10107 
TRIM33 214815_at Entrez: 51592 
TRIM45 242056_at Entrez: 80263 
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TRIM73 1554250_s_at Entrez: 375593 
TRNAU1AP 222800_at Entrez: 54952 
TSNAX 203983_at Entrez: 7257 
TSPYL4 212928_at Entrez: 23270 
TTC13 219481_at Entrez: 79573 
TTC14 225180_at Entrez: 151613 
TTC17 224852_at Entrez: 55761 
TTC31 218838_s_at Entrez: 64427 
TTF2 204407_at Entrez: 8458 
TUBD1 231853_at Entrez: 51174 
TUBGCP3 215739_s_at, 1554086_at Entrez: 10426 
TXNDC10 225302_at Entrez:  
TYMS 202589_at Entrez: 7298 
UBA2 229587_at Entrez: 10054 
UBE2K 225179_at Entrez: 3093 
UBR1 226921_at Entrez: 197131 
UBR7 218108_at Entrez: 55148 
UGCGL2 235749_at Entrez: 55757 
USP1 202413_s_at Entrez: 7398 
USP14 201671_x_at, 226567_at Entrez: 9097 
USP22 216957_at Entrez: 23326 
USP32 244871_s_at Entrez: 84669 
USP37 226730_s_at, 226729_at Entrez: 57695 
UXS1 225583_at Entrez: 80146 
VANGL1 229492_at Entrez: 81839 
VDAC3 208845_at Entrez: 7419 
VEGFA 210512_s_at Entrez: 7422 
VKORC1L1 224881_at Entrez: 154807 
VPS13C 218396_at, 235023_at Entrez: 54832 
VPS13D 1557571_at, 212324_s_at Entrez: 55187 
VPS33B 218415_at, 44111_at Entrez: 26276 
VRK1 203856_at Entrez: 7443 
WAPAL 212267_at Entrez: 23063 
WDR53 227814_at Entrez: 348793 
WDR67 214061_at Entrez: 93594 
WDR68 221745_at Entrez: 10238 
WHSC1 223472_at, 222777_s_at Entrez: 7468 
WSB1 201295_s_at Entrez: 26118 
WSB2 213734_at Entrez: 55884 
XPO1 235927_at Entrez: 7514 
YEATS4 218911_at Entrez: 8089 
YIPF5 224934_at Entrez: 81555 
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YME1L1 201352_at Entrez: 10730 
YWHAQ 212426_s_at Entrez: 10971 
ZBED5 218263_s_at Entrez: 58486 
ZBTB3 220391_at Entrez: 79842 
ZBTB44 225845_at Entrez: 29068 
ZCCHC10 221193_s_at Entrez: 54819 
ZFP1 226807_at Entrez: 162239 
ZFX 229022_at Entrez: 7543 
ZMYM6 227595_at Entrez: 9204 
ZNF137 207394_at Entrez: 7696 
ZNF22 218005_at Entrez: 7570 
ZNF223 207128_s_at Entrez: 7766 
ZNF238 212774_at Entrez: 10472 
ZNF25 228185_at Entrez: 219749 
ZNF264 230063_at Entrez: 9422 
ZNF274 232436_at Entrez: 10782 
ZNF302 228392_at Entrez: 55900 
ZNF33A 231864_at Entrez: 7581 
ZNF345 207236_at Entrez: 25850 
ZNF451 1556060_a_at Entrez: 26036 
ZNF468 214751_at Entrez: 90333 
ZNF519 1568873_at Entrez: 162655 
ZNF623 206188_at Entrez: 9831 
ZNF638 211257_x_at Entrez: 27332 
ZNF721 228029_at Entrez: 170960 
ZNF828 226194_at Entrez: 283489 
ZNF84 228630_at Entrez: 7637 
ZRSR2 208174_x_at, 213876_x_at Entrez: 8233 
unknown_217019_at 217019_at Entrez:  
unknown_227921_at 227921_at Entrez:  
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Appendix D  
ZZZ3 and SPT20 ChIP-seq peaks in human K562 cells.  
Peaks and analysis obtained from EnrichR database are shown below. 
GO Biological processes for ZZZ3 binding  
Term  Overlap  P-Value  Adjusted 
P-Value  
Z-score  Combine




67/233  1.4E-30  1.5E-27  -1.2E+00  8.4E+01  RPL9; RPL6; RPL7; RPS15; 
RPS4X; MRPL3; RPL7A; RPS14; 
MRPL1; RPS18; RARS; RPL35; 
RPL38; RPL37; RPL39; RPS10; 
RPS7; RPS8; RPL23; RPS6; 
RPS3A; MRPS7; MRPS6; 
MRPS18C; TUFM; EEF1A1; 
EEF1G; MRPL51; MRTO4; 
RPL27; TARS2; RPL26; RPL29; 
RPL12; MRPS34; RPL11; 
IGHMBP2; MRPL16; MRPL13; 
RPS15A; RPS3; RPL13; RPS2; 
RPL18; RPL17; ABCF1; EEFSEC; 
RPL41; MRPL27; RPL35A; 
EEF2; RPL17-C18ORF32; 
HARS2; RPS25; RPS20; 





62/203  5.3E-30  2.7E-27  -1.6E+00  1.1E+02  RPL5; RPL3; RPL32; RPL31; 
RPL34; FCF1; RPL10A; RPL8; 
RPL9; RPL6; RPL7; RPS15; 
RPS4X; FBL; RPL7A; RPS14; 
MRPL1; RPS18; RPL35; RPL38; 
RIOK1; RPL37; RPL39; RPS10; 
RRP15; RPS7; DIS3; RPS8; 
PIH1D1; RPL23; RPS6; 
CSNK1D; RPS3A; NSA2; 
MRTO4; RPL27; RPL26; RPL29; 
RPL12; RPL11; ISG20L2; NOL8; 
EXOSC4; RPS15A; BMS1; RPS3; 
RPL13; RPS2; EXOSC3; RPL18; 
RPL17; MDN1; RPL41; UTP3; 
RPL35A; BYSL; WDR55; RPS25; 
LAS1L; RPS20; RPS24; RPS23  







30/237  0.0000  0.0013  -1.2412  13.8052  ISY1; SF3B3; DHX9; CSTF2; 
CSTF2T; CWC27; SNRPD2; 
POLR2C; RALY; SNRPD3; 
POLR2K; HNRNPA0; AQR; 
PPIL1; CPSF1; NCBP2; CPSF3; 
PRPF40A; LSM5; CHERP; SFPQ; 
PRPF3; SNRNP27; RNPS1; 
GEMIN7; PPIL3; SNRNP200; 
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GO Cellular component for ZZZ3 binding  
Term  Overlap  P-Value  Adjusted 
P-Value  






52/125  6.3E-33  2.0E-30  -1.3E+00  9.9E+01  RPL5; DDX3X; RPL3; RPL32; 
RPL31; RPL34; RPL10A; RPL8; 
RPL9; RPL6; RPL7; RPS15; 
RPS4X; RPL7A; RPS14; MRPL1; 
RPS18; RPL35; EIF2D; RPL38; 
RPL37; RPL39; RPS10; RPS7; 
RPS8; RPL23; RPS6; RPS3A; 
MRPS18C; MRTO4; RPL27; 
RPL26; RPL29; RPL12; RPL11; 
RPS15A; RPS3; RPL13; RPS2; 
ZNF622; RPL18; RPL17; RPL41; 
RPL35A; LARP4; RPL17-
C18ORF32; RPS25; RPS20; 





31/73  1.8E-20  1.4E-18  -1.5E+00  6.9E+01  RPL5; RPL3; RPL32; RPL31; 
RPL12; RPL34; RPL11; RPL10A; 
RPL8; RPL9; RPL6; RPL7; 
RPL7A; MRPL1; RPL13; RPL35; 
RPL38; RPL37; ZNF622; RPL18; 
RPL17; RPL39; RPL41; RPL23; 
RPL35A; RPL17-C18ORF32; 






7/27  4.7E-04  9.2E-03  -2.1E+00  1.6E+01  NSA2; PPAN-P2RY11; LAS1L; 
PPAN; ZNF622; MDN1; RRP15  
 
GO Molecular function for ZZZ3 binding  
Term  Overlap  P-Value  Adjuste
d P-
Value  





33/180  6.9E-10  2.3E-07  -1.2E+00  2.5E+01  EIF4A1; RPL5; SLBP; DDX3X; 
SLC4A1AP; DHX9; CSTF2; 
CSTF2T; MRPL13; EDC3; RPL7; 
PURB; RPS14; DHX33; RPS3; 
RPL35; RPS2; RPL41; CPSF1; 
RPS7; NCBP2; RPS3A; MRPS7; 
PUM1; THOC5; SLPI; LUC7L3; 
TUT1; RNPS1; RPL26; DCP1A; 
EIF3D; EIF4G1  
rRNA binding 
(GO:0019843)  
12/44  2.6E-06  4.7E-04  -2.1E+00  2.7E+01  RPL5; RPS14; PPAN-P2RY11; 
RPL12; RPL23; RPL11; MDM2; 






15/68  2.9E-06  4.7E-04  -1.2E+00  1.6E+01  EEFSEC; EIF4A1; GFM1; GFM2; 
MTIF2; GTF2H3; TUFM; 
EEF1A1; EEF1G; EIF2D; EIF2B1; 
EIF3D; EIF4G3; ABCF1; EIF4G1  
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ENCODE TF ChIP-seq 2015 for combined ZZZ3 targets (top 3 hits) 
Term  Overlap  P-Value  Adjusted 
P-Value  







7.2E-243  5.9E-240  -1.7E+00  9.4E+02  … _ 
ZZZ3_GM12878
_hg19  
173/293  4.3E-143  8.7E-141  -1.9E+00  6.2E+02  RPL5; NUP107; TMEM41A; 
RPL3; SLC4A1AP; GMFB; 
RPL32; TACO1; RPL34; CASC4; 
ZDHHC6; UBE3B; PHB2; 
NDUFC2-KCTD14; IPO4; RPL6; 
RPL7; TATDN3; ALKBH3; 
MTBP; RPS14; FGF7; STX16-
NPEPL1; ALKBH1; CDK5RAP1; 
RPL35; RPL38; BANF1; 
MAP3K8; RPL37; ZNF165; 
RPS7; GIN1; TYW5; RPL23; 
RFX3; NOSIP; CSNK1D; 
SUPT7L; KCTD10; ZNF837; 
SNRNP27; TARS2; ZNF799; 
RPL27; RPL26; RPL29; VPS25; 
ALG10B; SNRPB; RTEL1; 
COX16; GSTCD; SH2D2A; 
SHOX2; MRPL16; COPS7B; 
MRPL13; PHF21A; TOR1AIP1; 
ZMPSTE24; TMEM242; NPAS3; 
EIF1AD; DHX33; ZNF827; 
VTI1A; MLEC; DMAP1; GRIA3; 
FZD1; RPL41; NR2F1; PUM1; 
RPL17-C18ORF32; MRPL21; 
KLHL20; MRPL30; LAS1L; 
COPS2; INTS5; DUS1L; NOL12; 
MNAT1; HNRNPA1L2; EIF4G3; 
BRWD3; ISY1; INTS12; 
C17ORF75; C11ORF31; 
C2ORF47; GFM2; ARHGAP1; 
EFCAB7; CHD2; SMG7; MRPL3; 
RPL7A; DSTYK; SPRED1; 
MRPL40; MRPL1; ZMYM3; 
ZNF408; AIFM2; NUF2; AP3S2; 
USP30; MAN2C1; TNPO3; 
TOP3B; COMMD2; VPS13B; 
NDUFC2; RPS3A; FAM126B; 
REXO4; MRPL44; NME1; 
SENP1; MED22; LSG1; NSA2; 
NDUFS7; NDUFS3; TUT1; 
ITGB3BP; SNAP47; GTF3C3; 
STX16; TIMM9; SEMA3A; GBA; 
NDUFB3; RPL11; MRPS31; 
IGHMBP2; CSTF2T; NOL8; 
HDAC8; CXXC4; NSL1; HIRA; 
FOXS1; RBBP5; C7ORF10; 
BMS1; PRRG2; KIAA1324; 
C11ORF49; STX6; RPS3; 
DCAF10; RPL17; KCNJ5; BRF2; 
SPAG8; NR1H2; RPL35A; 
KLK10; PEX13; MEIS2; SNX16; 
KIAA0586; FAM98B; MITD1; 







3.0E-169  8.2E-167  -1.8E+00  6.8E+02  … _ 
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GO Biological processes for SPT20 binding  
Term  Overlap  P-Value  Adjust
ed P-
Value  







26/1599  6.5E-04  1.4E-01  -1.8E+00  1.3E+01  KMT2A; RELA; HIRA; PPP3CB; 
SHH; IFI16; MYC; TTC21B; 
RPS6KA1; DMAP1; JARID2; 
FZD1; ZNF561; BRPF1; UBE2I; 
NFYB; STAT1; STAT3; ZNF76; 
ELF2; RYBP; KAT6A; BCOR; 




5/72  3.2E-04  1.2E-01  -1.5E+00  1.2E+01  BRPF1; KAT6A; DMAP1; 







12/503  9.8E-04  1.5E-01  -2.0E+00  1.4E+01  FZD1; PPP3CB; SHH; BRPF1; 
ELF2; RYBP; KMT2A; STAT1; 
KAT6A; MYC; STAT3; RELA  
 
GO Cellular component for SPT20 binding  
Term  Overlap  P-Value  Adjust
ed P-
Value  











2/8  1.8E-03  2.7E-02  -2.9E+00  1.8E+01  BRPF1; KAT6A  
chromatin 
(GO:0000785)  
8/297  3.3E-03  4.3E-02  -1.6E+00  9.1E+00  MBD3; HIRA; STAT1; MYC; 
STAT3; E2F4; IPO4; RELA  
 
GO Molecular function for SPT20 binding  
Term  Overlap  P-Value  Adjust
ed P-
Value  







6/54  5.4E-06  1.3E-03  -1.8E+00  2.1E+01  NFYB; STAT1; MYC; STAT3; 
DMAP1; RELA  
RNA polymerase 





9/263  3.5E-04  2.8E-02  -1.2E+00  9.4E+00  MBD3; IFI16; STAT1; MYC; 
STAT3; E2F4; SSBP2; RELA; 
SSBP4  






9/279  5.3E-04  3.2E-02  -1.6E+00  1.2E+01  MBD3; IFI16; STAT1; MYC; 
STAT3; E2F4; SSBP2; RELA; 
SSBP4  
 
ENCODE TF ChIP-seq 2015 for combined SPT20 targets (top 3 hits) 









45/172  6. 8E-
56  
5. 5E-53  -2. 0E+00  2. 5E+02  SLC4A1AP; CELF3; IGHMBP2; 
NOC4L; UBR1; CCDC106; 
NT5C2; RELA; PREX1; PPP3CB; 
SYNGR2; OGFOD2; CTNNA1; 
BMF; E2F4; AP3S1; DCAF11; 
PUSL1; JARID2; ARID2; 
HNRNPA0; FZD1; PIAS3; 
TIGD5; TPRA1; UBE2I; 
RHBDD3; NFYB; STAT3; 
VWA5A; MRPL28; ZNF76; 
DDX51; ARID3A; MRPL21; 
ATG12; SUPT7L; EEF1A1; 
ACAP3; EWSR1; EEF1D; 




64/1132  5. 1E-
37  
2. 1E-34  -1. 8E+00  1. 5E+02  FAM47E-STBD1; SLC4A1AP; 
CELF3; IPO4; PREX1; PPP3CB; 
NRD1; OGFOD2; AP3S1; 
JARID2; ARID2; TOP3B; PIAS3; 




46/945  3. 0E-
23  
8. 1E-21  -1. 8E+00  9. 4E+01  VWA5A; DDX51; SYP; ATG12; 
SUPT7L; MRPL44; EEF1A1; 
ACAP3; AIM2; EWSR1; EEF1D; 
KAT6A; TUT1; RNF121; 
B4GALT5; IGHMBP2; NOC4L; 
UBR1; CCDC106; NT5C2; RELA; 
SYNGR2; CTNNA1; BMF; 
DMAP1; E2F4; DCAF11; PUSL1; 
HNRNPA0; FZD1; UBE2I; 
RHBDD3; NFYB; STAT1; KLRC4; 
STAT3; MRPL28; ZNF76; 
ARID3A; HSPE1; MRPL21; 
VANGL2; DPY19L4; SNX15; 
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Appendix E  
Validation of a CRISPR/Cas9-KAT2A epigenetic editing tool  
 
 
Introduction   
Gene expression heterogeneity has the potential to alter fate decision probabilities in 
mammalian cells [323]. In the haematopoietic system, cell fate decisions associate 
with increased cell-to-cell transcriptional variability [43]. Our lab has shown that 
loss of Kat2a associates with enhanced transcriptional variability in a MLL-AF9 
mouse model, with reduction of leukaemia stem-like cells [260]. Furthermore, a 
single cell RNA-seq pilot study from the lab in Kasumi-1 cells upon KAT2A inhibition 
with MB-3 (unpublished) (Fig. E-1), revealed genes that are heterogeneously 
expressed following loss of KAT2A activity. Specifically, single-gene contribution to 
overall heterogeneity was either by the acquisition of an additional component 
(change from a unimodal to a bimodal distribution) in the case of CHEK1, EP300 and 
CEBPb genes, or by increased variance in a single-component, in the case of SOX4. 
Thus, it is possible that these genes play a role in leukaemic phenotypes mediated 
by the activity of KAT2A. However, assigning causal relationships between chromatin 
regulation to changes in gene expression, and ultimately, cell behaviour, remains a 
challenge.  
 
The CRISPR/Cas9 gRNA system adapted from the genomes of bacteria has been 
widely used as a gene editing tool due to its robust, versatile and easily 
programmable nature [324–325]. The utility of Cas9 is further expanded with the 
engineering of the nuclease-null Cas9 (dCas9), which can be fused to epigenetic-
effector domains for site-specific epigenome modifications [326–327]. Thus, by 
enabling precise manipulation of specific regulatory gene loci, CRISPR/ dCas9 tools 
may offer direct assessment of the impact of chromatin regulation and 
transcriptional activity to leukaemic phenotypes. In line with this view, our lab had 
cloned in a dCas9-KAT2A epigenetic tool that can direct KAT2A activity to putative 














FIGURE E-1 Single-cell transcriptomics identifies a KAT2A-dependent signature in 
Kasumi-1 AML cells. Analysis performed by Sonya Ridden and Ben 
MacArthur, University of Southampton. Single-cell RNA-seq experiment 
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Methods 
dCas9-KAT2A-core epigenetic tool  
I started by validating the editing capacity of the dCas-KAT2A tool, by directing its 
activity to one of the candidate target genes – CHEK1. To this end, I made use of a 
lentiviral vector previously cloned in the lab (Fig. E-2), in which dCas9 is fused to an 
expressed variant of KAT2A that includes its catalytic HAT domain and its reader 
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FIGURE E-3  Western blot analysis of dCas9- KAT2A-Core fusion. A band of ~230 kDa 
corresponding to the fusion between Cas9 and KAT2A was detected with an 
anti-Cas9 and an anti-KAT2A antibody in 293T cells transduced with the 
lentiviral vector shown in Fig. E-2 (left). A WB for detection of Cas9 in MOLM-
13 cells expressing WT Cas9 (MW ~160 kDa) is shown (right). Performed by a 
member of the Pina lab.   
 
Another member of the Pina lab had designed 2 sgRNA directed against the CHEK1 
promoter, which are represented in Fig. E-4. Single guide RNAs (sgRNAs) had been 














FIGURE E-4 Region encompassing the human CHEK1 locus on chromosome 11 
(125,586,692-125,701,556; GRCh38/hg38 assembly). A ChIP-seq region 
for H3K4me3 enrichment signal in K562 is shown in red and a known 
promoter in K562 cells shown in blue for mapping of the promoter region. Data 
generated in IGV, retrieved from ENCODE/Broad Institute. CHEK1 promoter 
gRNA target locations are indicated in green. Guides were designed using 
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CRISPR algorithms DNA 2.0, Zhang Lab and CHOP-CHOP. sgRNA sequences 
are CTTAAATGACGTACGCAGCT for CHEK1 guide 115 and 
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Experimental strategy  
As detailed in (Fig E-6), for establishing Kasumi-1 cell lines expressing dCas9 and 
dCas9-KAT2A, cells were lentiviral transduced with the plasmid in (Fig E-2), as well 
as with the same vector without the KAT2A-core part (dCas9 only), as control. 
Selection for transduced cells was initiated after three days post-transduction with 
Geneticin (750µg/mL). After stable Kasumi-1 lines were established, cells were 
subjected to a second round of lentiviral transduction with the vector containing 
sgRNAs (Fig E-6) directed at the promoter region of CHEK1. As control for the 
presence of the guides, cells were also transduced with the vector without sgRNAs, 
here designated ‘empty vector’.  Cells were sorted for BFP positivity (successfully 
transduced cells), expanded, and Doxycycline (2µg/mL) daily administrated to 
induce expression of the dCas9-KAT2A construct, from the start of the experiment 
(Day0). Cells were followed in culture for two weeks and collected at different time 
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Results  
Kasumi-1 cells transduced with lentiviral vector delivering the dCas9-KAT2A-Core 
fusion proliferate normally in culture  
 
When assessing cell growth (Fig. E-7), no difference was observed in cells transduced 
with dCas9-containing vector alone, or with the dCas9-KAT2A-Core fusion vector. 
Similarly, the presence of the sgRNAs (CHEK1 g115 and g210) did not seem to affect 
cell growth substantially, when compared to control, empty vector.  
 
FIGURE E-7 Cell proliferation curves of Kasumi-1 cells transduced with dCas9-KAT2A-
Core fusion and with dCas9 only, together with CHEK1 gRNAs or empty 
vector.  
 
No differences in cell viability were noted in cells expressing dCas9-KAT2A, compared 












FIGURE E-8 Cell viability of Kasumi-1 cells transduced with dCas9-KAT2A-Core fusion 
and with dCas9 only, together with CHEK1 gRNAs or empty vector.  
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This suggests that dCas9 expression has no detrimental effect on cell proliferation 
or viability. Thus, any phenotype observed in sgRNA-expressing cells is likely caused 
by genetic perturbation of the target gene, CHEK1, but at least for proliferation and 
viability I did not observe one.   
 
 
dCas9-KAT2A-Core deposits H3K9 and H3K27 at the CHEK1 promoter  
 
In order to understand if KAT2A was indeed being directed to the CHEK1 promoter, 
I assessed H3K9ac changes by ChIP-qPCR (Fig. E-9, left), using E2F3 as a positive 
control for KAT2A histone acetylation activity based on ENCODE data. I verified an 
increase in H3K9ac at the CHEK1 promoter region with CHEK1 gRNA 115 overtime. 
This was not observed at the E2F3 promoter until Day 10 (Fig. E-9, right). Thus, is 
possible that Day10 corresponds to maximal KAT2A expression, but this should be 
confirmed by WB at different time points. As for CHEK1 sgRNA 210, the levels of 
H3K9ac mark are no different from empty vector. This may be because the sgRNA is 
not working, thus not directing KAT2A to the target location, or because that region 
is not responsive to KAT2A activity. Both hypotheses need to be studied further.  
 
 
FIGURE E-9 ChIP-qPCR analysis of H3K9ac at the CHEK1 and E2F3 promoters. H3K9ac 
is shown as enrichment over Rabbit-IgG and normalised against GATA1 (n=1). 
 
H3K27ac, a well-documented mark of enhancer activity, was also investigated. It was 
shown to be enriched at the CHEK1 target region 115 (Fig. E-10, left). Therefore, it 
is possible that the acetylation driven by KAT2A at this location may promote 
proximal/facultative enhancer activity at promoters. Although, it more likely shows 
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promiscuity of mark deposition. Interestingly, a more robust enrichment of both 
H3K9ac and H3K27ac marks was observed overtime with the sgRNA at location 115.  
 
 
FIGURE E-10 ChIP-qPCR analysis of H3K27ac at the CHEK1 and E2F3 promoters. 
H3K27ac is shown as enrichment over Rabbit-IgG and normalised against 
GATA1 (n=1). 
 
These preliminary results show increased deposition of H3K9ac mark at the CHEK1 
promoter locus, deposited by KAT2A. The peak of H3K9ac should, in principle, 
correspond to the time point where I observed maximum d-Cas9-KAT2A expression, 
which may be at Day10, but this should be quantitatively measured to make firm 
conclusions. Failure of epigenetic remodelling at CHEK1 region 210 could be 
explained by (1) inefficiency of gRNA in directing KAT2A activity; (2) absence of HAT 
activity from the truncated KAT2A moiety of the fusion protein; (3) incorrect assembly 
of the endogenous KAT2A complexes with failure to recruit additional components 
that may be required to its acetyl-transferase activity. These points should be 
addressed with further experiments. In future, to employ the CRISPR tool in primary 
human AML samples, and screen KAT2A activity at putative target genes implicated 
in primary samples, including leukaemia, antibiotic-resistance cassettes should be 
avoided. Therefore, a vector encoding for the expression of a fluorescent reporter, 
instead of a neomycin resistance cassette would be desirable. Similarly, a new 
cloning strategy consisting of a single vector that contains both the dCas9-KAT2A 
fusion and the sgRNAs would avoid two consecutive rounds of transduction and 
selection, making the tool more versatile.   
 
